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Abstract 
 
Work described in this thesis shows the design, synthesis, DNA binding activity and gold 
nanoparticle interaction of functionalised triple stranded supramolecular helicates. 
DNA structures and the way molecules recognise and bind to them are reviewed, with specific 
emphasis on supramolecular compounds. Supramolecular helicates are discussed in detail with 
consideration of how they may be used as anticancer agents. Nanoparticles, specifically gold 
nanoparticles are studied, with specific reference to how they are able to enhance anticancer 
properties of drug molecules and how they may be used to develop potent anticancer therapies. 
The design and synthesis of novel functionalised supramolecular helicate structures is 
presented. Through the use of click chemistry, the supramolecular cylinder, [Fe2(LP)3]4+ (LP= 
C25H20N4), is successfully functionalised with ester, piperidine and thioacetate moieties to form 
the three new iron helicates [Fe2(LEster)3]Cl4, [Fe2(LPiperidine)3]Cl4 and [Fe2(LThioacetate)3][BF4]4. 
Each new structure is found to interact with ct-DNA and induce a structural change, through 
analysing DNA interactions with the use of circular and linear dichroism. The formation of 
DNA three-way junctions and these cylinder structures is also investigated, with the use of 
polyacrylamide gel electrophoresis. It is shown that such junction structures are stabilised by 
each of the three tetra-cationic compounds to varying degrees, [Fe2(LThioacetate)3][BF4]4 > 
[Fe2(LEster)3]Cl4 > [Fe2(LPiperidine)3]Cl4, showing the diversity of this class of compound. 
As well as DNA interactions, cell toxicity of the novel functionalised supramolecular helicates 
is investigated using human alveolar adenocarcinoma and breast cancer cell lines. It is found 
that these structures are able to enter such cell lines and induce cell death at concentrations ˂50 
µM. 
 
 
Attempts at attaching supramolecular helicates to gold nanoparticles is also described, via 
electrostatic interactions and covalent bonding. Stabilisation of the nanoparticles using a 
surfactant coating, allows for the tetra-cationic species to be attached successfully. Studies show 
that nanoparticles functionalised with the ruthenium helicate, [Ru2(LP)3]Cl4, and newly 
synthesised thioacetate functionalised iron helicate, [Fe2(LThioacetate)3][BF4]4 are able to interact 
with DNA structures and enter cancerous cell lines, to induce cell death. It is observed using 
circular and linear dichroism that these functionalised nanoparticles are able to interact with ct-
DNA and induce a structural change, however, are they are not as active as the ‘free’ 
compounds. TEM images show that these functionalised gold nanoparticles are able to enter 
cancerous cells, and through the use of MTT assays it is shown that they cause cell death at 
nanomolar concentrations after 72 hours incubation. 
With the formation of three novel supramolecular iron helicates and the incorporation of 
supramolecular chemistry and nanotechnology, foundations of work in this area is discussed, 
showing promising results for future research. 
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Chapter 1 
Introduction 
 
Deoxyribonucleic acid, DNA, encodes for all information essential to life in biological systems. 
For this reason, its structure and function are important to understand when developing new 
drug treatments. It plays a vital role within cellular processes, to maintain the cell function, for 
example within gene expression and DNA replication. As such, DNA can be a target for 
treatment of disease. A variety of natural and synthetic molecules are able to bind to DNA and 
affect the biological activity, resulting in therapeutic agents. Developing new drug molecules 
that have a high affinity to DNA or attaching therapeutic molecules to the surface of 
nanoparticles in order to direct delivery of compounds in high concentrations to DNA, may 
inhibit DNA replication, and as a result generate a potent anticancer therapy. 
 
1.1 DNA Structure 
The structure of B-DNA was discovered in 1953 [1] and consists of a sugar phosphate 
backbone, with interlinking base pairs, Figure 1. These four bases form complimentary pairings 
between a purine (adenine and guanine) and pyrimidine (thymine and cytosine) respectively. 
This results in a double helical structure which has both a major and minor groove, which is the 
most common form of DNA in vivo [2]. The major groove of DNA is 22 Å wide and the minor, 
12 Å wide [3]. Due to the minor groove being narrow, the major groove is more susceptible to 
interactions occurring with biomolecules due to the accessibility of the bases [4].  
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Figure 1: Watson-Crick DNA base pairings, with corresponding hydrogen bonding 
interactions (dotted lines) 
 
DNA also exists in other forms; including A and Z conformations which are present in living 
organisms, Figure 2 [5-7].  A-DNA occurs in dehydrated samples of DNA [8]; like B-DNA it 
is a right-handed double helix, but is flatter and wider giving it a deep major groove and shallow 
minor groove [9]. Z-DNA is a left-handed double helix with a zigzag backbone, resulting in no 
distinct major groove. It is not a stable conformation, and is formed via B-Z DNA transitions 
through biological activity [10]. 
(a)     (b)     (c) 
    
Figure 2: DNA conformations (a) A-DNA (PDB 5ANA) [5], (b) B-DNA (PDB 1BNA) [6], 
(c) Z-DNA (PDB 1DCB) [7] 
3 
 
Other DNA structures also occur in vivo, such as DNA junctions [11] and DNA tetraplex [12] 
which are important structures for gene expression, Figure 3. DNA junctions are intermediate 
structures formed by recombination events [11]. Three-way DNA junctions (3WJ) are formed 
during DNA replication [13]. Four-way DNA junctions are formed through homologous 
genetic recombination, a process which is important when repairing double-stranded DNA [11].  
(a)  (b) 
Figure 3: (a) DNA three-way junction [reproduced from ref13], (b) DNA 4-way junction 
[reproduced from ref11] 
 
Tetraplex or G-quadruplex DNA is a four stranded helix structure consisting of stacked G-
quartets, Figure 4 [14, 15]. Each quartet involves the planar association of four guanine bases 
in a cyclic hydrogen bonding arrangement, from one, two or four guanine rich DNA sequences 
interacting. Such structures are found at the end of eukaryotic chromosomes [14]. 
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 Tetramolecular       Biomolecular Unimolecular 
 
 
Figure 4: Guanine quartet showing hydrogen bonding interactions (left) [14] and the possible 
conformers of G-quandruplexes (right) [adapted from ref15] 
 
1.2 DNA Recognition 
Interactions with DNA have been explored for many years to develop drug molecules. Natural 
and synthetic small molecules are able to interact with DNA via a range of binding modes, 
categorically: major groove binders, minor groove binders, intercalators, sugar-phosphate 
backbone binders and through coordinative binding. Such interactions may effect the biological 
function of DNA, resulting in potential therapeutic agents. 
 
1.2.1 Major Groove Binders 
The major groove of B-DNA is prone to interactions with biological macromolecules, as the 
edge of the DNA bases are exposed due to the width of the groove (22 Å) [3, 4]. Zinc fingers 
are common motifs found on DNA-binding proteins which invoke a structural change on 
binding to DNA. They bind to the major groove of DNA, Figure 5, resulting in a globular 
structure as a result of the DNA being coordinated to a zinc centre [16]. Multiple zinc fingers 
interact with the DNA in a sequence-specific manner, to invoke structural changes. Such 
proteins are usually involved in gene transcription processes and as such have been targeted for 
use in new gene regulation [17] and HIV therapies [18]. 
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.  
Figure 5: Zinc finger interaction with the major groove of DNA (PDB 2GLI) [16] 
 
Other small synthetic molecules have also been found to bind to the major groove of DNA. For 
example Numistine, Figure 6, a derivative of nitrosourea acts as a major groove directed 
alkylating anticancer agent. Through interactions with specific bases in the major groove, the 
compound acts a therapeutic agent for glioma treatment [19]. 
N N
NH2
NH
ON
N
Cl
O
 
Figure 6: Structure of Numistine [19] 
 
1.2.2 Minor Groove Binders 
The minor groove of DNA is deeper and narrower than the major, being only 12 Å wide. As 
such, it partakes in fewer interactions with biological molecules, making it an ideal target for 
synthetic molecules. 
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Hoechst 33258 is a fluorescent DNA stain which binds in the minor groove of B-DNA, Figure 
7 [20, 21]. Research shows that the molecule binds preferentially to A-T rich DNA sequences, 
commonly found in the minor groove region [21]. On binding to DNA, the compound 
fluoresces and so is commonly used as a nuclear stain within cell studies to identify viable cells 
[22]. It can be used to investigate whether a new compound binds to the minor groove of DNA, 
via Hoechst displacement [23]. With reduction in fluorescence of the Hoechst/DNA conjugate 
on the addition of a new compound, it is possible to conclude that Hoechst is being displaced 
from the minor groove and being substituted for the new compound [23]. 
N
N
N
H
N
NH
N
OH
  
Figure 7: Structure of Hoechst 33258 (left) and the crystal structure of Hoechst binding to the 
minor groove of B-DNA (PDB 8BNA) [20] 
 
Metal complexes are also able to bind in the minor groove of DNA.  It has been shown that the 
copper complexes, [Cu(glygly)(PyTA)]ClO4.1.5H2O and [Cu(glygly)-(PzTA)]ClO4.1.5H2O, 
selectively bind to the minor groove, where they are able to partake in DNA cleavage through 
an oxidative mechanism [24]. They are able to act as nucleic acid probes and as such, can be 
utilised as chemotherapeutic agents. 
 
1.2.3 Intercalators 
Intercalation normally occurs through insertion of planar polycyclic aromatic compounds 
between the stacked base pairs with DNA. The overlapping π systems of the intercalator and 
nucleobases stabilise the interaction [25].  
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Positively charged compounds favour intercalation as the electrostatic interaction of the 
negatively charged phosphate backbone on the DNA and the positive compound stabilise DNA-
drug interactions [26]. A well-studied intercalating agent is Ethidium Bromide (EtBr), Figure 8 
[27, 28]. This cationic compound forms a fluorescent complex on binding with DNA and so 
can be used, like Hoechst 33258, to establish whether new drug molecules interact with DNA, 
in this case via intercalation. Through displacement of EtBr, fluorescence of the solution will 
decrease as a result of DNA/EtBr dissociation [28]. 
N
H2N
NH2
Br
 
Figure 8: Structure of Ethidium Bromide (EtBr) [27] 
 
By introducing metal centres into the design of intercalating compounds, a range of geometries 
can be achieved compared to solely organic compounds as a result of multiple binding sites 
[25]. By altering these metal centres, it has been found that binding affinities between DNA 
and complexes can be altered [26]. Ruthenium complexes formed with planar polycyclic 
organic ligands have been shown to intercalate with DNA [25, 29, 30]. [Ru(phen)2dppz]2+ for 
example, Figure 9 [29], exhibits luminescent properties on interacting with DNA [30]. In 
aqueous solution, emission of the compound is quenched, however on intercalation with DNA, 
luminescence is enhanced, providing positive indication that an interaction is occurring [30].  
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Ru
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N N
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Figure 9: Structure of rac-[Ru(phen)2dppz]2+ (left), intercalation of rac-[Ru(phen)2dppz]2+, 
showing enantiomer orientation (PDB 4JD8) (right) [29] 
 
1.2.4 Sugar-phosphate Backbone Binders 
The sugar-phosphate backbone of DNA comprises of alternating sugar and phosphate units. 
The phosphate groups are negatively charged and the oxygen rich structure is hydrophilic in 
nature [31]. As such, interactions with cationic species are favourable.  
There are few examples of compounds which exclusively bind to the sugar-phosphate backbone 
of DNA. However, a trinuclear platinum complex has been developed which interacts with the 
backbone, Figures 10 and 11 [32, 33]. 
H3N N
H2
Pt
NH3
H2
NH3N N
H2
Pt
NH3
H2
NH3N
8+
N
H2
Pt
NH3
H2
NH3N NH3
Figure 10: Farrell’s trinuclear platinum compound [32] 
 
This compound contains three square planar platinum atoms which are unable to participate in 
covalent bonding with DNA. As such, this long cationic molecule can span across the sugar-
phosphate backbone of DNA, spanning the minor groove, Figure 11.  
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Figure 11: Crystal structure of Farrell’s trinuclear platinum drug binding to the sugar-
phosphate backbone of DNA (PDB 2DYW) [33] 
 
1.2.5 Coordinative Binding 
Some molecules are able to bind directly to DNA, often selectively for a specific nucleotide or 
binding mode. The most celebrated metallodrug, cisplatin, is an example of a simple molecule 
which is capable of binding with DNA, resulting in distortion of the structure, Figure 12 [34].  
By coordinating specifically to two adjacent guanines in the double helix, it is able to 
manipulate the structure, generating kinks; so acting as an anticancer treatment by inducing 
apoptosis as a result of the cell cycle being terminated in the G2 phase [34, 35]. 
 
Figure 12: Structure of cisplatin (left), structure of cisplatin bound to DNA (right), 
demonstrating the kinking effect inflicted on the DNA structure (PDB 1AIO) [34] 
 
Pt
NH3
NH3Cl
Cl
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This molecule plays an important role in treatment for a range of cancers including testicular, 
ovarian and bladder. Severe side-effects are produced by this drug, including vomiting, kidney 
toxicity and bone marrow suppression [25]. Consequently, many variations on this molecule 
have been developed in an attempt to enhance the drug properties and reduce side-effects [36]. 
Compounds such as oxaliplatin and carboplatin, Figure 13, have been developed to target 
cancer cell lines which are cisplatin resistant and to reduce side-effects, respectively [37, 38]. 
On producing libraries of cisplatin analogues, research continues to build on and develop 
current cancer treatments [39]. 
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Figure 13: Structure of oxaliplatin (left) and carboplatin (right) [37] 
 
Based on the success of cisplatin, further research into the use of metal complexes in anticancer 
therapy has been carried out [40-42]. A variety of metal centres including iron, ruthenium and 
gold, have been used to create new therapeutic agent, Figure 14. 
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Figure 14: Representative metallodrug compounds being investigated for anticancer treatment 
[40, 42] 
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1.2.6 Drug Recognition of Other DNA Structures 
As well as duplex DNA, other DNA structures are present within cells, resulting from processes 
which occur in vivo, such as DNA replication, recombination and transcription. As such, these 
structures are also targets for new therapeutic agents. 
 
1.2.6.1 DNA Junctions 
DNA three-way junctions (3WJ) are Y-shaped DNA structures which contain a cavity where 
there is no helix stacking [43]. Such structures form during DNA rearrangements and so can be 
targeted by drug molecules. It has been found that such structures can be stabilised with the use 
of metal ions, forming stable structures within the junction [44]. On modifying DNA strands 
with bpy, it is possible to form stable 3WJs in the presence of Ni(II). Formation of [Ni(bpy)3]2+ 
within the centre of the cavity results in a stable junction formation [44]. 
Holliday junctions are also an important structure to consider when designing drug molecules. 
These four-way junctions (4WJ) are intermediate structures formed during homologous genetic 
recombination [45]. This exchange in nucleotide sequences may occur during meiosis or during 
DNA repair. As such, this has become a target of interest to develop new drug molecules. 
A bis-acridine compound has been developed which is able to bind noncovalently to the cross 
over region of a Holliday junction, Figure 15 [46]. The positively charged compound is able to 
neutralise the high charge density of DNA, allowing for the negatively charged DNA strands 
to come together in this fashion.  
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Figure 15: Structure of bis-acridine (left) and bis-acridine binding in a Holliday junction 
(right) (PDB 2GWA) [46] 
 
1.2.6.2 G-Quadruplex Structures 
Telomeric DNA is used within DNA replication and cell division. The ability of this replication 
to occur is determined by telomere length, if the sequence is too short then the cell will instigate 
apoptosis [47]. G-Quadruplex structures form at the terminals of telomeric DNA, and so pose 
a potential target to inhibit telomerase, the protein  used in cancerous cells to maintain telomere 
length and as a result cell division [47, 48]. 
Metallodrugs have been developed in an attempt to target G-quadruplex structures to inhibit 
telomerase, so acting as anticancer agents. Due to the planar guanine quartet formed within 
such DNA structures, cationic planar systems have been developed to bind to the top of a G-
quadruplex, so blocking the protein. Such compounds as CuGGHK-Acr [47] and the 
pentacationic manganese(III) porphyrin shown in Figure 16 [48] are able to stabilise these DNA 
structures and show potential as anticancer agents. 
13 
 
N
N
N
N
H
N
O
N
Mn
N
H
O
N
H
O
NN
H
N
O
N
5Cl
-
 
Figure 16: Pentacationic manganese(III) porphyrin G-quadruplex stabiliser [48] 
 
1.3 Supramolecular Chemistry 
Supramolecular chemistry is defined as ‘the chemistry of molecular assemblies and of the 
intermolecular bond’ [49]. It uses self-assembly of two or more molecules to form an array of 
structures such as helicates, catenanes, rotaxanes and molecular knots. These highly organised 
structures are bound by intramolecular interactions including; hydrogen bonding, metal 
coordination, pi-pi interactions, electrostatic effects and van der Waals forces [50]. Often metal 
centres are used to connect organic molecules via non-covalent bonds, bridging the gap between 
organic and inorganic chemistry. 
 
1.3.1 Supramolecular Helicates 
One class of supramolecular structure are supramolecular helicates. These self-assembled 
structures are formed using organic ligands containing several binding sites which interact with 
metallic cations, Figure 17. One or more ligand coordinates to one or more metal ion, with the 
resulting structure dependant on the metal coordination number and position of binding sites 
on the ligand [51]. If the same ligand strands coordinate, the resultant helicate is deemed 
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homotopic, whereas if different strands are coordinated a heterotopic helicate is formed, Figure 
17 [51]. 
 
 
Figure 17: Schematic representation of homophobic and heterophobic helicate formation 
(adapted from ref51) 
 
Each metal centre within a helicate is stereogenic, being either Δ or Λ configurations, which 
correspond to P and M enantiomers respectively, of the corresponding helicate, Figure 18 [52]. 
When achiral ligands are bound to the metal centres, a racemic mixture is formed. To obtain 
predominantly one enantiomer, stereogenic motifs may be attached to the ligand to encourage 
only one conformer to form [52], or the enantiomer may be separated through chiral 
chromatography [53]. 
  
Figure 18: P (left) and M (right) enantiomers of dinuclear helicates [reproduced from ref52] 
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1.4 Fe(II) Cylinder 
The iron based supramolecular cylinder [Fe2L3]4+ (L= C25H20N4), Figure 19, is a triple stranded 
helicate with octahedral environments around two Fe(II) centres. It is prepared with three bis-
pyridyl-imine ligand strands being wrapped around the two metal centres [54, 55]. 
H2N
N N
NH2
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RT
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N N
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Figure 19: The molecular structure of the ligand and the tetracationic triple helical 
supramolecular cylinder [Fe2(C25H20N4)3]Cl4 [reproduced from ref54] 
 
The size and shape of this supramolecular helicate, are comparable to that of zinc fingers [54, 
56]. Consequently, it is able to fit into the major groove of B-DNA and induce a structural 
change, thus acting as a potent apoptotic and cytostatic agent [54, 57, 58].  
The cationic nature of the cylinder allows a strong interaction with DNA [54, 59]. The major 
and minor grooves in DNA are flexible and have been found to respond to cationic binding 
[59]. This iron cylinder has a 4+ charge, so the attraction to negatively charged DNA is very 
strong, with the binding constant being in excess of 107 M-1 at 20 mM NaCl [60-62]. It is 
considered that a strong interaction between metallo-intercalators and ct-DNA when the 
binding constant is ˃106 M-1 [63]. As a result of the helicate interacting with the major groove 
of DNA, intramolecular coiling of DNA strands is induced, Figure 20, as well as DNA 
unwinding [54, 61].  
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Figure 20: AFM images showing dramatic intra-molecular coiling induced by the cylinders 
(reproduced from ref54) 
 
This supramolecular molecule is chiral, so present in the right handed (P, ΔΔ) and left handed 
(M, ΛΛ) forms, Figure 21 [61, 62]. During synthesis, a racemic mixture is formed, with both 
enantiomers being rac isomers, as the stereochemistry around each metal centre is the same 
[64]. 
 
Figure 21: 3D structures of M-[Fe2L3]4+ and P-[Fe2L3]4+ (reproduced from ref61) 
 
The racemic mixture causes intramolecular bending when interacting with DNA whereas the 
individual enantiomers invoke different structural effects [62]. It is possible to separate these 
enantiomers through the simple use of paper chromatography [53]. 
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The M enantiomer is proficient at unwinding DNA [61]. This may be the result of different 
binding modes as it has been proposed that the M enantiomer favours major groove binding 
and that the P possibly sits along the minor groove, across two phosphate backbones [62].  
This metallo compound has been shown to act as a potent cytostatic and apoptotic agent [57, 
65]. This water soluble complex is able to enter cancer cell lines, inducing cytostasis at low 
micromolar concentrations, and with slightly increased concentrations, apoptosis is reached in 
a number of cancer cells lines [57]. [Fe2(C25H20N4)3]Cl4 has also been shown to exhibit 
antimicrobial activity against E. coli and B. subtilis, demonstrating the diverse applications of 
this helicate [66]. 
 
1.4.1 Three-Way Junction Binding 
The same metallo-supramolecular cylinder is also able to bind to DNA within a three-way 
junction (3WJ), Figure 22. The helicate inhabits a Y-shaped junction of branched DNA, which 
has a trigonal hydrophobic cavity [60, 67, 68]. The palindromic duplex of DNA, Figure 22 
(left), allows for this structure to form on addition of the tetracationic complex. This 3WJ 
interaction has been fully characterised by NMR and X-ray crystallography [60].  
 
Figure 22: Schematic of the 3WJ (left) and 3D structure of the [Fe2L3]4+ interacting with the 
DNA 3WJ (PDB 2ET0) (right) [67] 
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One example of a Y-shaped junction is that of the DNA replication fork, formed during 
transcription [65]. Blocking the replication pathway can result in cytostasis and apoptosis, 
depending on concentration [65, 68].  
The binding of this metallo-complex to an RNA-3WJ was also investigated, as junction 
structures are common in RNA. It was found that the cylinder stabilises and promotes 3WJ 
formation with RNA strands, with similar binding affinity to the nucleic acid analogue [69]. 
 
1.4.2 Cylinder Analogues 
Spurred from the success of the ‘parent’ cylinder [Fe2(C25H20N4)3]4+, variations of the helicate 
have been developed, with the aim of enhancing binding interactions currently observed with 
DNA and to improve the selectivity of the complex [55, 61, 64, 70-72].  
 
1.4.2.1 Ligand Alteration 
By altering the ligand of this supramolecular cylinder, a number of properties of the resulting 
helicate can be changed.  
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Figure 23: Example analogues of parent ligand, LP [61, 64] 
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For example (La), Figure 22, has been made bulky compared to the parent ligand (LP). This 
addition to the ligand results in the meso isomer (ΔΛ) of helicate being the dominant species, 
which was thought to be due to the lack of CH∙∙∙π interactions in the complex [64]. 
The addition of CF3 (Lb) and phenyl groups (Lc) also resulted in the ligand becoming bulkier. 
It was observed that the bulkier cylinders did not induce DNA unwinding, thought to be due to 
the ligands being the incorrect dimensions to fit into the major groove of B-DNA [61, 64]. Size 
and shape of the cylinder are thought to be crucial to the binding activity observed with DNA 
[61]. 
The ligand has also been altered with the addition of chiral arginine residues, Figure 24. This 
was found to enhance recognition of the DNA 3WJ, resulting in an increased cytotoxic activity 
against cancer cell lines [72]. Such alterations to the parent cylinder can enhance properties 
exhibited by this class of compound. 
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Figure 24:  Structure of ligands modified with the addition of arginine residues, LL-Arg and LD-
Arg [72] 
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1.4.2.2 Metal Alteration 
The compound, [M2L3]4+ where L = C25H20N4 and the parent metal centre is Fe(II), has been 
investigated using alternative metal centres. Research has been carried out on cylinders 
containing ruthenium [73], nickel [74] and copper [75] centres.  
By altering the metal centres of the helicate to ruthenium, the size and charge of the cylinder 
remain virtually unchanged [73]. Synthesis of this complex however, requires intense heating 
to encourage the inert metal to form the triple stranded helicate and after purification by column 
chromatography a very low yield is achieved [73].  
Unlike the iron parent cylinder, this [Ru2L3]4+ compound is luminescent [73] and due to the 
photoredox and photophysical properties of ruthenium, it is capable of causing single-strand 
breaks in DNA when irradiated with UVA or visible light [55]. Studies show that the ruthenium 
complex unwinds DNA markedly less than the iron analogue [55], yet due to the high stability 
of the complex at 94 ºC, PCR studies could be performed to investigate whether the complex 
could interfere with DNA amplification, which was not possible for the iron cylinder [65].  It 
was found that the supramolecular cylinder inhibits binding of DNA polymerase, demonstrating 
the potential of this complex to inhibit DNA transcription and hence cell replication [65]. 
The nickel analogue of the metallo-supramolecular cylinder has also been studied and found to 
stabilise G-quadruplex DNA, with chiral selectivity, Figure 25 [74]. Research showed that the 
P-enantiomer was able to stabilise human telomeric (h-Telo) G-quadruplex DNA, increasing 
the melting temperature of the 1:1 [complex]/[DNA] species, whereas the M-enantiomer did 
not, even at higher ratios [74]. Comparison with different, longer flanking DNA sequences, 
showed the same chiral selectivity of the P-enantiomer, as it was able to bind to the end of the 
G-quartet by external stacking, unlike the M-enantiomer, Figure 25 [74]. 
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Figure 25: Representative illustration of chiral supramolecular complex selective recognition 
of human telomeric G-quadruplex DNA [reproduced from ref74] 
 
1.5 Nanoparticles  
Nanoparticles range in size, between 1 to 100 nm, making them a similar size to many 
biomolecules such as membrane receptors, proteins and nucleic acids [76, 77]. Nanoparticles 
are of great interest within medicine as they are anticipated to eradicate limitations of 
conventional treatments such as toxicity and bioavailability due to their unique properties of: 
nano size, high solubility, large surface area: volume ratio and varying geometries [77, 78]. 
Hence, nanomedicine is an exciting area of research being applied in many fields including 
drug delivery, therapeutics, biomedical imaging and biodiagnostics [76, 79].  
There are a vast range of nanostructures being used to develop drug treatments including; 
quantum dots, carbon nanotubes, magnetic nanoparticles and gold nanoparticles [77]. The 
chemical composition and shape of nanoparticles influence both their chemical and physical 
properties [77].  
Nanoparticles have some limitations, primarily that the long term side effects and toxicological 
risks are unknown [77]. It is thought that the properties of nanoparticles which make them 
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distinctive may also be the cause of their toxicity. A number of studies have been performed 
regarding the risks of exposure, with inconclusive results [76, 77, 80].  
 
1.5.1 Gold Nanoparticles (AuNPs) 
Gold has been utilized in medicine for many years; ancient cultures used gold for treating 
diseases such as measles, small pox and syphilis [81]. It is an inert metal and as a result is non-
toxic, making it an ideal material to use in medicine [82]. Organogold compounds have been 
developed for antimicrobial, antitumour and anti-HIV treatments [78, 83].  
Gold also exhibits the unique optical property, whereby electrons on the surface oscillate in the 
presence of incident photons hitting the metal surface, resulting in surface plasmon resonance 
(SPR). This resonance can be used to investigate materials adsorbing onto a gold surface and 
results in solutions of gold nanoparticles being a characteristic deep red/purple colour [76, 84-
89].   
Gold nanoparticles, AuNPs, are the most stable metallic nanoparticle [84, 85]. They can have 
many geometries including nanorods, nonocages and nanospheres, which are usually less than 
50 nm in size [77]. The size of nanoparticle can be adjusted by varying synthetic conditions. 
One common method of forming AuNPs is using the Turkevich method, where gold salts are 
reduced in the presence of a stabilizing agent to form spherical, monodispersed particles in 
aqueous solution [86, 87]. Altering the ratio of ligand to gold during synthesis affects the 
nanoparticle size, with a larger ligand molar ratio giving a smaller core size of AuNP [85, 88, 
89]. This method commonly uses a citrate salt in AuNP formation, as it acts as both a reducing 
agent and capping agent, stabilising the nanoparticles through electrostatic interactions between 
the lone pair on the oxygen and the metal surface [90]. The composition of this monolayer 
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coating the particles governs their chemical behaviour, whereas the core dictates their physical 
behaviour [91].  
The size and surface charge of AuNPs greatly effects the cellular interaction they partake in. 
For example it has been shown that negatively charged AuNPs are able to accumulate in 
different organs size dependently, with smaller nanoparticles tending to accumulate in higher 
quantities [92, 93].  In comparison with positively charged AuNPs, the positive particles 
accumulated less within organs, and show higher levels of toxicity [92]. This difference in 
toxicity is likely due to the interactions between AuNPs and the cell membrane. Mammalian 
cell membranes are typically negatively charged, and so cationic AuNPs have a greater affinity 
to cellular structures than anionic particles [80, 94]. As such, it is proposed that such particles 
are able to enter cells through direct diffusion, and induce cell death [94].  
 
1.5.2 Applications in Medicine 
AuNPs can be used in a range of medical applications including drug delivery, biosensing, 
therapeutics, and diagnostic imaging [76, 78, 92]. They have many unique characteristics which 
make them useful, including their electrical and optical properties [76].  
 
1.5.2.1 Drug Delivery 
AuNPs provide an ideal scaffold for the targeted delivery of drugs, as it has previously been 
shown that nanosystems can accumulate within cells at high concentrations, potentially 
enhancing bioavailability for targeted sites [78, 82, 96-98].  
Delivery systems can be formed through functionalising AuNP surfaces, to form a monolayer 
of drug molecules via thiol-linkers [82, 97]. The thiol groups are mobile and exchangeable on 
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the gold surface [99] and can stabilise AuNPs, resulting in air and thermally stable particles 
[85]. The binding mode of sulphur to gold is usually via a thiolate linkage (RS-) [100].  
Compared to free drugs, AuNPs have been shown to improve the biodistribution and solubility 
of drug molecules on binding, providing sustained and controlled release [82].  
For example, by tethering oxaliplatin to the surface of AuNPs via coordination of the platinum 
to carboxylate functionalised AuNPs, activity towards cancerous cells can be increased up to 
6-fold compared to the free drug [98]. This increase in potency was thought to have resulted 
from increased cellular uptake of the nanoparticles and hence the drug molecule [98]. 
Other potential drug compounds have successfully been delivered into cells with the use of 
AuNPs, including Pt(IV) prodrugs [101] which exhibit no cytotoxicity without being delivered 
into cell lines with the use of AuNPs and Ru(II) compounds [102] which can be released from 
the surface of AuNPs once within cells, to induce cell death through exposure to light . 
It is also possible to use AuNPs to deliver other biomolecules [97], including nucleic acids and 
proteins [103]. AuNPs are diverse nanocarriers which can hold large biomolecules without any 
hindrance to their function [77, 82]. The addition of DNA to AuNPs can also stabilise particles 
in solution [104] and enhance cellular uptake of the AuNPs [103-105]. It is possible to visualise 
such DNA/AuNP hybrids within cells [103] and can be characterised using circular dichroism 
[106]. 
Such research demonstrates how AuNPs can be utilised to increase drug potency, by ensuring 
drug molecules enter the cell as a result of proficient uptake of the nanoparticle vehicles. Due 
to the liable nature of the thiol linkers binding compounds to the nanoparticle surface, evidence 
suggests that the mode of action the drug molecules would take to induce cell death are not 
hindered as a result of being initially bound to a gold surface. As such, this is a stimulating area 
of research, which will be explored further within this thesis. 
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1.5.2.2 Gene Therapy 
Another use of AuNPs is in gene therapy, where they are able to act as non-viral system for 
gene delivery [77]. Viruses are a well-known medium for gene therapy; however they have 
safety concerns. Due to the number of barriers being encountered (blood-retinal, blood-brain 
etc.) the efficiency of non-viral gene delivery systems has been found to be poor [77, 82]. 
Nanoparticles, however, have been shown to cross these same barriers [77, 96] and due to their 
large surface to volume ratio, the payload to carrier ratio is optimised, making them an ideal 
alternative to viral treatments [82].  
 
1.5.2.3 Sensors 
Through selectively functionalising the surface of AuNPs with specific analytes, it is possible 
to utilise them as sensors. For example, by attaching a chelating ligand to the surface, lanthanide 
ions can be incorporated into the surface monolayer, resulting in phosphorescent nanoparticles 
which can detect the presence of other metal cations [107]. It has been shown that G-quadruplex 
functionalised particles can also be used as sensors, specifically detecting the presence of Pb2+ 
through changes in LSPR absorbance [108]. By immobilising organoruthenium(II) complexes 
onto AuNPs, an effective electrochemical system has been developed with the capability to 
detect iodate and nitrite in solution [109]. As such it is possible to dramatically alter the 
properties of AuNPs through their functionalisation, making them an adaptive platform to 
utilise. 
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1.5.3 Gold Nanoparticles in Cancer Treatment 
One area of research under continual development, is the use of AuNPs for treatment and 
detection of cancer. It has been shown that AuNPs have the great advantage of accumulating in 
cancerous cells, increasing cell stress and hindering cell growth [98, 110, 111]. Consequently, 
the use of AuNPs may potentially decrease toxicity levels seen with other treatment methods 
and are hoped to reduce limitations of dosage levels and drug resistance to certain cancer types. 
By tethering known drug molecules to AuNPs, it is possible for drug potency to be increased. 
The potent anticancer metallo-drug cisplatin has successfully been attached to AuNPs, in an 
attempt to enhance the selectivity of drug administration [112]. The functionalised 
nanoparticles were able to enter cancerous cells and exhibit enhanced in vitro anticancer 
activity, comparable to free cisplatin [112]. 
A cisplatin Pt(IV) prodrug, which is reduced to Pt(II) in cells to give active cisplatin has also 
been attached to AuNPs [113]. In its prodrug form, attached to AuNPs, it can successfully be 
delivered to prostate cancer, resulting in reduction of tumour size, at significantly reduced 
concentrations compared to the free drug [110]. By combining this technology with protein 
recognition on cell surfaces, delivery can be targeted specifically to prostate cancer cells, using 
the prostate specific membrane antigen, PSMA [113].  
 As well as prostate cancer, breast [114], lung [115] and head and neck cancer [110] have also 
been targeted by AuNP treatments, showing the diverse capability of these nanostructures. 
Early-phase clinical trials and single-dose pilot studies have been performed with AuNP 
therapies, showing some positive results, indicating that nanoparticles could be a treatment 
option in the future. 
AuNPs have been used in radiotherapy studies. Nanoparticles capped with glucose, function by 
accelerating the G1/S cell cycle phase, leaving cells in the G2/M phase, sensitising cancer cells 
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to radiotherapy. This treatment process has been found to be affective in prostate cancer cells 
[116]. 
AuNPs can also be used for the detection of cancer. The intense scattering of large AuNPs 
allows for imaging of cancerous cells. It is possible to label cancer cells using immunotargeting. 
By attaching particular antibodies to the AuNP surface, specific cells are targeted and detected 
[117]. 
Photothermal cancer therapy can also be used with AuNPs. Research has been carried out on 
nanoparticles which aggregate in acidic conditions, similar to those found in cancerous cells. 
As such, an absorbance shift to far-red and NIR is observed for the aggregate species, which 
can be exploited for photothermal therapy, demonstrated within in vivo models [118]. Breast 
cancer can be targeted via this treatment, using doxorubicin-loaded DNA wrapped gold 
nanorods [119]. It was found that cell apoptosis was induced by these nanosystems, and on laser 
irradiation, growth of primary breast tumours were reduced and distant metastasis inhibited 
[119]. By attaching prodrugs the surface of AuNPs, it is possible to photoactivate the drug 
molecule with near infrared light, so controlling the activity of the drug molecule until it has 
accumulated in cancerous cells as a result of being nanoparticle bound [120]. Such 
photothermal therapy can also be used with clusters of AuNPs, resulting in high ablation 
temperatures, shown to be effective towards breast cancer cell lines [121].  
By combing nanotechnology and supramolecular chemistry, it is therefore proposed to imitate 
some of the success described with respect to combining therapies to produce an effective 
anticancer agents, through delivery of supramolecular complexes to the desired cancerous cells. 
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1.5.4 Metal Compound Functionalised Nanoparticles 
As described with the platinum anticancer compounds oxaliplatin and cisplatin, inorganic 
molecules can be attached to the surface of nanoparticles via ligand displacement, to enhance 
drug delivery. Through the diverse nature of metallic complexes, it has also been possible to 
attach compounds to AuNPs with a variety of metal centres. For example, ruthenium 
compounds have successfully been attached to AuNPs in order to form luminescent particle for 
use in cellular imaging, Figure 26 [120]. Through attaching the complex via long alkyl chains, 
the luminescent properties of the complex remain unquenched by the nanoparticle surface, 
resulting in a system which can be used for imaging in cells [120]. 
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Figure 26: Structure of the ruthenium(II) polypyridyl complex developed in the Pikramenou 
group [125] 
 
Nickel [121] and iron complexes [122] have also be attached to AuNPs, for use as protein 
sensors and for the adsorption of microbes respectively. 
Nanoparticles can be used to hold lanthanide ions, for use in phosphorescent and fluorescence 
applications [107, 126-128]. Eu(III) complexes can be attached to AuNPs, to give water soluble 
luminescent particles [125]. When combined with peptide coated AuNPs, it is possible to 
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monitor peptide interactions from the red luminescent properties generated on lanthanide 
binding [126]. The advantage of using AuNPs is that a high concentration of material can be 
obtained without affecting emission properties. This produces efficient sensors for metal 
cations and is thought could be utilized in other areas such as in biomolecular and optoelectronic 
systems [107]. It has been shown therefore, that a range of metal complexes can be bound to 
the surface of AuNPs, without the properties of the compounds being jeopardised as a result. 
 
1.5.5 Reactions on Gold Nanoparticles 
To functionalise the surface of AuNPs, ligands on the surface can be displaced or reactions can 
be performed on the surface monolayer to attached desired functionality, Figure 27. The latter 
enables nanoparticles to be functionalised with a variety of compounds, not just those with a 
thiol/sulphur containing moiety. 
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Figure 27: Schematic representation of AuNPs being functionalised through ligand 
displacement and through reactions on the surface monolayer 
 
By attaching one reactant to the AuNP surface, reactions can be carried out on the monolayer 
using similar reaction conditions to those used without nanoparticles present. 
30 
 
For example, ‘click’ reactions have been performed on nanoparticles as a method to attach 
metal complexes to the surface [128] and as a method of detecting Cu2+ in solution, through the 
binding and aggregation of complementary crosslinking nanoparticles [129]. This versatile 
coupling technique has also been used to functionalise AuNPs for use as an electrochemical 
aptasensor [130]. Using this technique allowed for self-assembly of the nanoparticle coating, 
which was able to detect the presence of lysozyme [130]. 
Another coupling technique which has been used on AuNPs is peptide coupling [131]. The 
reaction between carboxylate coated nanoparticles and a peptide chain with amine terminal, 
allows for peptide structure to be easily bound to AuNPs [131]. Such systems are then able to 
go on to further react in reactions such as oxidative coupling [132], showing the diverse 
capabilities of functionalising AuNPs for a desired purpose. 
 
1.6 Summary and Thesis Aims 
Vast amounts of research has been conducted to understand the varying DNA structures and 
target sites for drug recognition. Previous research has been carried out to use supramolecular 
structures to target these biomolecules to induce a structural change, and the use of AuNPs has 
become profound in resent year as a method of directing the delivery of drug molecules and 
enhancing the potency of a range of drug molecules through a range of means. 
The work described in this thesis, aims to synthesise novel supramolecular helicate structures 
which are able to bind to a range of DNA structure to induce structural change. By adding new 
functionality to the known class of triple stranded iron helicate, it is aimed to enhance the 
kinking and coiling observed when interacting with ct-DNA, with a view to producing highly 
potent cytotoxic compounds. It is also aimed that these novel compounds will stabilise and 
encourage the formation of DNA 3WJs, and as a result, create compounds which can interact 
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with DNA via multiple binding modes, to enhance the ability of this class of compound to 
inhibit DNA replication. 
It is also aimed to combine this supramolecular chemistry with nanotechnology. Through the 
addition of new functionality to the supramolecular helicate [Fe2L3]4+ (L= C25H20N4), it is hoped 
to increase the DNA recognition and cytotoxicity properties of the complex. By then attaching 
this iron cylinder to the surface of gold nanoparticles, it is hoped to enhance interactions 
currently observed with DNA. By attaching multiple cylinders to the AuNP surface, it is 
hypothesised that higher concentrations of the compound can be used to treat cells and as such 
an increased number of interactions will occur with DNA, increasing potency of the complex. 
Ultimately the aim being to increase the kinking and coiling effect on binding with DNA, 
causing hindrance to replication, producing a potentially potent anticancer therapy.  
By attaching this class of compound to the surface of AuNPs it is also anticipated that this will 
direct delivery of the complex to cancerous cell lines. As AuNPs accumulate within cancerous 
cells, it is hoped that this too will increase the cytotoxic nature of the helicates, as well as 
minimise possible side effects from the compound entering non-cancerous cells. Ultimately, it 
will be aimed to synthesise multi-functionalised nanoparticles, containing a supramolecular 
drug molecule and targeting agent on the AuNP monolayer, in order to target delivery to a 
specific cancer cell line through targeted recognition.  
By exploring interactions of the developed helicates and AuNPs with DNA and cells, using the 
DNA binding techniques; circular dichroism, linear dichroism and polyacrylamide gel 
electrophoresis, and cell toxicity studies such as MTT assays, it is hoped to show that 
supramolecular chemistry and nanotechnology can be combined to produce exciting results 
within this area of research.  
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Chapter 2 
Novel Functionalised Triple Stranded Helicates 
 
2.1 Introduction and Aims 
Within the Hannon group, the iron supramolecular helicate [Fe2L3]4+ (L= C25H20N4), has been 
developed [1]. This cylindrical structure interacts with a variety of DNA structures, including 
the major groove of B-DNA and within the heart of three way junctions, 3WJ, to induce 
structural changes, Figure 1 [1-3]. Consequently, this complex is able to prevent DNA 
transactions in vitro [4], resulting in a potent apoptotic and cytostatic agent [5]. 
  
Figure 1: Structure of triple stranded supramolecular cylinder [Fe2(C25H20N4)3]Cl4 
[reproduced from ref1] (left); AFM images showing intra-molecular coiling induced by the 
cylinders [reproduced from ref1] (middle); Model structure of cylinder bound in the heart of a 
DNA three-way junction [reproduced from ref2] (right) 
 
Research has previously been carried out in an attempt to improve and tune the DNA binding 
interaction and cytotoxicity effects of this compound, through altering the ligand and metal 
centres of the helical structure [6-10].  
The ‘parent’ bis-pyridyl-imine ligand is formed through a 2:1 condensation reaction between 
2-pyridine carboxaldehyde and 4,4’-methylenedianiline. Three ligands are then coordinated 
around two metal centres, forming a triple stranded helicate [1]. The iron complex and ligand 
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are sensitive to a range of reaction conditions, specifically acidic environments. As such, most 
structural alterations are performed during ligand synthesis, commonly to the aldehyde, prior 
to forming the potentially labile imine bond by reaction with ‘spacer’ 4,4’-methylenedianiline. 
Reactions such as peptide coupling [6] and Suzuki couplings [7] have previously been used to 
add a range of functionality to the ligand, Figure 2. 
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R R
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Figure 2: Example modifications previously made to the ‘parent’ complex, 
[Fe2(C25H20N4)3]Cl4 [6-9] 
 
Inspired by the success of the iron helicate, and with a view to explore the capabilities of the 
supramolecular complex further, in this thesis click chemistry will be used as a novel method 
to functionalise the cylindrical structure. As such it is hoped to probe and potentially improve 
the DNA binding properties of this class of supramolecular helicate. Subsequently, it is hoped 
to establish an easy and reproducible method of attaching useful functionality to the helicate, 
whilst maintaining the solubility and cytotoxic nature of the compounds. 
Alongside this, the ability and viability of attaching such helicate structures to the surface of 
gold nanoparticles (AuNPs) will be investigated. By attaching many cylinders to the gold 
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surface, it is hoped numerous interactions will occur with DNA at one time, as occurs with 
multiple zinc fingers on a protein surface [11]. As such, it is anticipated that the intramolecular 
coiling effect previously seen when the helicate interacts with B-DNA [1], would be enhanced 
in confined areas of binding. Consequently, this may boost activity inhibiting DNA replication, 
resulting in potential a potent anticancer treatment.  
In order to achieve this, the parent cylinder [Fe2(LP)3]4+ (LP= C25H20N4), will be attached to 
AuNPs via sulfide linkers, as has previously been demonstrated for other inorganic drug 
molecules [12, 13]. Once synthesised, the cylinder coated nanoparticles will be tested for their 
binding effects on DNA (see Chapter 4). It is hoped that the cylinder is still able to bind to the 
major groove of DNA and, as many cylinders will be attached to the gold surface, it is 
anticipated enhanced intramolecular coiling will be induced, resulting in highly cytotoxic 
nanoparticles.  
 
2.2 Novel Functionalisation Route 
2.2.1 Click Chemistry 
In order to add new functionality to the triple stranded iron helicate, a simple coupling reaction 
was used to combine new moieties with the original bis-pyridyl-imine ligand. Click chemistry 
is a widely used reaction, where azide and alkyne functional groups are coupled together with 
the aid of a copper(I)-catalyst, Scheme 1. This 1,3-dipolar cycloaddition, results in the 
formation of a 1,4-disubstituted 1,2,3-triazole [14]. 
 
Scheme 1: General reaction scheme for a click reaction using a copper catalyst 
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Within the Hannon Group, the triple stranded iron helicate has previously been functionalised 
with alkyne groups, [Fe2(LALK)3][BF4]4,  Figure 3 [7]. 
 
 
 
Figure 3: Structure of LALK ligand present in complex, [Fe2(LALK)3][BF4]4, previously 
synthesised by Jenna Norman [7] 
 
This alkyne cylinder is known to be soluble in a variety of water miscible solvents, and has 
shown promising results in DNA binding studies [7]. It is simply synthesised using the 
commercially available iron source, Fe(BF4)2.6H2O, ‘spacer’ 4,4’-methylenedianaline and an 
aldehyde functionalised with an alkyne group, aldehyde 1. 
 
 It was therefore decided to investigate the reactivity of this compound, and explore whether 
click chemistry could be used as a novel way to functionalise the cylinder, Scheme 2. 
 
Scheme 2: Proposed cylinder functionalisation using click-chemistry 
 
2.2.2 Sulphur Functionality 
Due to the strong affinity of sulphur to gold [15] a large amount of research has previously been 
carried out with the connection of molecules to AuNPs via sulphur linkages [13, 16-18].  
Therefore it was decided to attach a sulphur moiety to the parent ligand (LP), in order to 
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subsequently attach it to the surface of AuNPs. With this addition to the parent cylinder, it was 
hoped that only the physical properties would be altered and not the ability of the complex to 
interact with DNA. 
As discussed, numerous coupling reactions have previously been utilised in the Hannon group 
to add functionality to the triple stranded iron helicate [6, 7]. In this instance, the novel use of 
click chemistry will be investigated, as well as peptide coupling which has previously been used 
to successfully functionalise the cylinder, whilst maintaining the characteristic DNA binding 
properties [6], in order to attach the desired sulphur moieties to the complex. 
 
2.2.2.1 Click Chemistry 
As demonstrated in section 2.2.1, an alkyne group has previously been attached to the ligand 
system [7], making this the ideal starting material for a click reaction. By reacting aldehyde 1 
with an azide, containing a sulphur moiety, it is proposed that sulphur can be incorporated into 
the ligand system as demonstrated in Scheme 3. The subsequent helicate structure will then 
contain six sulphur linkers able to interact with the surface of AuNPs. 
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Scheme 3: Proposed synthetic route to functionalise an iron helicate with a sulphur moiety by 
click chemistry 
 
2.2.2.2 Peptide Coupling  
Peptide coupling is a proven technique of adding functionality to these triple stranded helicates, 
enhancing the binding activity of the cylinders with DNA structures [6].  
 
Scheme 4: General peptide coupling reaction scheme, where X=activating group [19] 
 
The amide bond generated during this coupling reaction between an amine and acid, does not 
adversely affect complex solubility in water miscible solvents, or how the complex interacts 
with biological systems [6]. As such, it was theorised that this technique could be used to add 
sulphur functionality to the complex, Scheme 5, which may result in biologically active 
complexes, able to bind to AuNPs and be cytotoxic in nature. 
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Scheme 5: Proposed synthetic route to functionalise the iron helicate with a sulphur moiety by 
peptide coupling 
(a) I2, DMSO (b) Trimethyl orthoformate, formic acid, sulphuric acid (c) MeOH, 1M NaOH, 
(d) EDC, HOBt, DMF (e) 1M HCl, THF (f) 6 equiv. aldehyde, 3 equiv. 4,4’-methylenedianiline, 
2 equiv. FeCl2.4H2O. 
 
2.3 Iron Cylinder Synthesis 
2.3.1 Parent Cylinder 
The iron based supramolecular cylinder [Fe2(LP)3]4+ (LP= C25H20N4), is a triple stranded helicate 
with two Fe(II) centres. It is easily prepared from three bis-pyridyl-imine ligand strands being 
wrapped around the two metal centres. This ‘parent’ complex has previously been synthesised 
and characterised within the Hannon group, so the synthetic route followed was from the 
literature [1]. This complex was synthesised in order to compare results from DNA binding and 
cytotoxicity studies of new complexes with those of the original structure, Chapter 3. 
Firstly the ligand (LP) was formed in a high yielding reaction, 92 %, by mixing 4,4’-
methylenedianiline and 2-pyridine carboxaldehyde in 1:2 stoichiometry, Scheme 6. On 
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refluxing this ligand in a methanolic solution of iron(II) chloride, in 3:2 equivalents, a purple 
solution was formed, indicating that the iron complex had been synthesised. On purification of 
the product through counterion exchange from [Fe2(LP)3]Cl4 to [Fe2(LP)3][PF6]4 and isolation 
of the product through re-precipitation, [Fe2(LP)3]Cl4 was obtained as a purple solid (87 %). 
 
Scheme 6: Synthetic route for preparation of [Fe2(LP)3]Cl4, parent cylinder 
a) 0.5 equiv. 4,4’-methylenedianiline, EtOH, rt., 2 hr; b) FeCl2.4H2O, MeOH 
 
1H NMR of the complex, Figure 4, has a peak corresponding to the imine proton (Him), showing 
that the ligand has remained intact as the complex has been formed. On binding to the metal 
centres, the four phenyl protons in the ligand give rise to two broad peaks in the spectrum, due 
to rotation of the phenylene rings at room temperature. Only one peak is seen for the phenyl 
protons in the ligand 1H NMR, giving a strong indication that the complex has formed. 
 
 
Figure 4: 1H NMR (300 MHz, CD3OD, 298 K) of [Fe2(LP)3]Cl4 
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The compound is purple in colour, which is characteristic to this class of triple stranded helicate, 
due to metal-ligand charge transfer, MLCT, which occurs between the iron centres and the 
ligands. This generates a peak in the UV-Vis spectrum at 574 nm as a result of the MLCT, 
giving a strong indication that the triple stranded iron complex has formed. 
 
Figure 5: UV-Vis spectrum of the [Fe2(LP)3]Cl4 (17 µM, H2O) 
 
2.3.2 Alkyne Functionalisation 
As discussed in section 2.2.1, aldehyde 1 has previously been synthesised within the Hannon 
group [7]. This structure contains the key alkyne functionality to participate in a click reaction, 
and so was re-synthesised using the known route, to use in new experimental procedures. 
 
Scheme 7: Synthetic route for the preparation of aldehyde 1 
a) Pd(PPh3)2Cl2, CuI, PPh3, NEt3, THF, Trimethylsilylacetylene b) K2CO3, MeOH 
 
Aldehyde 1, was formed through a two-step reaction from 5-bromopyridine-2-carboxaldehyde, 
Scheme 7. The first step uses the palladium catalysed Sonogashira reaction, to replace the 
bromide with a protected alkyne at the C5 position. This is a high yielding reaction (85 %) 
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which is then followed by deprotection of the alkyne (H5) to give aldehyde 1 as a cream solid 
(75 %). 
 
Figure 6: 1H NMR (300 MHz, CDCl3, 298 K) of 5-ethynylpicolinaldehyde, aldehyde 1 
 
The additional functionality is placed at position five on the aromatic ring, as it has previously 
been found that this location maintains the binding activity of the subsequent iron helicates 
towards DNA [20, 21]. It is apparent that retaining the linear shape of the ‘cylinders’ is a key 
attribute to the binding action of this class of compound. 
By adding an alkyne moiety to the pyridine carboxaldehyde, six additional groups can be added 
to the subsequent triple stranded helicate structure via click chemistry. Functionalisation of 
aldehyde 1 will be carried out prior to ligand formation, ensuring that the imine bond formed 
during ligand synthesis is not affected by click chemistry reaction conditions. 
 
2.3.3 Click Reactions 
2.3.3.1 Ester Cylinder  
It was decided to investigate the reactivity of aldehyde 1 in a click reaction, by first using the 
simple, commercially available, cheap azide: 5-ethynylpicolinaldehyde. This was used to form 
aldehyde 2, and the subsequent iron helicate structure, Scheme 8. 
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Scheme 8: Synthetic route for the preparation of supramolecular helicate [Fe2(LEster)3]Cl4 via 
aldehyde 2 
 
The click reaction was performed in a 1:1 mixture of H2O/t-butanol with the Cu(I)- catalyst, 
formed in situ through reduction of copper(II) sulphate with sodium ascorbate. This 1,3-dipolar 
cycloaddition was a high yielding reaction (76 %) which produced the peach solid, aldehyde 2. 
There were many advantages to using click chemistry to incorporate functionality into this 
system. The key aldehyde moiety needed to form the imine bonds with the diamine ‘spacer’ of 
the ligand did not need protecting under these click chemistry conditions. As a result, this 
method of adding functionality is more efficient than those which have previously been used 
[6]. Aldehyde 2 was isolated by extraction from the H2O/t-butanol mixture with DCM and after 
washing with water, no further purification was required. The 1H NMR shows that the click 
reaction was successful, through the presence of a proton from the triazole ring, H7. Both the 
aromatic aldehyde, H6 and ester functionality H8+9 are present in the structure, Figure 7 (2D 
NMR in Appendix A.1.1). 
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Figure 7: 1H NMR (400 MHz, CDCl3, 298 K) of 2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-
triazol-1-yl)acetate: ester aldehyde 2, assignment based on 2D-NMR spectroscopy 
 
Aldehyde 2 was then used to form LEster in a 2:1 reaction with 4,4’-methylenedianiline (94 %). 
The two functionalised aldehydes bound to the ‘spacer’ group via imine bonds. The product of 
this reaction was a brown solid, isolated by filtration and purified with copious washing with 
MeOH.  
The ligand was only soluble in DMSO, which is known to breakdown these helicate complexes 
as it is able to coordinate to the iron centres, consequently the helicate was synthesised using a 
one-pot reaction from aldehyde 2 [7]. The chloride salt of the helicate was therefore synthesised 
in a 6:3:2 reaction mixture of aldehyde 2/4,4’-methylenedianiline/FeCl2.4H2O. The aldehyde 
and spacer were first stirred in MeOH followed by a methanolic solution of the Fe(II) source. 
On addition of the iron, the solution immediately started to turn from yellow to purple in colour, 
indicating that despite the ligand not being pre-formed, the helicate is a favourable 
conformation for the substituents to form. This complex was soluble in MeOH and so was 
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isolated by precipitation with diethyl ether and collected by filtration. Copious washing with 
diethyl ether yielded a purple solid (83 %).  
 
 
 
Figure 8: 1H NMR (300 MHz, CD3OD, 298 K) of [Fe2(LEster)3]Cl4, assignment based on 2D-
NMR spectroscopy 
 
The presence of the characteristic imine (H4), split phenyl (H2/3) and spacer (H1) protons in the 
1H NMR, Figure 8, at expected integrations and chemical shifts were found. The presence of 
ester functionality could be identified by peaks from H9+10, joined to the structure through the 
formation of a 1,4-disubstituted triazole, indicated by H8 (2D NMR in Appendix A.1.2).  
The distinctive deep purple colour of the product indicated that the triple stranded helicate had 
been formed. The expected MLCT absorption at 590 nm, gives the complex its colour and 
indicates that the triple stranded helicate has been synthesised, Figure 9. Through use of mass 
spectrometry, complex formation was confirmed by the presence of peaks at 519 m/z 
corresponding to the 4+ charged species [Fe2(LEster)3]4+ and at 698 m/z corresponding to the 3+ 
charged species [Fe2(LEster)3]3+ (Appendix A.1.2). 
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Figure 9: UV-Vis spectrum of the [Fe2(LEster)3]Cl4 (25 µM, MeOH) 
 
Click chemistry appeared to be a simple, efficient and high yielding method of functionalising 
the parent cylinder. This method was therefore used to functionalise the cylinder with functional 
groups which may enhance the DNA binding properties of the helicate. 
 
2.3.3.2 Piperidine Cylinder  
Piperidine structures have been found to interact with the phosphate backbone of B-DNA when 
protonated [22]. It was hypothesised that this interaction could potentially enhance the binding 
affinity observed between the iron helicate and DNA.  It was therefore attempted to attach this 
functionality to the cylinder via addition to the precursor aldehyde, with click chemistry, 
Scheme 9. 
 
Scheme 9: Synthetic route for the preparation of aldehyde 3 using click chemistry 
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1-(2-chloroethyl)piperidine hydrogenchloride was first converted into an azide using sodium 
azide, in an overnight reflux to give a yellow oil (91 %). This was then attached to the alkyne 
functionalised aldehyde 1, via a click reaction to produce aldehyde 3 as a yellow solid (59 %). 
As with the formation of aldehyde 2, catalytic quantities of CuSO4.5H2O and sodium ascorbate 
were used to form a Cu(I) catalyst in situ. A 1,4-disubstituted 1,2,3-triazole was formed through 
the reaction between stoichiometric quantities of the azide and alkyne. The reaction was 
complete after reacting at room temperature overnight, so no further purification was required 
after extraction of the product from the reaction mixture with DCM. The catalytic species were 
retained in the aqueous layer, making addition of the piperidine group easily achieved.  
 
      
 
 
Figure 10: 1H NMR (300 MHz, CDCl3, 298 K) of 5-(1-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-
triazol-4-yl)picolinaldehyde: piperidine aldehyde 3, assignment based on 2D-NMR 
spectroscopy 
 
Presence of the proton within the triazole ring (H7) and absence of the alkyne peak at 3.4 ppm 
in the 1H spectrum, Figure 10, indicate that the click reaction was successful. Both the aromatic 
species from the aldehyde >7.5 ppm and piperidine functionality <5.0 ppm are present in the 
resulting structure (2D NMR in Appendix A.1.3). 
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Aldehyde 3 was converted into the ligand via a 2:1 reaction with 4,4’-methylenedianiline (30 
%). On formation of the ligand, a cream solid precipitated out of methanolic solution, allowing 
for collection and purification by filtration and washing with excess methanol. 
 The triple stranded helicate was then synthesised in a 3:2 reaction of the ligand and FeCl2.4H2O 
(41 %), Scheme 10. The reaction was performed in EtOH, as it was known from the previous 
reaction step, that the ligand was insoluble in MeOH. The iron complex was formed at room 
temperature overnight, producing a purple compound which was partially soluble in EtOH. The 
product was isolated from the reaction mixture via precipitation with diethyl ether and collected 
by suction filtration. The yield of this reaction was less than that previously observed for 
complex formation, so it was attempted to synthesise this complex straight from aldehyde 3 
using the ‘one-pot’ method described in section 2.3.3.1. However, using this method gave rise 
to side products from the reaction, which could not be separated from the desired product. As 
a result, it was concluded that this technique could not be used to synthesise the piperidine 
helicate.         
Scheme 10: Synthetic route for the preparation of the piperidine functionalised iron cylinder, 
[Fe2(LPiperidine)3]Cl4 
 
Within the 1H NMR spectrum, Figure 11, characteristic imine (H2) and spacer (H7) protons, 
appear at expected integrations and chemical shifts. The fact that the phenyl protons (H1a/b) 
have split into two broad signals in the spectrum, highly indicates that the ligand is coordinated 
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to iron centres, since this effect is also seen with the parent ligand on helicate formation. The 
piperidine functionality could be identified from peaks corresponding to H10-12, linked to the 
aromatic structure through the formation of a 1,4-disubstituted triazole, indicated by H5 (2D-
NMR in Appendix A.1.4). 
 
 
 
 
 
Figure 11: 1H NMR (300 MHz, CD3OD, 298 K) of [Fe2(LPiperidine)3]Cl4, assignment based on 
2D-NMR spectroscopy 
 
The product formed from this reaction was a purple coloured compound, which strongly 
indicated that a triple stranded iron helicate was formed upon reaction of LPiperidine with an 
iron(II) source. UV-Vis spectroscopy, Figure 12, confirmed presence of the characteristic 
MLCT absorbance expected at 589 nm, showing that the metal is present within the resulting 
structure. Further analysis from mass spectrometry confirmed that the triple stranded iron 
complex was formed, through the presence of peaks at 577 m/z corresponding to the 4+ charged 
species [Fe2(LPiperidine)3]4+ and at 782 m/z corresponding to the 3+ charged species 
[Fe2(LPiperidine)3]Cl3+ (Appendix A.1.4). 
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Figure 12: UV-Vis spectrum of [Fe2(LPiperidine)3]Cl4 (25 µM, MeOH) 
 
Addition of piperidine functionality to the helicate complex, shows that click chemistry is an 
easy and reproducible method of functionalising this class of compound. The addition of a 
triazole ring to the ligand structure, does not dramatically affect the solubility properties of the 
complex. Both complexes functionalised through click chemistry were soluble in MeOH when 
in the chloride salt forms. Additional solubility in MeCN was also achieved by converting the 
counterion to PF6-. As such, these ‘clicked’ helicates are soluble in water miscible solvents, 
allowing studies into their DNA binding and cell toxicity to be performed (Chapter 3). 
 
2.3.3.3 Sulphur Functionalised Helicates for Gold Nanoparticle Attachment  
As described in section 2.1, an aim of this research is to attach sulphide linkers to the parent 
cylinder [Fe2(LP)3]4+ (LP= C25H20N4), in order to attach the helicate structure to AuNPs.  
Click reactions have been performed on the surface of AuNPs, by various research groups, as 
a means to detect polymers [23] and Cu(II) in solution [24]. 1-azidoundecan-11-thiol has been 
used to coat nanoparticles with azide functionality, to subsequently react with an alkyne moiety 
[24, 25]. It was therefore considered whether a cylinder structure might be attached to AuNPs 
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via a simple click reaction, between the alkyne functionalised cylinder, [Fe2(LALK)3][BF4]4 
Figure 3, and an azide coated nanoparticle.  
When the alkyne cylinder was tested for its stability under click reaction conditions, it was 
found that the helicate structure was not retained; indicated by loss of the purple colour, 
characteristic of the complex. This was most likely due to interference in metal coordination 
from the catalytic copper present in the reaction mixture.  
To circumvent this an alternative strategy was employed, where the sulphur moieties were 
attached by click reaction to the cylinder during ligand synthesis, with the formed cylinder then 
attached to the nanoparticle surface by thiol displacement (Chapter 4). 
  
2.3.3.3.1 Undecyl-thioacetate Cylinder 
As stated, 1-azidoundecan-11-thiol has previously been attached to AuNPs, functionalising 
them with azide which can subsequently participate in click reactions [24, 25]. Research 
indicates that having a long linker between the nanoparticle surface and bound substituent can 
be advantageous in maintaining desired properties of the bound compound [26, 27]. In this case, 
it will beneficial to have distance between the nanoparticle and cylinder, to ensure the iron 
complex is still able to interact and bind with DNA structures when nanoparticle bound. 
As such, it was proposed to synthesise a new cylinder with 1-azidoundecan-11-thiol as addition 
to the parent structure. Using the alkyne functionality on aldehyde 1, this sulphur linker can be 
clicked onto the ligand, to be incorporated into the helicate structure.  
Synthesis began with the formation of 1-azidoundecan-11-thioacetate from Br(CH2)11OH in a 
three step reaction, Scheme 11. 
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Scheme 11: Synthetic route of the protected thiol functionalised azide: 1-azidoundecan-11-
thioacetate 
 
The first reaction step introduced azide functionality into the compound, through nucleophilic 
substitution of the bromide, forming a yellow oil in stoichiometric quantities (100 %). The 
alcohol was then converted into a methyl sulfonate leaving group; in a high yielding reaction 
step, to give a pale yellow oil (98 %). Finally sulphur was introduced into the compound, 
through displacement of the methyl sulfonate group with a thioacetate (19 %). This step was 
low yielding as a result of multiple chromatography columns required to purify the compound. 
At this stage in the synthesis, the thiol was left protected with an acetate group, so as not to 
react in forthcoming reaction conditions, specifically with the copper catalyst present in the 
click reaction. 
This azide was then clicked onto aldehyde 1, so incorporating a sulphur moiety into the aromatic 
aldehyde structure, forming aldehyde 4, Scheme 12.  
 
Scheme 12: Preparation of aldehyde 4 via click reaction 
  
5-ethynylpicolinaldehyde was reacted with 1-azidoundecan-11-thioacetate in 1:1 ratio over six 
days. The click reaction was catalysed with a Cu(I) catalyst formed in situ from the reduction 
of CuSO4.5H2O with sodium ascorbate. On formation of aldehyde 4, the product precipitated 
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out of solution, so was collected by filtration and purified by washing with copious quantities 
of water, methanol and diethyl ether, to yield a light brown solid (189 mg, 94 %). 
 
 
 
 
Figure 13: 1H NMR (300 MHz, CDCl3, 298 K) of aldehyde 4, assignment based on 2D-NMR 
spectroscopy 
 
It was then attempted to convert aldehyde 4 into the subsequent ligand and triple stranded iron 
helicate, Scheme 13. 
Scheme 13: Preparation of ligand (LUndecyl) and cylinder ([Fe2(LUndecyl)3][ClO4]4 from 
aldehyde 4 
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On mixing aldehyde 4 with 4,4’-methylenedianiline overnight in a 2:1 ratio, a product 
precipitated out of methanolic solution, and so was collected by filtration and purified through 
washing with methanol and diethyl ether (52 %). However, this suspected ligand, LUndecyl, was 
highly insoluble, resulting in limited characterisation analysis being able to be performed. 
On reacting this solid with Fe(ClO4)2.7H2O, it was suspected an iron helicate was synthesised 
due to the purple solid formed. This reaction was low yielding (12 %) and required heating due 
to the insoluble nature of the ‘ligand’.  
Syntheses of the triple stranded helicate with chloride, hexafluorophosphate and 
tetrafluoroborate counterions were attempted, yet were unsuccessful, deemed from lack of 
colour change in the reaction mixture over time. Synthesis was also attempted using the ‘one-
pot’ method described in section 2.3.3.1, however this gave rise to a black insoluble solid which 
could not be analysed. Using the perchlorate counterion seemed to promote solubility, resulting 
in a purple solid which could be partially dissolved in MeOH. 
The 1H NMR was obtained for this compound, showing the expected ratio of peaks for the iron 
complex, suggesting it was formed during the reaction. However, the phenyl protons (HPha/b) 
do not appear as broad or shifted into different environments as previously witnessed with the 
iron complexes, possibly a result of insolubility in CD3OD. Due to the insoluble nature of the 
compound, full characterisation of the complex was not accomplished. 
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Figure 14: 1H NMR (300 MHz, CD3OD, 298 K) of [Fe2(LUndecyl)3][ClO4]4 
 
Consequently, likely due the aliphatic chain from the attached azide, the complex was highly 
insoluble in water miscible solvents, making it inappropriate for the desired application. When 
combined with ct-DNA in buffer solution, it immediately precipitated out of solution. As such 
it would not be possible to combine with AuNPs suspended in water or interact with cells in 
media without precipitating out of solution. As a result, synthesis of a more soluble complex 
was investigated. 
 
2.3.3.3.2 Thioacetate Cylinder 
In order to create a more water compatible complex, a polyethylene glycol, PEG, chain was 
used in the linker between the azide and sulphur moieties. Oxygen atoms within the PEG chains 
promote water solubility, due to the formation of hydrogen bonds [28]. 
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An azide was therefore synthesised which contained a PEG chain and sulphur containing 
moiety. This was achieved over three reaction steps to form S-(2-(2-(2-
azidoethoxy)ethoxy)ethyl) ethanethioate, Scheme 14.  
 A slightly shorter linker length was also used in an attempt to promote solubility, making the 
resulting iron complex slightly smaller and less bulky. 
 
Scheme 14: Preparation route of S-(2-(2-(2-azidoethoxy)ethoxy)ethyl) ethanethioate 
 
Firstly 2-(2-(2-chloroethoxy)ethoxy)ethan-1-ol was converted into an azide through 
substitution of the chloride using sodium azide. On refluxing overnight, conversion of the 
starting material was complete to yield a colourless oil (76 %). The alcohol was then converted 
into a methyl sulfonate leaving group; in a high yielding reaction step, to give a pale yellow oil 
(74 %). Finally, sulphur was introduced into the compound, through displacement of the methyl 
sulfonate group with a thioacetate. This overnight reaction requiring purification of the product 
by column chromatography, to yield a yellow/orange oil (93 %). The sulphur atom was kept 
protected for subsequent click reaction and complex formation steps, to avoid side reactions 
occurring between the thiol, copper catalyst and iron source. 
S-(2-(2-(2-azidoethoxy)ethoxy)ethyl) ethanethioate was then reacted with aldehyde 1 in a 
copper catalysed click reaction to produce aldehyde 5, Scheme 15. Stoichiometric quantities of 
the azide and alkyne were reacted overnight with a Cu(I) catalyst, formed in situ from reduction 
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of CuSO4.5H2O with sodium ascorbate. After purification by column chromatography, the 
product was obtained as a yellow solid (68 %). 
 
Scheme 15: Preparation of aldehyde 5 through a click reaction 
 
Presence of the proton produced from the newly formed triazole ring (H7) and absence of the 
alkyne peak at 3.4 ppm in the 1H spectrum, Figure 15, indicate the click reaction was successful. 
Aromatic protons from the aldehyde >8.0 ppm, as well as those from the PEG chain and 
thioacetate protons <5.0 ppm, were also present in the spectra (2D NMR in Appendix A.1.5). 
Through mass spectrometry and infra-red analysis, the structure was confirmed through the 
presence of signals corresponding to the aldehyde (2893 cm-1), carbonyl (1694 cm-1) and C-N 
(1354 cm-1) functionalities. 
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Figure 15: 1H NMR (400 MHz, CDCl3, 298 K) of S-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethoxy) ethyl) ethanethioate: aldehyde 5, assignment based on 2D-
NMR spectroscopy 
 
Aldehyde 5 was then converted to the ligand and iron complexes, Scheme 16. On reacting 
aldehyde 5 with 4,4’-methylenedianiline (spacer) in 2:1 stoichiometry, the ligand, LThioacetate, 
was formed and precipitated out of methanolic solution to form a pale brown solid (86 %). This 
was isolated by filtration and purified by washing with methanol and diethyl ether. This ligand 
was not very soluble in an alcohol solution, so formation of the cylinder was performed through 
a ‘one-pot’ reaction containing 6:3:2 aldehyde 5/4,4’-methylenedianiline/Fe(BF4)2.6H2O. The 
aldehyde and spacer were first stirred in MeOH followed by a methanolic solution of the iron 
source. On addition of Fe(II), the solution immediately started to turn purple and was left for 
the reaction to complete overnight. The product was partially soluble in MeOH, so was 
precipitated out of solution using diethyl ether, collected by filtration and washed with copious 
quantities of diethyl ether. The tetraborofluorate salt form of this complex was synthesised, as 
attempted synthesis using the more commonly used chloride or hexafluorophosphate salts, 
resulted in green, insoluble precipitates forming, thought to be either double stranded helicates 
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or polymer species. The tetraborofluorate product, [Fe2(LThioacetate)3][BF4]4 , was formed in  high 
yield (94 %) and was highly soluble in MeCN. 
Scheme 16: Preparation of the ligand (LThioacetate) and cylinder [Fe2(LThioacetate)3][BF4]4 from 
aldehyde 5 
 
The structure of the complex was confirmed through analysis.  
Presence of the characteristic imine (H2), split phenyl (H15/16) and spacer (H17) protons in the 
1H NMR, Figure 16, at expected integrations and chemical shifts indicated the presence of a 
cylinder species. The new side chain functionality could be identified from peaks corresponding 
to H8-14, linked to the aromatic structure through the formation of a 1,4-disubstituted triazole, 
indicated by H7. 
The presence of ester functionality could be identified by peaks from H9+10 (2D NMR in 
Appendix A.1.6).  
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Figure 16: 1H NMR (400 MHz, CD3CN, 298 K) of [Fe2(LThioacetate)3][BF4]4. Assignment based 
on 2D-NMR spectroscopy 
 
The distinct purple colour of the product indicated that the triple stranded helicate has been 
formed. Within the UV spectrum of the complex, Figure 17, there is a MLCT band at 589 nm 
which gives rise to this colour and shows that the metal is present within the resulting structure. 
Through used of mass spectrometry and elemental analysis, it was confirmed that the triple 
stranded iron complex was formed, through the presence of peaks at 696 m/z corresponding to 
the 4+ charged species [Fe2(LThioacetate)3]4+, 956 m/z corresponding to the 3+ charged species 
([Fe2(LThioacetate)3][BF4]3)3+ and at 1497 m/z corresponding to the 2+ charged species 
([Fe2(LThioacetate)3][BF4]2)2+ (Appendix A.1.6). 
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Figure 17: UV spectra of [Fe2(LThioacetate)3][BF4]4 (25 µM, MeCN) 
 
Through the use of click chemistry, a triple stranded iron helicate was synthesised, containing 
sulphur moieties. This thioacetate cylinder is soluble in water miscible solvents, and so can be 
analysed within DNA binding studies as to whether it can bind and manipulate different DNA 
structures and whether the complex is toxic towards cancer cell lines (Chapter 3). The iron 
helicate is functionalised with a sulphur containing moiety and as such, it can be investigated 
whether the structure binds to AuNPs, with the view to enhancing DNA binding and cell 
toxicity activity through directed delivery of the compound to cancerous cells (Chapter 4). 
 
2.3.4 Peptide Coupling Reactions 
Peptide coupling is a known method of adding functionality to the triple stranded iron helicates 
described, enhancing the binding activity of the cylinders with DNA [6]. This coupling method 
was therefore used to attach sulphur moieties to the ligand structure, in an attempt to produce a 
stable, water soluble complex able to interact with DNA and bind to AuNPs. 
 
2.3.4.1 Lipoic Acid Cylinder 
A common linker used to attach molecules to the surface of AuNPs is lipoic acid [16, 29, 30]. 
This compound contains two sulphur atoms capable of binding to a gold surface, so is the ideal 
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addition to a molecule. Lipoic acid also contains an acid group capable of participating in a 
peptide coupling reaction [19], so was subsequently added to the 2-pyridine carboxaldehyde 
structure used within ligand synthesis, Scheme 17.  
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Scheme 17: Synthesis scheme for formation of and reactions with aldehyde 6 
(a) I2, DMSO (b) Trimethyl orthoformate, formic acid, sulphuric acid (c) MeOH, 1M NaOH 
(d) CDI, CHCl3, ethylenediamine (e) EDC, HOBt, DMF (f) 1M HCl, THF. 
 
 
Synthesis began with commercially available methyl 6-methylnicotinate. The pyridine ring was 
functionalised at the C2 and C5 positions which are the sites of substitution for the designed 
ligand. 
An aldehyde was first introduced at the C2 position to allow binding of spacer, 4,4’-
methylenedianiline, during ligand formation. Through reacting the methyl group with iodine 
and DMSO, the key aldehyde functionality was produced, yielding a cream/yellow solid (37 
%). This was subsequently protected with an acetal group (50 %), ensuring that the C5 position 
could be functionalised in successive reaction steps, without the newly formed aldehyde being 
destroyed. The ester was then hydrolysed overnight to give an acid group (84 %), which could 
be utilised in a peptide coupling reaction. 
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(±)-α-Lipoic acid was first aminated with ethylenediamine in a peptide coupling reaction. This 
diamine linker allows for the sulphur moiety and pyridine carboxaldehyde to be combined, 
providing a long linker to separate the cylinder structure from the intended AuNP surface [26, 
27]. 
The acid group on the pyridine ring was then utilised in a peptide coupling reaction with this 
aminated lipoic acid, in a low yield (17 %). This poor yield was thought to be due to the 
aminated lipoic acid being only partially soluble in the reaction solvent and the fact that some 
product may have been lost through purification by column chromatography. 
This product was then converted to the desire aldehyde 6, via acid deprotection of the acetal 
over six days to give a cream solid (72 %).  
Presence of peaks corresponding to the amide protons (H5 and H8) in the 1H NMR, Figure 18, 
indicate that the peptide coupling reactions were successful. A peak corresponding to the 
aldehyde (H1) shows that deprotection was achieved, allowing for ligand synthesis to be 
conducted. Both, aromatic protons (H2-4) and lipoic acid functionality (H9-15) are present in the 
resulting structure.  
Figure 18: 1H NMR (300 MHz, CDCl3, 298 K) of aldehyde 6, assignment based on 2D-NMR 
spectroscopy 
 
Aldehyde 6 was converted into the ligand structure, LLipoic, via a 2:1 reaction with 4,4’-
methylenedianiline. This reaction formed an insoluble pale cream solid which was collected by 
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filtration (94 %). The solid product was attempted to be dissolved in a variety of solvents: 
CDCl3, CH3CN, H2O, CH3OH and DMSO, however despite sonication and being left for long 
periods of time in the various solvents, the compound did not dissolve into solution. As such, 
full analysis to characterise the structure could not be achieved. Yet due to the change in 
solubility and appearance of the product, it was concluded that aldehyde 6 had reacted with the 
dianiline to yield the desired ligand product. 
Due to the insoluble nature of LLipoic, the iron helicate, [Fe2(LLipoic)3][BF4]4, was synthesised 
using a ‘one-pot’ reaction where the ligand was formed in situ, Scheme 18. 
 
Scheme 18: Preparation of the lipoic acid cylinder [Fe2(LLipoic)3][BF4]4 from aldehyde 6, via 
ligand (LLipoic) 
 
Reaction of aldehyde 6/4,4’-methylenedianiline/Fe(BF4)4.6H2O in a 6:3:2 mixture yielded a 
blue/purple solid (71 %). On formation, this purple product precipitated out of ethanolic 
solution, so was isolated by filtration and washed with copious quantities of EtOH and diethyl 
ether. 
Again, this reaction formed a highly insoluble compound, meaning analytical data could not be 
obtained. The colour of the product was typical of a triple stranded iron helicate, indicating that 
the iron complex had formed. It was attempted to form the complex in different salt forms to 
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aid solubility. Yet, when using the Cl- and PF6- iron salts, the triple stranded helicates did not 
form under the same reaction conditions, indicated by the green precipitate.  
As a result, it was concluded that this sulphur functionalised cylinder would not be appropriate 
to bind to DNA structures or AuNPs due to its insolubility in water miscible solvents. Despite 
work previously performed using peptide coupling [6], it appeared that for the purpose of this 
project, ‘click’ functionalised cylinders gave the best results. 
 
2.4 Asymmetric Ligand Synthesis 
The aim of introducing sulphur into the ligand structure was to bind the subsequent helicates 
structures to AuNPs. Through the 2:1 reaction between the functionalised aldehyde and spacer 
compound 4,4’-methylenedianiline, both ends of the helicate become functionalised with 
sulphur and so can go on to bind to the gold surface. It was anticipated that this double 
functionalisation of the helicate may result in aggregation of the AuNPs on binding, as one 
cylinder molecule is capable of forming multiple interactions with nanoparticles [31]. As such, 
an asymmetrical ligand was attempted to be synthesised, with only one sulphur residue per 
ligand. 
 
2.4.1 Parent Half Ligand, LHalf 
Within the Hannon group a ‘half’ ligand has previously been developed [32], where the spacer 
molecule is functionalised, on only one side, Scheme 19. Addition of a pyridine ring, through 
an azo bond, leaves a free amine to react with an aldehyde, as in the formation of parent ligand. 
Preparation of this compound had previously been performed, but was replicated in order to 
further react with new aldehydes synthesised within this research.  
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Scheme 19: Preparation of half ligand, LHalf 
(a) N-chlorosuccinimide, dimethyl sulfilimine, sodium methoxide (b) m-chloroperoxybenzoic 
acid, DMSO, dimethyl sulfide (c) 4,4’-methylenedianiline (excess), glacial acetic acid 
 
Synthesis began with commercially available 2-aminopyridine, where a nitro group was 
introduced at the C2 position by a two-step process. Firstly a dimethyl sulfilimine group was 
formed (48 %) which was then oxidised with m-chloroperoxybenzoic acid to give the nitro 
moiety (31 %). Both products were purified by recrystallisaton, resulting in yellow crystals 
which were then reacted with to form the half ligand. 
Through using a 4:1 ratio of 4,4’-methylenedianaline : 2-nitrosopyridine, LHalf was formed. 
Using an excess of the spacer molecule, encouraged the half ligand to form, as opposed to the 
full ligand where both amine groups react to form azo bonds. It was attempted to purify the 
ligand by flash column chromatography, but this was unsuccessful as a result of the large excess 
of 4,4’-methylenedianaline being carried through with the product. Recrystallisation of the 
product was achieved from methanol giving an orange solid (22%). 
It was clear from the 1H NMR spectrum, Figure 19, that the symmetrical ligand was not formed 
as there is a peak relating to the unreacted amine (HNH2). The aromatic protons of the spacer 
have different chemical shifts, showing that they are in different environments. If the molecule 
was symmetrical, both aromatic rings would give the same NMR shifts. 
73 
 
 
Figure 19: 1H NMR (300 MHz, CDCl3, 298 K) of LHalf 
 
 
2.4.2 Asymmetric Lipoic Acid Ligand: LAsym-Lipoic 
It was attempted to react aldehyde 6 with this half ligand, in an attempt to synthesise asymmetric 
ligand, LAsym-Lipoic, Scheme 20. However, from past research within the Hannon group, it has 
been shown that it can be difficult to form the subsequent asymmetrical ligands from this half 
ligand [32]. 
 
Scheme 20: Preparation of asymmetric ligand LAsym-Lipoic 
 
Figure 20 shows 1H NMR spectra from the reaction mixture after four days, compared to the 
corresponding starting materials. After four days it was clear from TLC and NMR analysis that 
unreacted LHalf was still present within the reaction mixture, Figure 20. The reaction mixture 
did, however, show absence of the aldehyde peak above 10 ppm, indicating that some 
asymmetric ligand may have been synthesised. 
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Figure 20: Figure 19: 1H NMR (300 MHz, CDCl3, 298 K) of (a) reaction mixture after 4 days 
(b) LHalf  (c) aldehyde 6 
 
The impure ligand could not be purified by column chromatography due to the labile nature of 
the imine bond, so it was attempted to purify the reaction mixture through recrystallization, in 
order to identify compounds present. As such it became apparent that the aldehyde may have 
degraded over time, as only starting materials were present in the mass spectrum, with no peaks 
relating to the asymmetric product.  
Different reaction conditions were attempted in order to get the reaction to reach completion. 
Firstly glacial acetic acid was added to the reaction mixture which can catalyse imine formation. 
3Å molecular sieves were also added, to remove water made during imine bond formation, in 
an attempt to force the reaction to continue as per Le Chatelier's principle [33]. However, results 
from using these reaction conditions showed similar outcomes to that demonstrated by Figure 
20.  
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An insoluble dark orange/red product was also formed from the reaction, showing that some 
reaction had occurred between the yellow and orange starting materials, although due to the 
insoluble nature of this solid, analysis of this product was inconclusive. 
 
2.4.3 Asymmetric Thioacetate Ligand: LAsym-Thioacetate 
It was also attempted to form an asymmetric ligand with the thioacetate aldehyde 5. This too 
was functionalised with sulphur, yet was successfully converted into a ligand and triple stranded 
helicate structures, section 2.3.3.3.2. 
As with LAsym-Lipoic, aldehyde 5 was reacted in a 1:1 mixture with LHalf in the presence of glacial 
acetic acid and molecular sieves, Scheme 21. 
Scheme 21: Attempted preparation of LAsym-Thioacetate, from LHalf and aldehyde 5 
 
After a week of reacting, the reaction had not reached completion, despite the addition of excess 
aldehyde 5, and heating the reaction mixture to 50 ˚C. As such, it was not possible to isolate 
any asymmetric ligand which may have been formed. 
It was therefore concluded that synthesis an asymmetric ligand via this method was unlikely.  
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2.5 Ruthenium Cylinder Synthesis 
The ruthenium analogue of the original unsubstituted helicate described in section 2.1, has 
previously been synthesised within the Hannon group [34, 35]. It shows different chemical 
properties to the iron complex, exhibiting higher stability due to the inert Ru(II) centres. The 
ruthenium triple stranded helicate is however more difficult to synthesise than the iron complex, 
requiring high temperatures and increased reaction time to form. Microwave reactor synthesis 
can be used to synthesise this complex, allowing equivalent yields to be achieved within a 
fraction of the time required by conventional thermal heating chemistry techniques [36]. 
Consequently, it was also hoped to synthesise stable ruthenium structures, with the view to bind 
them with the surface of AuNPs. 
 
2.5.1 Parent Ruthenium Cylinder 
The parent ruthenium complex, [Ru2(LP)3]Cl4, has previously been synthesised [34-36], 
however it was hoped to replicate this synthesis in order to interact the complex with AuNPs, 
to investigate whether the DNA binding interactions currently observed could be enhanced. 
This ruthenium cylinder was synthesised from LP (synthesis described in section 2.3.1) over 
four hours in the microwave reactor with Ru(DMSO)4Cl2, Scheme 22. The reaction was 
performed at 200 ºC, forming a deep orange/red solution characteristic of ruthenium complexes. 
 
Scheme 22: Preparation of the parent ruthenium cylinder via microwave reactor synthesis 
 
In order to isolate the product from the reaction mixture, the ruthenium complexes were 
precipitated out of solution with a methanolic solution of ammonium hexafluorophosphate. 
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This converted the counterion to PF6-, allowing it to be collected by suction filtration and 
washed with copious quantities of H2O. 
The major products of this reaction, were the double stranded complex and polymer species. 
The desired triple stranded helicate was formed in very low yield, meaning purification and 
isolation of [Ru2(LP)3][PF6]4 was difficult. However, through multiple purification columns on 
alumina (20:1:1 MeCN/ H2O/KNO3(aq)) the complex was isolated as a dark orange solid (1 %). 
1H NMR spectrum of the complex, Figure 21, shows a corresponding spectra to that seen for 
the iron parent cylinder, Figure 4, having similar chemical shifts for the respective protons. For 
the ruthenium complex, the phenyl proton signals are less broad compared to the iron complex, 
likely due to the inert nature of the ruthenium centres the ligands are coordinated to. 
 
Figure 21: 1H NMR (300 MHz, CD3CN, 298 K) of [Ru2(LP)3][PF6]4 
 
The ruthenium complex, [Ru2(LP)3]Cl4, is dark orange in colour and so λmax appears at a lower 
wavelength within the UV-Vis spectrum, compared to the iron analogue, Figure 22.  
    
Figure 22: UV spectra of [Ru2(LP)3]Cl4 (10 µM, H2O) 
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2.5.2 Thioacetate Ruthenium Cylinder 
It was also attempted to form the ruthenium analogue of the thioacetate complex, synthesised 
in section 2.3.3.3.2. This new cylinder structure contains key sulphur moieties required to attach 
such a complex to AuNPs. Through forming the ruthenium analogue of the complex, it was 
hoped to form a highly stable, water soluble compound, capable of binding to AuNPs and 
maintain the DNA binding activity. 
As such, the ruthenium complex was synthesised within the microwave reactor, as per 
[Ru2(LP)3]Cl4. On reacting the thioacetate functionalised ligand, LThioacetate with Ru(DMSO)4Cl2 
a dark orange/red solution was formed, Scheme 23. As with the parent complex, the ruthenium 
species were precipitated out of solution using methanolic hexafluorophosphate, to give a dark 
orange solid.  
Scheme 23: Attempted preparation of [Ru2(LThioacetate)3]Cl4 within a microwave reactor 
 
It was attempted to purify the product of this reaction through column chromatography (on 
silica, alumina and cellulose) and through recrystallization, in an attempt to isolate the product 
from its impurities. However, this was to no avail as pure product was not attained. From 
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previous research, it was found that such metal complexes are retained on HPLC columns [36], 
so this technique was not used in an effort to purify the thioacetate ruthenium complex. 
The 1H NMR of the product, Figure 23, demonstrates that purification of the triple stranded 
helicate was not achieved. The peaks appear broad and undefined, indicating that some 
paramagnetic Ru(III) species are present in the sample solution, and as such the compound was 
not pure. This was also confirmed through mass spectrometry which showed peaks in the 
spectra corresponding to impurities.  
It did however appear that in the 1H NMR there were peaks corresponding to the ligand in 
solution, with aromatic protons and those corresponding to the thioacetate functionalised side 
chain of the compound being present. This indicates that the triple stranded complex may have 
formed in low yield, and that a more proficient purification technique is required to isolate the 
complex. 
 
Figure 23: 1H NMR (300 MHz, CD3CN, 298 K) of [Ru2(LThioacetate)3][PF6]4 
 
2.6 Conclusions 
In this chapter, the novel use of click chemistry was employed to end functionalise the bis-
pyridyl-imine ligand present within [Fe2(LP)3]4+ (LP= C25H20N4). These functionalised ligands 
were subsequently synthesised into triple stranded iron helicates.  
aromatic protons 
side chain protons 
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Three new Fe(II) cylinders were successfully functionalised with the use of click chemistry, 
outlined in section 2.2.1. Firstly an ester moiety was conjugated to the cylinder structure via 
four reaction steps, with an overall yield of 40 %.  This produced a purple compound, soluble 
in MeOH. Through addition of these ester groups, it is hoped that enhanced DNA binding 
activity will be observed compared to the parent cylinder, as a result of additional hydrogen 
bonding between oxygen atoms in the ester and the DNA structure. The complex is not water 
soluble, yet can be dissolved into a water miscible solvent, allowing for DNA binding and cell 
toxicity studies to be performed (Chapter 3). 
The second new complex formed was a piperidine functionalised cylinder. Through six 
reactions steps, piperidine groups were incorporated into the ligand structure, adding an 
additional six groups to the resulting helicate, with overall yield of 4 %. It is hoped that the 
additional piperidine moieties will interact with the backbone of DNA, resulting in a more 
potent anticancer agent as a result of inhibiting DNA replication on binding, compared to the 
parent cylinder. 
The third new complex synthesised was functionalised with thioacetate groups, over seven 
reaction steps, with an overall yield of 21 %. This cylinder is also soluble in a water miscible 
solvent, allowing for subsequent DNA binding and cell toxicity studies to be performed with it. 
Through addition of thioacetate terminated side chains, it is hoped that additional hydrogen 
bonding interactions will occur between the oxygen atoms in the side chains and DNA, resulting 
in an enhanced coiling and kinking effect to the DNA as compared with the parent complex 
(Chapter 3). This cylinder also contains sulphur moieties able to interact and functionalise the 
surface of AuNPs (Chapter 4). On addition to nanoparticles, it is anticipated that high 
concentrations of the cylinder compounds will interact with DNA, resulting in a structural 
change which may inhibit DNA replication and hence result in a potent anticancer therapy.  
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The iron and ruthenium centred parent cylinders were also synthesised within this chapter, in 
order to compare activity of the new complexes with DNA, cancer cell lines and AuNPs, with 
the original structures (Chapters 3 and 4). 
Other sulphur functionalised cylinders were also synthesised, however due to insolubility, it 
was not possible to fully characterise the structures and as a result, were deemed inappropriate 
structures for the purpose of this research. 
It was also attempted to form asymmetric ligands through use of the half ligand formerly 
synthesised within the Hannon group, section 2.4. However, due to an inability to purify the 
structures, it was not possible to fully characterise the compounds, or form the subsequent 
iron(II) helicate structures. 
As such the three new helicate structures functionalised via click chemistry will be investigated 
further, with respect to their DNA binding, cell toxicity and AuNP functionalising abilities 
(Chapters 3 and 4).  
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Chapter 3 
DNA and Cell Interactions of Helicate Complexes 
 
The triple stranded helicates developed within the Hannon group are known to interact with a 
variety of DNA structures. Due to the size, shape and charge of these complexes they have the 
capability to interact with the grooves found in duplex DNA as well as Y-shaped and three way 
junction (3WJ) structures present when DNA is in a replication state [1, 2]. More recently, the 
interactions with quadruplex DNA [3] have been investigated, showing that these cylindrical 
structures have the ability to bind to a diverse range of DNA structures.  
As a result of these interactions, the iron helicates are capable of inhibiting DNA replication 
and are able to do so in vitro [4]. Consequently, those helicates functionalised with additional 
groups described in Chapter 2 will in this chapter, be tested for DNA interactions and cell 
toxicity using a variety of techniques including; circular and linear dichroism, hoechst and 
ethidium bromide displacement studies, polyacrylamide gel electrophoresis and MTT assays.  
 
3.1 Circular Dichroism 
Circular dichroism (CD) is a technique used to investigate interactions between proteins or 
DNA with other molecules. Specifically it is the difference in absorption of left and right 
circularly polarised light [5]. CD is used for studying chiral molecules as they exhibit a CD 
signal, due to enantiomers absorbing left and right handed circularly polarised light in different 
quantities. In this case, calf thymus DNA (ct-DNA) will be investigated as a long ‘genomic’ 
DNA. Due to the helical structure of duplex DNA, it is a chiral species exhibiting a 
characteristic CD spectrum, Figure 1.  
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Figure 1: Spectra of 100 µM ct-DNA (B conformation) 
 
When an achiral ligand or a racemic mixture, in this case racemic iron(II) helicate complexes, 
bind to DNA, an induced CD signal (ICD) may arise. This ICD can be used to determine that a 
binding interaction has occurred as the compound is now in a fixed chiral environment, and can 
indicate what kind of interactions are occurring between the ligand and DNA [5]. 
Each chiral molecule has a characteristic CD spectrum, so any variation from this on addition 
of an achiral compound can be used to confirm that an interaction between the two species is 
occurring. Different forms of DNA structures have alternative CD spectra, Figure 2. As a result, 
it may be possible to determine how DNA is being manipulated on binding.  
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Figure 2: Characteristic CD spectrum for B, Z and A type DNA between 220-300 nm 
[reproduced from ref6] 
 
The cylinder compounds discussed in Chapter 2 are formed in a racemic mixture consisting of 
equal quantities of M and P enantiomers. These complexes do not therefore exhibit a CD signal 
unless the enantiomers are isolated [7]. 
It is known that these iron helicates are able to interact with B-DNA, resulting in induced 
chirality from the formation of complex-DNA conjugates. Figure 3 demonstrates this for the 
‘parent’ cylinder, [Fe2(LP)3]4+ (LP = C25H20N4), showing increasing interactions with ct-DNA, 
with an increasing ratio of DNA bases to complex in solution.  
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Figure 3: CD of 300 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of parent cylinder. Legend shows ct-DNA : [Fe2(LP)3]Cl4 
ratios  
 
Figure 3 shows results consistent with those previously observed by Meistrmann et al. [7]. The 
generation of ICD signals around 340 nm and 590 nm indicate that the cylinder is binding to 
ct-DNA, producing signals from the complex’s ligand and MLCT bands. These peaks increase 
in intensity with increased loading of the cylinder into a solution of ct-DNA maintained at 300 
µM.  
Below 300 nm there appear to be competing ICD signals from the DNA and complex, though 
the B-form signal is retained. Reduction in the magnitude of the characteristic B-DNA peaks 
does not necessarily mean that the form of DNA is being altered on addition of the complex, 
but may indicate that a structural change is occurring as a result of the cylinder interacting with 
ct-DNA.  
The same experiment was performed for each of the functionalised cylinder, to compare 
whether the additional functional groups altered how the helicates interact with DNA. 
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3.1.1 Stability in Solvent 
In order to test the click functionalised cylinders synthesised in Chapter 2, on their ability to 
interact with ct-DNA, it was necessary to make them soluble in an aqueous solution. Due to 
their high insolubility in water, it was necessary to mix these complexes with a water miscible 
organic solvent, MeOH or MeCN, to dissolve them into aqueous buffer. In doing so, it was 
important to ensure that the effects observed in the CD experiments, were caused from only the 
addition of the respective compounds and not the solvents they are being administered with. 
Solutions of MeOH and MeCN (20 % in water) corresponding to the levels used to dissolve the 
click cylinders in future experiments, where titrated into a solution of ct-DNA (100 µM) to 
observe if the organic solvent altered the ct-DNA characteristic spectra. 
 
Figure 4: CD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of MeOH. Legend shows ct-DNA:20 % MeOH solution ratios 
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Figure 5: CD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of MeCN. Legend shows ct-DNA:20 % MeCN solution ratios 
 
On addition of solutions of MeOH/H2O and MeCN/H2O, the maximum volumes of solvent 
added to the ct-DNA solutions was 6 %. The same ratios as those tested with the complex 
solutions were added, producing no observable alteration to the ct-DNA. As a result, it was 
concluded that any effects observed to the CD signal from addition of a complex solution to ct-
DNA, are the result of complex-DNA interactions, and not an effect of the experimental 
procedure. 
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3.1.2 Ester Cylinder, [Fe2(LEster)3]Cl4 
 
Figure 6: Structure of ligand present in [Fe2(LEster)3]Cl4 
 
CD experiments were performed with [Fe2(LEster)3]Cl4, Figure 6, to investigate whether this new 
complex interacted with ct-DNA, and how addition of the ester group by click chemistry may 
have altered the properties of such a complex. [Fe2(LEster)3]Cl4 does not give a CD signal itself 
as it exists as a racemic mixture, so this complex was titrated into a solution of ct-DNA to 
investigate if any interactions between the complex and DNA occur, evident from induced and 
altered signals. 
CD experiments were performed with a constant concentration of ct-DNA (300 µM) in aqueous 
buffer with increasing ratios of complex. The concentration of ct-DNA stated, corresponds to 
the concentration of bases in solution based on UV calculations using ɛ= 6600 moldm-3 at 260 
nm. Experiments were carried out in a 1 cm cuvette to allow for visualisation of weaker signals 
in the MLCT region (450-750 nm), Figure 7, and a 1 mm cuvette to avoid signal saturation 
between 200-450 nm, Figure 8, which can occur at high concentrations of the loaded complex. 
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Figure 7: CD of 300 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of ester cylinder. Legend shows ct-DNA: [Fe2(LEster)3]Cl4 
ratios. UV region (200-750 nm) was analysed in 1 cm cuvette 
Figure 8: CD of 300 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of ester cylinder. Legend shows ct-DNA: [Fe2(LEster)3]Cl4 
ratios. UV region (200-450 nm) was analysed in 0.1 cm cuvette  
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The CD spectra shows ICD signals being produced on increasing concentration of complex at 
301 nm (negative) and 322 nm (positive) which correspond to transitions from the ligand. There 
is also a weak peak observed at 615 nm, corresponding to the MLCT of the complex. These 
induced signals endorse that the iron(II) helicate is binding to ct-DNA. The intensity of the 
characteristic DNA bands are altered through addition of the complex, with both peaks between 
220-300 nm decreasing in magnitude on addition of complex. This change in spectra does not 
correspond to the characteristic CD signals of A or Z-DNA, Figure 2, therefore it is likely that 
a B-DNA conformation is retained, and that as a result of competing induced signals from the 
helicate and DNA, the intensity of the curve is reduced. 
These experiments are performed in an aqueous buffer solution to stabilise the DNA. It is 
therefore essential that complexes investigated using this technique, dissolve in such a solution. 
In order to dissolve [Fe2(LEster)3]Cl4 in aqueous solution, it was necessary to add 20 % MeOH 
to the starting complex solution, corresponding to a maximum of 6 % MeOH in the resulting 
DNA/complex mixtures. The effect of this level of organic solvents in such an experiment was 
shown to have no observable effect on the DNA, section 3.1.1 [8].  
However, when using the conditions stated above, the complex was seen to precipitate out of 
solution at high DNA/complex ratios. Consequently, the results shown in Figures 7 and 8 do 
not reflect the true complex concentrations interacting with DNA. A less concentrated solution 
of DNA (100 μM) was investigated, allowing for a lower concentration of complex to be added 
to the buffered solution, decreasing the chance of precipitation. Only a 1 cm path length was 
used to investigate the lower concentrated solutions, Figures 9 and 10. 
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Figure 9: CD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of ester cylinder. Legend shows ct-DNA: [Fe2(LEster)3]Cl4 
ratios. UV region (200-750 nm)  
 
Figure 10: CD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of ester cylinder. Legend shows ct-DNA: [Fe2(LEster)3]Cl4 
ratios. UV region (200-450 nm)  
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An ICD signal was observed at 326 nm, corresponding to that seen at higher concentration, 
corresponding to transitions from the ligand. The magnitude of this ICD peak is greater than 
that previously detected, with the induced peak being almost the same magnitude as the 
characteristic DNA peak at 274 nm. In the previous experiment, Figure 7, only half of this 
response was observed, corresponding to an increased water solubility of the complex at lower 
concentration, ensuring the complex is able to interact with the DNA. A weak ICD signal at 
613 nm is observed, corresponding to MLCT signals, suggesting that the iron cylinder is 
binding to ct-DNA.  
The characteristic B-conformation signals are altered on addition of the iron(II) helicate, as the 
binding sites become occupied by complex, the intensity of these peaks reduces in magnitude. 
The negative peak between 220-260 nm decreases in intensity, possibly resulting from 
competing ICD signals from the complex and DNA, or it may correspond to the DNA being 
manipulated to a more A-DNA like structure, Figure 2. A-DNA is more compact and shorter 
than B-DNA, with the base pairs no longer being perpendicular to the helical axis [9], an effect 
which could have occurred, consequence of the new complex binding to the ct-DNA.  
Figure 11: Intensity of ICD signals at 326 nm with increasing concentration of 
[Fe2(LEster)3]Cl4 for a) 100 µM ct-DNA (60:1-6:1) and b) 300 µM ct-DNA (60:1-6:1) 
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On addition of the ester cylinder to ct-DNA, ICD signals were observed at 326 nm, 
demonstrated by Figure 11. The magnitude of this ICD signal increased in intensity with 
increasing complex concentration. The curve of the graph, Figure 11 (a), starts to level off at 
10 µM [Fe2(LEster)3]Cl4 (10:1 DNA/complex). This implies that there is an interaction of ~5:1 
DNA base pairs/cylinders. This value reflects results observed for the parent cylinder, which is 
known to span over five base pairs [4]. The addition of ester groups to the cylinder would have 
increased the length of the complex by ~1 nm. It was therefore expected that the binding ratio 
observed would be lower than 5:1, through poor fit of the complex into ct-DNA binding sites. 
However, this result suggests that the binding constant of this complex is likely lower than that 
of the parent cylinder, allowing for a similar overall ratio. 
 
3.1.3 Piperidine Cylinder, [Fe2(LPiperidine)3]Cl4 
 
Figure 12: Structure of ligand in [Fe2(LPiperidine)3]Cl4 
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Due to results found in section 3.1.2, all future CD experiments were performed with 100 µM 
solutions of ct-DNA in order to get the maximum loading of complexes, whilst maintaining 
solubility in buffer solution. 
 
Figure 13: CD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of [Fe2(LPiperidine)3]Cl4. Legend shows ct-DNA:complex ratios. 
Maximum 4% MeOH in titration solution 
 
Consequence of using lower concentrations of ct-DNA and complex, no ICD signal were 
observed corresponding to the MLCT of the complex. Spectra are therefore shown up to 450 
nm, despite the full scan to 750 nm being run, as no useful information was gained from the 
higher wavelengths. 
The characteristic B-DNA conformation signals are again altered on addition of the iron(II) 
helicate, similar interactions as seen with the ester cylinder were observed for the piperidine 
complex. With increasing concentration of complex, the magnitude of the DNA signals 
decreased. This could be the result of competing ICD signals from the complex and DNA, or 
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could show the DNA structure being manipulated into a different form, shortening and 
distorting the DNA as a consequence of complex-DNA interactions. 
On addition of the piperidine complex to ct-DNA, a large ICD at 338 nm is generated, 
corresponding to transitions from the ligand. The relationship between intensity of the peak and 
complex concentration is shown in Figure 14. 
 
Figure 14: Intensity of ICD signal at 338 nm with increasing concentration of 
[Fe2(LPiperidine)3]Cl4 in 100 µM ct-DNA (60:1-4:1 ct-DNA/complex) 
 
The signal at 338 nm increases in magnitude until ~ 17 µM, indicating that there is an interaction 
of 3:1 base pairs to cylinders. This increase in binding ratio for the piperidine cylinder, may be 
the result of the piperidine functionality being able to interact with the DNA backbone [10]. If 
the cylinder is able to wrap around the DNA, an increased number of interactions may be able 
to occur. It may also suggest that the binding strength is weaker for this functionalised cylinder 
compared to the parent, meaning not every complex in solution is bound to the DNA.  
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3.1.4 Thioacetate Cylinder, [Fe2(LThioacetate)3][BF4]4 
 
Figure 15: Structure of ligand in [Fe2(LThioacetate)3][BF4]4 
 
Solubility of the thioacetate cylinder was different to that of the previously functionalised 
helicates. The longer chain, despite being a polyethylene glycol (PEG) chain makes the 
complex insoluble in water and MeOH. As a result, MeCN was used to solubilise the complex 
in water, to allow addition to buffered DNA solution. 
 
Figure 16: CD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of [Fe2(LThioacetate)3][BF4]4. Legend shows ct-DNA:complex 
ratios. Maximum 3% MeCN in titration solution 
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On addition of increasing concentrations of thioacetate cylinder, an ICD signal is observed at 
328 nm, corresponding to transitions from the ligand. This indicates that the cylinder is binding 
to the ct-DNA as chirality of the complex is induced. The characteristic B-DNA conformation 
signals are reduced in magnitude on addition of the iron(II) helicate. Both the negative and 
positive peaks between 220-300 nm decrease as binding sites become occupied through 
complex binding. This could be the result of competing ICD signals from the complex and 
DNA, or the result of the DNA being manipulated into another conformation as a result of the 
complex binding. 
 
Figure 17: Intensity of ICD signal at 328 nm with increasing concentration of 
[Fe2(LThioacetate)3][BF4]4 in 100 µM ct-DNA (60:1-4:1 ct-DNA/complex) 
 
With addition of increasing thioacetate cylinder concentrations to ct-DNA, an ICD signal is 
produced at 328 nm. When a complex/DNA ratios of 4:1 is reached, an increased binding 
affinity is observed, compared to the ester and piperidine cylinders. A linear relationship is 
observed between the ICD peak intensity and complex concentration, indicating that the ct-
DNA has a higher affinity of this complex than seen previously. Due to solubility issues, it was 
not possible to increase the ratio of DNA:complex tested by CD titration, and so from these 
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results it can be estimated that there is an ~5:3 interaction between DNA bases and thioacetate 
cylinder. This increased ratio compared with the ester and piperidine cylinders may be the result 
of many factors. For example: it could be due to the new sulphur containing moieties attached 
to the complex, the increased length of the linker arm between the triazole formed during the 
click reaction, the fact there are now oxygen atoms in the structure thanks to the PEG chain 
linker or that the binding constant is much lower than the other cylinders due to the increased 
size, so not all of the cylinders in solution are on the DNA. These modifications have resulted 
in slightly altered effects to those seen with the ester and piperidine functionalised cylinders, 
the interaction between this complex and DNA structures will be further investigated.  
 
3.2 Linear Dichroism 
Linear dichroism is a technique used to monitor the interactions between bio-macromolecules 
and ligands [5], as with circular dichroism, however this technique uses linearly polarised light. 
In this instance the interaction between iron(II) helicate complexes with ct-DNA are being 
investigated. 
Linear Dichroism uses an orientated sample to measure the difference between light absorbed 
which has been polarized parallel and perpendicular to the axis of orientation [5, 11].  
ܮܦ ൌ ܣ‖ െ 	ܣ ٣ [12] 
In order to orientate the sample, a couette cell, Figure 18 [13], is used which spins the sample 
solution, resulting in the sample becoming orientated at velocity. Small molecules are unable 
to be orientated in this manner, so no LD signal is observed. Due to the molecular size of ct-
DNA, it is possible to orientate in solution, producing a characteristic LD signal, Figure 19. 
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Figure 18: Schematic diagram of a Couette flow cell [reproduced from ref13] 
 
 
Figure 19:  Spectrum of 100 µM ct-DNA (B conformation) 
 
The iron(II) helicates being discussed are nanoscale, resulting in no LD signals, through lack 
of orientation. As ct-DNA has a characteristic LD spectrum, Figure 19, it is possible to monitor 
compounds interacting with the structure, by looking at alterations in the LD signal. These 
alterations can then be rationalised to identify what type of interaction and effect the addition 
of complexes can have on the orientation and hence structure of the DNA. 
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It is known through previous research that the parent cylinder is able to alter the structure of ct-
DNA on binding [7]. This activity was reproduced through titrating increasing concentrations 
of cylinder with a consistent concentration of ct-DNA, Figure 20. 
 
Figure 20: LD of 300 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of [Fe2(LP)3]Cl4. Legend shows ct-DNA:complex ratios 
 
On addition of increasing ratios of the parent cylinder, the characteristic DNA peaks at 210 nm 
and 260 nm continually decrease in magnitude. This is due to the cylinder binding in the major 
groove of the helical DNA, causing kinking and coiling of the structure [1]. As a result the DNA 
strands become less orientated in solution and hence the LD signal decreases.  
Induced LD signals (ILD) are also produced on addition of the complex. The growth of peaks 
at 212 nm and between 500-600 nm show that the cylinder is becoming orientated in solution. 
As a result it can be concluded that the complex is binding in a specific manner to the DNA [1]. 
As the ratio of ct-DNA:complex reaches above 4:1, these induced signals decrease, perhaps 
reflecting the reduced orientation of the DNA. 
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3.2.1 Stability of ct-DNA in Solvent 
As with the CD experiments performed in section 3.1, a portion of water miscible organic 
solvents had to be used in LD experiments in order to get the newly functionalised cylinder 
complexes into aqueous buffer solution. Equivalent portions of solvent were therefore tested 
with ct-DNA to ensure that the quantities used within these experiments had no effect on the 
DNA, and that changes in LD spectra observed were as a result of the complexes only. 
On addition of equivalent ratios of MeOH, as used in the experimental procedure, no observable 
alteration to the LD signal of ct-DNA was detected, Figure 21. Slight alterations to the intensity 
of the peaks appear, likely due to pipetting error. 
 
Figure 21: LD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of MeOH. Legend shows ct-DNA:20 % MeOH solution ratios 
 
When aliquots of MeCN/H2O were titrated into a solution of ct-DNA, Figure 22, little effect on 
the LD spectrum of ct-DNA was observed. The ratios analysed were equivalent to those used 
when analysing the thioacetate cylinder, indicating that any observations made from future 
experiments, were as a result of the functionalised cylinder and not due to the solvent it was 
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administered in. The intensity of the characteristic peak at 260 nm decreases slightly on addition 
of MeCN, likely due to pipetting error. 
 
Figure 22: LD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of MeCN. Legend shows ct-DNA:20 % MeCN solution ratios. 
 
3.2.2 Ester Cylinder 
 
 
 
As discussed in section 3.1.2, the functionalised helicates are not as water soluble as the parent 
cylinder, so experiments were performed at a lower concentration in order to get a high ratio of 
DNA:complex whilst avoiding precipitation. 
A solution of the ester cylinder was therefore titrated into the orientated sample of ct-DNA, 
keeping DNA concentration constant, producing results shown in Figure 23.  
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Figure 23: LD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of [Fe2(LEster)3]Cl4. Legend shows ct-DNA:complex ratios. 
Maximum 3% MeOH in titration solution 
 
On addition of increasing concentrations of ester cylinder, ILD peaks were produced at 312 nm 
and ~585 nm. These signals indicate that the cylinder becomes orientated when added to a 
solution of ct-DNA, impling that the helicate is binding in a specific manner to the DNA.  
The characteristic negative DNA peaks at 210 nm and 260 nm reduce in magnitude on addition 
of complex, mirroring that observed with the parent cylinder, Figure 20, suggesting that the ct-
DNA becomes less orientated in solution. 
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Figure 24: Normalised LD signal intensities at 260 nm for increasing ratios of parent 
[Fe2(LP)3]Cl4 and ester [Fe2(LEster)3]Cl4 cylinder complexes 
 
By comparing the reduction of LD signal at 260 nm on addition of the parent cylinder and ester 
functionalised cylinders at equivalent ratios of DNA:complex, Figure 24, it is observed that the 
ester cylinder kinks and coils the DNA to 89 % of what the parent cylinder is capable of. This 
interaction suggests that the ester cylinder has a similar binding mode to the parent cylinder, 
and due to the structure being slightly more bulky with additional ester groups, binding is 
slightly hindered, but still takes place, resulting in loss of orientation for the DNA.     
 
3.2.3 Piperidine Cylinder 
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Through titrating the piperidine cylinder into an orientated solution of ct-DNA, no ILD signals 
are observed. The absence of ILD signals does not necessarily mean that the cylinder is not 
orientated on addition to the DNA, but could be the result of conflicting spectroscopy, 
cancelling out signals or could be the result of the cylinder binding unspecifically onto the 
DNA. If the cylinder has multiple binding modes, not all will be orientated in one direction to 
produce an ILD. This could be the case, as the piperidine functionality is also known to have 
the ability to bind to the backbone of DNA [10]. 
 
Figure 25: LD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of [Fe2(LPiperidine)3]Cl4. Legend shows ct-DNA:complex ratios. 
Maximum 4% MeOH in titration solution 
 
It is apparent however, that through adding this complex to ct-DNA, the structure is altered 
with increasing DNA:complex ratios. The reduction in characteristic LD signals is observed, 
indicating that the DNA is becoming less orientated on addition of piperidine cylinder, Figure 
26. 
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Figure 26: Normalised LD signal intensities at 260 nm for increasing ratios of parent 
[Fe2(LP)3]Cl4 and piperidine [Fe2(LPiperidine)3]Cl4 complexes 
 
By comparing the reduction in magnitude of the characteristic LD signal at 260 nm for the 
parent and piperidine cylinders, it is apparent that the interactions with ct-DNA are different. 
At a ratio of 3:1 DNA:complex, 96 % equivalent of the ct-DNA has been kinked/coiled by the 
piperidine cylinder compared to the parent cylinder. This coiling effect is only observed 
however at high loading. Below a DNA:piperidine complex ratio of 6:1, the signal at 260 nm 
had only decreased in magnitude by 18 %, indicating that there are two binding modes for this 
complex. The initial binding mode has a small effect on the ct-DNA structure, potentially just 
bending the DNA, to reduce its orientation slightly. The second binding mode has a strong 
effect on the DNA structure, dramatically reducing orientation in solution, suggesting that the 
DNA becomes kinked and coiled in solution on binding to the piperidine functionalised 
cylinder. This multiple binding mode may also reiterate why no ILD signals are observed on 
addition of the complex. If the piperidine helicate is binding to multiple sites on the DNA, it 
may not be in high enough concentration, in a specific orientation to be detected. 
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3.2.4 Thioacetate Cylinder 
 
 
 
 
Through addition of the thioacetate cylinder to ct-DNA, numerous alterations to the 
characteristic DNA spectrum are observed, Figure 27. An ILD signal at 329 nm is produced, 
indicating that the cylinder is binding to ct-DNA in a specific manner to become orientated with 
the DNA. It was also found that the characteristic DNA peaks are not as greatly reduced in 
magnitude by addition of the thioacetate cylinder, as previously observed with the other 
functionalised helicates. 
 
Figure 27: LD of 100 μM ct-DNA in 20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
with increasing concentrations of [Fe2(LThioacetate)3][BF4]4. Legend shows ct-DNA:complex 
ratios. Maximum 3% MeCN in titration solution 
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With increasing concentration of the thioacetate cylinder with ct-DNA, the ILD peak intensity 
also increases, Figure 28. The peak does not appear to be reaching a maximum intensity for the 
concentrations analysed. This may suggest that higher loading of the complex could be achieved 
onto the DNA. However, due to the insolubility of complex in aqueous buffer, a ratio of 4:1 
DNA/complex was the highest ratio that could be achieved without over loading the DNA 
solution with MeCN. The presence of this peak does show that the cylinder is indeed binding 
to ct-DNA. 
 
Figure 28: Intensity of ILD at 329 nm with increasing [Fe2(LThioacetate)3][BF4]4 concentration 
 
Unlike with the ester and piperidine cylinders, the characteristic DNA peaks at 210 nm and 260 
nm are not greatly affected by addition of the thioacetate cylinder. Figure 29 shows that a 
gradual reduction of the peak at 260 nm is observed, but only 25 % of the orientation is lost 
compared to the parent cylinder. This indicates that the thioacetate cylinder may have a different 
binding mode on ct-DNA to the parent cylinder or that the binding constant is lower. This could 
be due to the large moieties added to the ligand making the cylinder too bulky to fit in the major 
groove of the DNA, or that the sulphur groups increase the affinity of the cylinder to an 
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alternative binding site on the DNA. As a result, it appears that the DNA is being bent or kinked 
on binding, and not dramatically coiled which would result in the DNA becoming disorientated 
in solution. These results indicate that the longer/more bulky the cylinder becomes, it appears 
to coil the DNA less effectively. 
 
Figure 29: Normalised LD signal intensities at 260 nm for increasing ratios of complex 
 
3.3 Stability 
It has been noted that adding functionality onto the ligand of the parent cylinder dramatically 
alters the complex solubility and stability [14]. As stated in the previous sections, a portion of 
organic solvent was needed in order to get the newly functionalised clicked compounds into 
aqueous solution to analyse their interactions with DNA. It has also been noted, by previous 
Hannon group members that on addition to ct-DNA, complex stability can increase on binding 
[8]. This was analysed for the click functionalised cylinders. 
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3.3.1 Cylinder Buffer Stability 
3.3.1.1 Parent Cylinder 
The parent cylinder is soluble in 100 % H2O and as shown by Figure 30, is stable in buffer 
solution also. A concentration of 17 µM was analysed as this is approximately the concentration 
of complex in a 6:1 solution ratio of ct-DNA (100 µM)/complex, which will be evaluated during 
this section. 
 
Figure 30: UV spectra of [Fe2(LP)3]Cl4 (17 µM) in 20 mM NaCl and 1 mM 
(CH3)2AsO2Na.3H2O (pH 6.8) over time/hrs 
 
3.3.1.2 Ester Cylinder 
The ester cylinder is not water soluble, so was dissolved in buffer with ~3 % MeOH, equivalent 
to that used within DNA binding experiments. After only five hours, the complex degraded in 
buffered solution, indicated by loss of the MLCT band at 590 nm which results in the triple 
stranded helicate structures having a purple colour, Figure 31. The loss of this peak therefore 
corresponds to the degradation of the cylinder structure into former counter parts. 
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Figure 31: UV spectra of [Fe2(LEster)3]Cl4 (17 µM) in 20 mM NaCl and 1 mM 
(CH3)2AsO2Na.3H2O (pH 6.8) over time/hrs 
 
3.3.1.3 Piperidine Cylinder 
The piperidine cylinder was dissolved in buffer with ~3 % MeOH, equivalent to that used within 
DNA binding experiments. After only five hours, the complex degraded in buffered solution, 
indicated by 70 % loss of the MLCT band at 589 nm, which gives the triple stranded helicate 
structures a purple colour, Figure 32. The loss of this peak therefore corresponds to the 
degradation of the cylinder structure into former counter parts. 
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Figure 32: UV spectra of [Fe2(LPiperidine)3]Cl4 (17 µM) in 20 mM NaCl and 1 mM 
(CH3)2AsO2Na.3H2O (pH 6.8) over time/hrs 
 
3.3.1.4 Thioacetate Cylinder 
The thioacetate cylinder is not water soluble, so was dissolved in buffer with ~3 % MeCN, 
equivalent to that used within DNA binding experiments. After six hours, the complex degraded 
in buffered solution, indicated by loss of the MLCT band at 589 nm which results in the triple 
stranded helicate structures having a purple colour, Figure 33. The loss of this peak therefore 
corresponds to the degradation of the cylinder structure into former counter parts. 
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Figure 33: UV spectra of [Fe2(LThioacetate)3][BF4]4 (17 µM) in 20 mM NaCl and 1 mM 
(CH3)2AsO2Na.3H2O (pH 6.8) over time/hrs 
 
3.3.2 Cylinder/DNA Stability 
3.3.2.1 Parent Cylinder 
The parent cylinder in the chloride salt form is water soluble and stable in aqueous solution for 
extended periods of time. The stability of a 6:1 ct-DNA:cylinder solution was tested for its 
stability by UV spectroscopy, Figure 34.  
The MLCT band from the UV-Vis spectrum of the complex, shows that the cylinder is in 
solution. A reduction in this peak over time would indicate that the complex is breaking down 
to the ligand and counterparts. It was therefore this region which was of interest, as it is solely 
produced from the complex without interference of the DNA spectrum. 
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Figure 34: UV-Vis spectra of 6:1 ct-DNA (100 µM) / [Fe2(LP)3]Cl4 over time/hr in 20 mM 
NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
 
By analysing the λmax of the MLCT band present at 574 nm, Figure 34, it is apparent that the 
parent cylinder is highly stable in aqueous solution, with 95 % retention in the intensity of the 
absorption band over 72 hours. This was therefore used as a comparison to assess the 
functionalised cylinders.  
It was hypothesised, that any potential degradation in the cylinders may be the result of one 
helicate enantiomer having a higher affinity to the DNA, which would result in degradation of 
the non-bound enantiomer. The enantiomers of the parent cylinder are known to have higher 
affinities for different binding sites [7], which could result in the compounds high stability in 
solution as it all interacts with DNA in some manner.  
If this were the case, over time a CD signal would be produced from the one enantiomer that 
was binding, Figure 35. Through recording the CD spectra of the same 6:1 ct-DNA/complex 
solution over time, enaniomeric selectivity and stability were analysed. 
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Figure 35: CD spectra of M-[Fe2L3]4+ (solid line) and P-[Fe2L3]4+ (dashed line) 
[reproduced from ref7] 
 
Due to the high stability of the parent cylinder, it was expected that there would be no alteration 
of the CD spectra over time. This was largely true, Figure 36, however a reduction in signal at 
323 nm was observed. This slight shift in the spectra could be result of the 5 % degraded species 
in solution, or an increased interaction between the cylinder and ct-DNA when left for an 
extended period of time. 
 
Figure 36: CD spectra of 6:1 ct-DNA (100 µM) / [Fe2(LP)3]Cl4 over time/hrs in 20 mM NaCl 
and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
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3.3.2.2 Ester Cylinder 
On analysing the UV absorbance of the MLCT band present in the characteristic UV spectrum 
of the ester cylinder, it is possible to identify the relative stability of the compound in the 
presence of ct-DNA. This area of the UV spectrum, 500-800 nm, is not affected by the UV 
spectrum of ct-DNA; hence any alteration in this peak will correspond to the cylinder only. It 
is apparent that the ester cylinder is not as stable as the parent in aqueous solution, through 
reduction of the signal in this region, Figure 34.  
 
Figure 37: UV-Vis spectra of 6:1 ct-DNA (100 µM) / [Fe2(LEster)3]Cl4 over time/hrs in 20 mM 
NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
 
The intensity of λmax, at 590 nm decreases in magnitude over time, Figure 37. Compared to 
the 95 % of parent cylinder intact after 72 hours, only 60 % of the ester cylinder is still in its 
helicate formation after the same period of time.  After 17 hours, 94 % of the cylinder is still 
intact however, showing that results from the CD and LD experiments, shown in sections 3.1.2 
and 3.2.2, will be the effects of the intact cylinder, rather than any degraded species as the 
titration experiments were performed within this time. It also shows that stability of the complex 
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has been greatly increased on interaction with ct-DNA, compared to the complex in just 
buffered solution, section 3.3.1.2. 
As a result of 40 % of the ester complex breaking down over 72 hours, it was investigated 
whether this was the result of instability of one enantiomer, due to lack of interaction with ct-
DNA.  
Figure 38 shows CD spectra of the same solution over 72 hours, showing changes of peak 
intensities between 280-330 nm and the evolution of peaks at 236 nm and between 500-650 
nm. These slight changes in the spectra over time correspond to an M enantiomer spectrum 
becoming more apparent, Figure 35 [7]. This suggests that the M enantiomer of the ester 
cylinder has a higher affinity to ct-DNA than the P, resulting in P degrading over time as not 
stabilised by the DNA structure. Consequently, with time a larger proportion of M enantiomer 
becomes present in the solution mixture and a CD signal for the cylinder is observed. It was not 
possible to isolate the M and P enantiomers of the ester cylinder, and so CD spectra could not 
be obtained of the pure samples. Consequently it was not possible to quantify the amount of 
enantiomer created during this experiment. 
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Figure 38: CD spectra of 6:1 ct-DNA (100 µM) / [Fe2(LEster)3]Cl4 over time/hrs in 20 mM 
NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
 
3.3.2.3 Piperidine Cylinder 
Analysis of piperidine cylinder stability on binding to ct-DNA was also analysed through the 
measurement of the UV absorbance between 500-800 nm, over a 72 hour period. It is apparent 
that the piperidine cylinder is not as stable as the parent in aqueous solution, indicated by the 
decreased magnitude of λmax, at 589 nm over time, Figure 39.  
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Figure 39: UV-Vis spectra of 6:1 ct-DNA (100 µM) / [Fe2(LPiperidine)3]Cl4 over time/hrs in 20 
mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
 
Compared to the 95 % of parent cylinder being intact after 72 hours, only 64 % of the piperidine 
cylinder remains in solution after the same period of time.  This degradation occurs gradually 
over the three days, apparent by the shallow gradient of the curve. After 17 hours, 96 % of the 
cylinder was still intact, showing that results from the CD and LD experiments, shown in 
sections 3.1.3 and 3.2.3, will be the effects of the intact piperidine complex, rather than any 
degraded species, as the titration experiments are performed within this time. It also shows that 
on interaction ct-DNA, the stability of the complex is greatly increased compared to that 
observed in section 3.3.1.3. 
As 35 % of the piperidine complex degraded over 72 hours, it was investigated whether this 
was the result of one enantiomer being unstable, due to lack of interaction with the ct-DNA. 
Figure 40 shows little alteration in the CD spectrum over time, with no detectable ICD signals 
being produced, suggesting that degradation is equal for both enantiomers, and neither has a 
higher affinity to ct-DNA. 
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Figure 40: CD spectra of 6:1 ct-DNA (100 µM) / [Fe2(LPiperidine)3]Cl4 over time/hrs in 20 mM 
NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
 
3.3.2.4 Thioacetate Cylinder 
When the stability of the thioacetate functionalised cylinder was monitored by UV-Vis 
spectroscopy, Figure 41, it appeared that a large portion of the cylinder quickly degraded with 
time. By evaluating the λmax intensity at 589 nm of the MLCT signal, a large decrease in 
absorbance was observed within 24 hours and then the degradation of the complex declined 
slowly to an almost steady state. After 24 hours almost 50 % of the MLCT signal had been lost. 
After a further two days, 37 %  remained in solution, indicating that those cylinders coordinated 
to the DNA structure are stabilised.  
Due to the increased size of the thioacetate cylinder compared to the parent, the complex may 
not be able to bind as strongly to DNA due to steric hindrance. Consequently less complex (~40 
%) may only be able to bind to the DNA, resulting in the dramatic loss in complex stability 
after a short period of time and then the steady levels of stability thereafter. 
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Figure 41: UV-Vis spectra of 6:1 ct-DNA (100 µM) / [Fe2(LThioacetate)3][BF4]4 over time/hrs in 
20 mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
 
CD spectra were then taken on an equivalent solution of ct-DNA and thioacetate cylinder over 
a period of 72 hours, Figure 42. The CD spectra does not greatly alter with time, however there 
are slight increases in peak intensities at 243 nm and 282 nm. This may be the result of increased 
interactions between ct-DNA and ligand which occur in solution as a result of the degraded 
cylinder. Small additional peaks between 500-650 nm were detected, which would suggest the 
evolution of one enantiomer with time. This change in spectra comparable to the ester cylinder, 
indicating that the M enantiomer has a slightly higher binding affinity to the DNA, making it 
more stable over time compared with the degrading P enantiomer.  
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Figure 42: CD spectra of 6:1 ct-DNA (100 µM) / [Fe2(LThioacetate)3][BF4]4 over time/hrs in 20 
mM NaCl and 1 mM (CH3)2AsO2Na.3H2O (pH 6.8) 
 
3.4 DNA Melting Experiment 
On binding to DNA, it is known that compounds are able to stabilise the overall DNA structure 
resulting in more energy needed to disrupt and unwind the double stranded helix [15]. This 
change in the energy it takes to ‘melt’ DNA gives another indication that the compound is 
indeed binding to DNA.  Solutions of ct-DNA (100 µM) containing each complex were tested 
to see whether they stabilised the structure of DNA on binding, Figure 43. 6:1 DNA/complex 
solutions were heated from 25-100 °C. 
On heating each solution, the intensity of absorbance for the characteristic DNA peak at 260 
nm was measured. This peak corresponds to the bases present in the DNA structure [16]. On 
melting the ct-DNA, the double helix becomes unwound, resulting in unpaired bases and an 
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increase in the peak intensity at 260 nm. As such, if the temperature for unwinding increases, 
the DNA is held in the helical structure due to increased stability. 
 
Figure 43: Normalised DNA melting curves for 6:1 ct-DNA (100 µM) /complex solutions at 
260 nm 
 
The melting temperature (Tm) of DNA can be calculated from the point where half of the helical 
structure has unravelled, hence the mid-point of the gradient to each curve. These values were 
calculated for DNA in the presence of each complex, Figure 44. From these values it can be 
concluded that the parent cylinder stabilises the DNA structure, whereas the functionalised 
helicates reduce stability of the DNA to varying degrees. 
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Figure 44: Tm values calculated for each 6:1, ct-DNA (100 µM) / cylinder solution  
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As stated, these values are gained from measuring the UV-Vis signal at 260 nm, which is a 
characteristic λmax for ct-DNA. However, this region in the UV spectra is also where peaks 
from the ligands are found in the spectra on the cylinders alone. This is the reason for differing 
absorbance’s present at the start of the experiments, despite using the same concentrations of 
DNA in each sample. It was thought that the results shown in Figures 43 and 44 may not show 
just the stability of DNA, but also that of the complexes. As the solutions are heated, it is likely 
that the functionalised helicates become unstable and so degrade into the ligand and iron species 
in solution. As a result, if free ligand were in solution, the UV-Vis absorbance at 260 nm would 
increase, and so may not be just the result of ss-DNA as assumed above.  
The stability of the DNA/complex solutions were further investigated at elevated temperatures, 
by observing the UV region around the MLCT band, analysing if the iron complex remains 
intact on heating, Figure 45. 
As temperature increased, the intensity of the MLCT bands decreased for each of the iron 
helicates, with no complex being present over 75 ºC, apart from the parent complex. These 
results strongly correlate to the apparent Tm of each of the cylinders, with the least stable 
cylinder, according to the rate at which the λmax at 589 nm decreases, having the lowest Tm. It 
can therefore be concluded that the stability of the DNA/helicate complexes cannot solely be 
evaluated using UV melting techniques as results are ambiguous due to cylinder degradation 
and ligand absorbance overlapping DNA UV signals.   
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Figure 45: λmax of MLCT band at 589/590 nm with increased temperature 
 
3.5 Ethidium Bromide Displacement  
Ethidium bromide, Figure 46, is a cationic dye which intercalates with DNA resulting in a 
DNA:EB complex which is fluorescent [17]. Displacement of this fluorescent tag by another 
complex can be used to investigate the intercalating nature of compounds. When ethidium 
bromide becomes displaced from DNA, it no longer fluoresces; hence the quenching of this 
system by addition of the click functionalised cylinders was investigated. It is known that the 
parent cylinder is able to displace this intercalator [18]; hence all results will be compared to 
the original helicate.  
 
Figure 46: Structure of Ethidium Bromide 
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a) Parent Cylinder [Fe2(LP)3]Cl4  b) Ester Cylinder [Fe2(LEster)3]Cl4 
 
 
 
 
 
 
c) Piperidine Cylinder    
  
c) Piperidine Cylinder [Fe2(LPiperidine)3]Cl4  d) Thioacetate Cylinder [Fe2(LThioacetate)3][BF4]4 
 
 
 
 
 
 
 
e) Buffer control 
 
 
 
 
 
Figure 47: Ethidium Bromide displacement curves, displaying emission signal between 500-
750 nm with increasing ethidium bromide (15 µM) : complex ratios of 200:1 to 1:1 
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On addition of each complex to a solution containing DNA:EB, the fluorescent signal 
decreased. Whilst titrating in the cylinder solutions, aliquots of DNA:EB were also added to 
the solution in order to maintain the concentration of ethidium bromide, so any effects on the 
emission signal would be the result of adding the complex solution. A solution of buffer was 
also added to the ethidium bromide solution, to determine whether the effects observing were 
due to the photo-bleaching of the fluorescent tag on repeated exposure to light during the scans. 
The intensities of λmax over increasing concentrations of ethidium bromide:complex were 
therefore compared to determine the intercalating ability of the new iron helicates, Figure 48. 
As stated, the parent cylinder is known to displace ethidium bromide from ct-DNA and 
intercalate into the structure. This is observed from the reduction in emission signal from the 
solution on addition of the parent compound. A gradual decrease is observed, with 43 % of the 
original emission signal being retained at a 1:1 ratio of EB:parent cylinder.  
When only buffer was added to the same solution, the emission signal decreased during the 
experiment. This indicates that there was some photobleaching of the fluorescent solution as a 
result of exposure to light on addition of the titration solutions. 
On addition of the ester cylinder, [Fe2(LEster)3]Cl4, 50 % of the emission signal was lost at 1:1 
ratio of EB:complex. This complex exhibits similar activity to the parent cylinder, indicating 
that on addition of the small ester groups, the chemical properties of this class of compound 
were not dramatically altered, allowing for intercalation into the DNA structure to still occur. 
The cylinders functionalised with piperidine and thioacetate moieties showed little reduction of 
emission at ratios under 40:1 EB:complex. At higher ratios, a decrease in emission was 
observed to ~60 % of the original emission signal. This decrease in intercalating ability may be 
the result of the additional functionality on the cylinders, making the structures too bulky to be 
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able to intercalate into DNA. It can be concluded however, that these new complexes are less 
proficient intercalators than ethidium bromide.    
 
Figure 48: Normalised λmax intensities at 619 nm for DNA:EtBr/complex solutions with 
increasing concentration of complex 
 
3.6 Hoechst Displacement 
Hoechst compounds are blue fluorescent dyes which bind to the minor groove of DNA [19]. 
They are commonly used in microscopy as nucleus dyes, and can be used to investigate whether 
compounds are minor groove binders. As a result, it was investigated whether the iron helicate 
complexes are able to bind to DNA via the minor groove, through measuring displacement of 
hoechst from a solution of DNA. When Hoechst 33258, Figure 49, is bound to DNA, it has a 
fluorescent signal [20]. When the hoechst is displaced from the minor groove, the compound is 
no longer fluorescent. Hence, by titrating compounds into a solution of hoechst and DNA, it 
can be investigated whether these new iron complex are able to bind in this manner, Figure 50. 
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Figure 49: Structure of Hoechst 33258 
 
It has previously been shown that the parent cylinder is able to displace hoechst 33258 from ct-
DNA, resulting in loss of fluorescence from the dye. This shows that the cylinder is capable of 
using the minor groove as a binding site, despite the major groove being the preferred site of 
binding [7]. This may enlighten to why the parent cylinder is able to bind to, and affect the 
structure of ct-DNA to such a high degree, consequence of the ability to bind to multiple binding 
sites.  
The displacement of hoechst 33258 was therefore investigated with the three iron helicate 
complexes previously discussed. They were each titrated into a solution of hoechst/ct-DNA, 
and the emission signal measure, with increasing ratios of complex:hoechst, Figure 50.  
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a) Parent Cylinder [Fe2(LP)3]Cl4                    b)  Ester Cylinder [Fe2(LEster)3]Cl4 
 
c)   Piperidine Cylinder [Fe2(LPiperidine)3]Cl4    d) Thioacetate Cylinder [Fe2(LThioacetate)3][BF4]4 
 
e) Buffer Control 
 
Figure 50: Hoechst displacement curves, legend shows hoechst (1.5 µM):complex ratios 
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On addition of each complex to the solution of hoechst coordinated ct-DNA, a reduction in 
emission signal was witnessed. This was compared to just the addition of buffer to the solution, 
as it is known that hoechst dyes quench easily when exposed to light [20]. On comparison of 
the λmax intensities, with increasing hoechst:complex ratios, Figure 51, it is apparent that none 
of the compounds have a large effect on the fluorescence at low concentrations. Only when the 
ratio reaches ˃10:1 does displacement occur. This indicates that below these concentrations, 
the cylinders are not a strong enough minor groove binder in comparison of hoechst for it to be 
displaced. This reiterates the fact that the parent cylinders preferred binding site is the major 
groove and not the minor. 
 
Figure 51: Normalised λmax intensities for DNA:hoechst/complex solutions with increasing 
concentration of complex 
 
On closer examination of these results, Figure 49, the parent cylinder displaces the most hoechst 
when a 1:1 concentration is reached. This resulted in virtually no emission signal being 
recorded, indicating that all hoechst had been displaced under these conditions. It appears that 
the ester and piperidine functionalised cylinders had no effect on the hoechst fluorescence and 
the pattern of the curves match that of the buffer experiment. This result may reflect those seen 
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during CD experiment, sections 3.1.1 and 3.1.2. It was concluded that the ester cylinder 
interacted similarly to the parent cylinder and so is likely to bind to the major groove. And the 
piperidine cylinder was expected to also bind in the major groove at high concentrations, so any 
binding of this cylinder at low ratios, may not have been detectable due to other factors, such 
as fluorescence quenching. 
The thioacetate cylinder does show some displacement of hoechst. The reduction in signal 
equates to 64 % displacement in comparison to the parent cylinder, Figure 52. This may support 
the results produced from LD, section 3.2.3, where the thioacetate cylinder did not show to have 
a large structural effect on binding to DNA. As previously found [1], it is thought that the 
dramatic kinking and coiling of ct-DNA that the parent cylinder exhibits is as a result of major 
groove binding. The slight bending of the DNA exhibited by the thioacetate cylinder may 
therefore be the result of binding primarily to the minor groove. It can be concluded however, 
that due to the large functional groups added to the cylinder structure, it is not as good of a 
minor groove binder as the parent cylinder. 
 
Figure 52: λmax intensities of each complex with increasing ratios of hoechst (1.5 
µM):complex from 10:1 to 1:1 
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3.7 Three Way Junction (3WJ) Studies 
As well as double stranded DNA, the parent cylinder has also been shown to interact with other 
DNA structures. Specifically, it is able to interact and stabilise fork and three way junction 
(3WJ) structures [2]. Due to the size, shape and charge of the helical structure, it is the perfect 
fit to stabilise the heart of a 3WJ, Figure 53. 
 
Figure 53: Parent cylinder binding in a 3WJ [reproduced from ref2] 
 
The cationic nature of the triple stranded helicate attracts the negatively charged DNA strands, 
resulting in the stable 3WJ structure forming around the cylinder. The construction of this 3D 
DNA structure does not occur at room temperature when the cylinder is not present. It was 
therefore investigated whether the click functionalised cylinders were able to interact with this 
3WJ, and whether there was a greater or lesser interaction compared with the parent cylinder 
as a result of the additional functionality attached to the helicates. 
In order to investigate this, polyacrylamide gel electrophoresis was utilised. By radio labelling 
a strand of DNA with 32P, it is possible to track the formation of varying DNA structures by 
analysing how they travel through the gel. It was possible to monitor and quantify the degree 
of 3WJ formation on the addition of each cylinder, through monitoring the location of the 
radiolabelled DNA stand, Figure 54.  
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Figure 54: Autoradiogram of PAGE gel demonstrating 3WJ formation in the presence of iron 
triple stranded helicates at 3:1 DNA strands:complex concentration 
 
In order to form a DNA 3WJ, three complementary strands were incubated with the respective 
cylinders, before being passed through polyacrylamide gel, which separated the 3WJ structures 
from the unbound, single stranded (ss) DNA. These single stranded species have a lower 
molecular weight to the 3WJ/complex conjugates, so travel further through the gel, as 
demonstrated in Figure 55. By identifying these two structural differences in the gel, the 
proportion of radiolabelled DNA in each state can be evaluated, and a comparison of the 
percentage of 3WJ formed can be determined. Each lane corresponds to a different set of 
experimental conditions, as outlined in Figure 56. 
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Figure 55: Highlighted view of gel shown in Figure 54, with lane assignment 
 
In lanes 1-4 and 10, no cylinders were present during incubation of the DNA strands. As a 
result, no 3WJ was formed, or could be detected within the PAGE gel. This corresponds to 
results previously found using this method [21]. It was found however, that in the presence of 
each of the cylinders evaluating, some 3WJ species were formed, as determined through the 
presence of a band in equivalent location to that found when the parent cylinder is present. 
Through calculating the percentage of radiolabelled DNA present in each band present in the 
gel, it can be concluded that the functionalised cylinders are unable to stabilise the 3WJ 
structure to the same degree as the parent cylinder, with the order of cooperation between the 
DNA strands and the cylinders follow that the parent ˃ thioacetate ˃ ester ˃ piperidine, Figure 
56.  
Each of the cylinders carries a 4+ charge, so it is likely due to electrostatic interactions that this 
class of compound is able to encourage formation of the 3WJ. Despite the ester cylinder having 
the smallest alteration to the original parent cylinder structure, it does not form the greatest 
amount of 3WJ/complex conjugate. This may indicate that the chemical properties of the 
cylinder have been altered to hinder the promotion of 3WJ formation. Despite the thioacetate 
3WJ 
 
SS 
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cylinder being functionalised with a larger group clicked onto the structure, it is able to promote 
3WJ formation. This indicates that the shape of the cylinder has only increased on one plane, 
resulting in the complex being able to still fit within the heart of the junction. These results 
indicate that as a result of the additional functionalities clicked onto the helicates, the structures 
are not such a ‘perfect fit’ as the parent cylinder for this type of DNA interaction [22]. 
LANE LANE CONTENT 3WJ SS-DNA % 3WJ 
1 S1* - 87 - 
2 S1* + S2 - 1137 - 
3 S1* + S2 + S3 - 1261 - 
4 S1* + S2 + S3 + MgCl - 1408 - 
5 S1* + S2 + S3 + [Fe2(LP)3]Cl4 657 558 54 
6 S1* + S2 + S3 + 
[Fe2(LThioacetate)3][BF4]4 
264 914 22 
7 S1* + S2 + S3 + [Fe2(LEster)3]Cl4 141 750 16 
8 S1* + S2 + S3 + 
[Fe2(LPiperidine)3]Cl4 
52 946 5 
9 S1* + S2 + S3 + [Fe2(LP)3]Cl4 711 525 58 
10 S1* + S2 + S3 - 82 - 
Figure 56: Table showing contents of each gel lane and the quantification of 3WJ formed on 
cylinder binding 
 
3.8 Cell Studies 
Knowing that these click functionalised cylinders are able to interact and cause a structural 
change to DNA on binding, it was investigated whether they were cytotoxic to various cancer 
cell lines. By disrupting the structure of DNA, it was hoped that these complexes would be able 
to cause cell death as a result. The parent cylinder has been shown to enter cells and cause cell 
death via this manner [4]. In order to analyse cell toxicity, MTT assays were performed using 
a variety of cancer cells lines, to obtain the relative IC50 values for each complex. This technique 
is a tetrazolium based colorimetric assay, which analyses cell growth through conversion of 
thiazolyl blue tetrazolium bromide (MTT) to MTT-formazan by mitochondrial dehydrogenase 
which is present in living cells [23]. 
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Figure 57: Conversion off MTT to formazan via mitochondrial reductase 
 
3.8.1 MTT Assays 
MTT assays were performed on two cancer cell lines: A549: Human alveolar adenocarcinoma 
cell line and MDA-MB-231: breast cancer cell line.  
Through testing the toxicity of each of the iron helicates on different cancer cell lines, it was 
hoped to identify some selectivity between the different complexes. 
 
24 hr Treatment:  
The toxicity of these iron helicates was first analysed after treatment for 24 hours. After this 
period, a solution of MTT was added to the cells. This, however, showed that the compounds 
were not toxic to cells as the IC50 values were all ˃100µM. As a result, all future cell studies 
were performed with 72 hour treatments. 
 
72 hr Treatment: 
After treatment for 72 hours, the click functionalised iron helicates were all toxic to cells to 
varying degrees, Figure 58. All experiments were repeated in triplicate and in both cell lines 
tested the toxicity of the helicates followed the pattern of thioacetate ˃ piperidine ˃ ester. 
For the lung cancer cell line, A549, the parent cylinder appeared most toxic, with it being even 
more toxic than cisplatin. By functionalising the cylinder, it required at least three times the 
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concentration to result in cell death. This may indicate that the parent cylinder could be used as 
a drug candidate for this type of cancer as it is highly active at low concentrations. 
For the breast cancer cell line, MDA-MB-231, toxicity of the thioacetate functionalised cylinder 
was comparable to that of the parent cylinder and cisplatin. This may indicate that the 
thioacetate cylinder is able to interact with this cancer cell type similarly to the parent complex. 
The ester functionalised cylinder was half as toxic as these compounds, indicating that this 
helicate would not be an appropriate drug treatment for these cancer cell lines. The piperidine 
functionalised cylinder showed it was toxic to this cell line, however, not comparable to the 
known drug molecule, cisplatin. 
 
Compound Cell Type 
A549  MDA 
Parent 11 ± 4 27 ± 3 
Ester 47 ± 2 51 ± 2 
Piperidine 36 ± 6 32 ± 5 
Thioacetate 31 ± 6 23 ± 4 
Cisplatin 17 ± 4 24 ± 1 
Figure 58: Average IC50 values (µM) of iron helicate complexes with respective cell lines  
 
It can be concluded from these toxicity results, that the addition of functional groups to the 
parent cylinder alters cell toxicity, with varying outcomes depending on how the helicate was 
functionalised. The ester cylinder appeared to be least active against these cancer cell lines and 
the thioacetate cylinder being comparably most active, with similar activity to cisplatin when 
treating a breast cancer cell line. 
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3.9 Summary 
Overall it was found that by functionalising the triple stranded iron helicates described using 
click chemistry, a range of functional groups could be incorporated into the structure easily, 
including ester ([Fe2(LEster)3]Cl4), piperidine ([Fe2(LPiperidine)3]Cl4) and thioacetate 
[Fe2(LThioacetate)3][BF4]4 moieties. In doing so, the fundamental DNA binding properties of such 
triple stranded iron helicates was retained, with each new complex showing some binding 
interaction with DNA. On addition of these different moieties the physical and chemical 
properties of the compounds were manipulated, with a decrease in stability and solubility in 
aqueous solution being observed compared to the parent compound. Despite this, each novel 
complex interacted with ct-DNA and were able to stabilise DNA 3WJ formation. It was also 
shown that the functionalised supramolecular helicates were toxic towards cancerous cell lines, 
to varying degrees, and as such show promising results towards the aims of this research. 
 
3.9.1 Ester Cylinder, [Fe2(LEster)3]Cl4 
 
 
The ester functionalised cylinder, [Fe2(LEster)3]Cl4, was soluble in methanol and partially 
soluble in acetonitrile, which allowed for the complex to be dissolved in aqueous solution, 
meaning that the interactions between this complex in different biological systems could be 
investigated. 
It was found that this cylinder complex interacted with ct-DNA to induce a CD signal as a result 
of DNA/cylinder interactions. On addition of [Fe2(LEster)3]Cl4 to a solution of ct-DNA, 
orientation of the genomic DNA was reduced as a result of the kinking and coiling of ct-DNA 
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occurring on complex binding. The presence of an induced LD signal indicated that the cylinder 
incurs a specific binding mode when interacting with ct-DNA, likely to be major groove binding 
which is backed up through the lack of ethidium bromide and hoechst displacement observed. 
On binding to ct-DNA, stability of the cylinder was increased, however it was found that the P 
enantiomer had a lower affinity to ct-DNA compared with the M, resulting in an enantiomeric 
excess of the M conformer over time.  
As well as interacting with ct-DNA, this complex was also able to stabilise a DNA 3WJ. 
Through addition of the ester groups, however, it was found that the complex became least toxic 
towards certain cancer cell lines, compared to the parent and other newly functionalised 
cylinders. 
 
3.9.2 Piperidine Cylinder [Fe2(LPiperidine)3]Cl4 
 
 
The piperidine cylinder, [Fe2(LPiperidine)3]Cl4, was soluble in methanol, however addition of the 
piperidine groups made it the least soluble of those new cylinders analysed, as such slightly 
higher ratios of solvent were required to dissolve the complex in aqueous solution. On addition 
of this compound to ct-DNA an induced CD signal was produced, indicating a binding 
interaction was occurring between the two species. No induced LD signal was observed on 
titrating [Fe2(LPiperidine)3]Cl4 with ct-DNA, showing that the complex did not become orientated 
in solution, indicating that the binding interaction with DNA was not specific. Despite this, 
orientation of the ct-DNA was greatly reduced on addition of this cylinder, comparable to that 
of the parent cylinder, indicating that a structural change was occurring. 
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Through lack of ethidium bromide and hoechst displacement, it was theorised that the complex 
bound to ct-DNA via major groove binding, with the side chains being able to interact with the 
sugar backbone of DNA. 
Very little 3WJ structure was stabilised by this cylinder, likely due to the bulky side chains 
added when functionalised. Cell toxicity was reduced slightly compared to that observed for 
the parent cylinder, however, the complex was still able to enter the cancerous cells to induce 
cell death. 
 
3.9.3 Thioacetate Cylinder [Fe2(LThioacetate)3][BF4]4 
 
 
 
The thioacetate cylinder, [Fe2(LThioacetate)3][BF4]4, was highly soluble in acetonitrile, allowing 
for dilution into aqueous solution for biological studies. On addition of this complex to ct-DNA, 
induced peaks were observed within the CD and LD spectra. This indicated that the cylinder 
was binding to ct-DNA via a specific binding mode and causing a structural change. 
It was theorised that this iron helicate binds to ct-DNA via the minor groove. This was indicated 
by the compounds ability to displace hoechst from ct-DNA and through the lack of 
kinking/coiling of DNA observed in the LD spectrum. Both results are indicators that the 
complex is able to bind into the minor groove of DNA, which would suggest that the long 
chains added to the cylinder structure have resulted in this altered binding mode. 
The complex was able to stabilise DNA 3WJ structures, showing that the long side chains did 
not dramatically alter the height of the complex which is known to be crucial in its ability to 
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enter the central cavity and stabilise such structures. It was also found that this compound had 
similar toxicity results to those observed with the parent cylinder towards cancer cell lines. As 
such, addition of the thioacetate group via click chemistry to the helicate structure has altered 
the binding affinity/mode to DNA, compared to the parent cylinder, yet has maintained the 
toxic nature desired from this class of compounds. By incorporating this moiety into the 
structure, a sulphur atom has been introduced which can consequently be used to explore the 
limitations of this complex further, through AuNPs interaction (Chapter 4). 
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Chapter 4 
Gold Nanoparticle/Helicate Interactions 
 
The research area of nanomedicine is being applied to a range of fields including drug delivery, 
biodiagnostics, therapeutics and biomedical imaging [1, 2]. Nanoparticles in particular, have 
unique properties which are anticipated could have the potential to eradicate limitations of 
conventional treatments such as bioavailability and toxicity [3, 4], through targeted delivery 
and proficient bioaccumulation. Of these, gold nanoparticles (AuNPs), are the most stable 
metallic nanoparticle [5, 6].  
For this research spherical AuNPs were utilised, as they are easily synthesised [7] and extensive 
research has previously been performed on such particles [8]. Research has shown that AuNPs 
can be easily up taken in mammalian cells [9, 10] and are able to accumulate in cancer cells 
[11] and depending on their size and charge, can amass in different organs [12]. As such the 
use of such particles may allow for targeted drug delivery to specific cancer cell lines. 
 
4.1 Research Objective 
The aim of this project was to attach the know iron(II) helicate structure, discussed in previous 
chapters, to the surface of AuNPs. By attaching many cylinders to the gold surface, it is hoped 
that high concentrations of complex can be achieved in aqueous solution, resulting in numerous 
interactions occurring with DNA simultaneously, as with multiple zinc fingers on a protein 
surface [13]. Consequently, it was anticipated that the intramolecular coiling and kinking affect 
seen with this class of compound [14] may be enhanced and as such, DNA replication could be 
inhibited; resulting in a potential anticancer treatment. On addition of this complex to AuNPs, 
it is also anticipated that the nanoparticles can be used as a targeting delivery devise towards 
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cancerous cell lines [9-11]. As nanoparticles are shown to accumulate in cancerous cells, this 
may result in an increased potency of the complex as an anticancer agent, as well as reducing 
the possible toxicity effects towards healthy cell lines. 
It will be attempted to attach the parent cylinder [Fe2(LP)3]Cl4 (LP = C25H20N4), to the surface 
of AuNPs via two methods. Firstly, it will be attempted to attach the complex using electrostatic 
interactions, between the tetracationic charge of the cylinder and the negatively charged 
nanoparticle surface. Addition of a positively charged compound onto the stabilised gold 
surface will reduce the overall stabilising charge on the nanoparticle, which could lead to 
aggregation of the nanoparticles, so it is possible this may not be a viable method. 
Secondly, the iron cylinder will be attached to AuNPs via sulphur linkers. The thioacetate 
cylinder [Fe2(LThioacetate)3][BF4]4 (LThioacetate = C45H50N10O6S2) synthesised and discussed in 
chapters 2 and 3, has an additional side arm linked onto the ligand which contains a sulphur 
group. It will therefore be attempted to attach this cylinder onto the nanoparticle surface by 
adsorption [15], Figure 1. The resulting functionalised nanoparticles will then be tested for their 
effects on DNA with a hope that the cylinder is still be able to interact with DNA structures to 
cause a structural change. As many cylinders will be attached to the gold surface, it is 
anticipated that the effects currently observed between such structures and DNA, chapter 3, 
will be enhanced as a result of incorporating with nanotechnology. 
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Figure 1: Schematic drawing of the Fe(II) cylinder interacting with the surface of a AuNP 
 
4.2 Gold Nanoparticles 
4.2.1 Gold Nanoparticle Synthesis 
The synthesis of citrate coated gold nanoparticles, cAuNPs, by the Turkevich method is a well-
known process [7] whereby spherical, monodispersed particles can be synthesised in aqueous 
solution using a simple technique. The citrate ions act as both a reducing and capping agent, 
hence the concentration of reagents and reaction time given, govern the particle size 
synthesised, with a higher concentration of reducing agent giving a smaller particle size [16, 
17]. 
For this research nanoparticles of approximately 16 nm in diameter were synthesised, as 
research into functionalising such particles for use in anticancer research has previously been 
performed [8-11]. Citrate coated AuNPs are very stable as the negative charge of the citrate 
coating causes repulsion between the particles, ensuring they do not aggregate in solution and 
remain a colloidal suspension.  
For that reason, a solution of gold(III) chloride, HAuCl4.3H2O, (1 mM, 100 mL) was reacted 
with sodium citrate, Na3(C6H5O7).2H2O, (38.8 mM, 10 mL) to reduce the Au3+ to colloidal Au0. 
To the vigorously stirred, boiling solution of HAuCl4, the reducing agent was added. This 
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mixture was heated for 10 mins and then stirred without heat for a further 15 mins. Adding the 
citrate solution into the centre of the vortex of the stirring Au3+ solution aided formation of 
uniform AuNPs. This resulted in a deep red solution with a UV λmax absorption of 524 nm, 
which is the characteristic surface plasmon resonance (SPR) of such cAuNP, Figure 2. The 
cAuNPs were further tested for their size, stability and appearance using dynamic light 
scattering (DLS), zeta potential and transmission electron microscopy (TEM) respectively. 
 
Figure 2: UV spectrum of citrate coated AuNPs (2.5 nM) 
 
4.2.2 Gold Nanoparticle Analysis 
4.2.2.1 Dynamic Light Scattering (DLS) 
DLS measures the light scattered from particles moving in Brownian motion and relates this to 
particle size; with smaller particles having a larger Brownian motion causing laser light to be 
scattered at different intensities. This is then corresponded to the size of particle using the 
Stokes-Einstein relationship, resulting in a size distribution profile of the nanoparticles in 
suspension [18, 19]. 
This technique uses a number of assumptions to produce this derivative. Firstly that the particles 
are in Brownian motion, so a probability density function can be used, Eq.1. Secondly that the 
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particles are spherical, so the Stoke-Einstein equation can be used; Eq. 2, to gain the diffusion 
constant and subsequently information on the particle radius. 
ܲሺݎሻ ൌ ሺ4πDtሻିଷ/ଶ	exp	ሺെ ௥మସ஽௧ሻ (Eq. 1) 
ܦ ൌ ௞்଺గఎோ (Eq. 2) 
Equations used within DLS measurements, where: D: diffusion coefficient, k: boltzmann 
constant, T: temperature, η: viscosity, RH: hydrodynamic radius 
 
When assuming the sample measured relates only to spherical material, it may result in bias or 
inaccurate results being given. Figure 3 demonstrates how the data could be misinterpreted, 
given different sample situations. For this project, it is expected that the nanoparticles made 
were spherical, and it is desired to analyse the change in size of these particles when the surface 
is functionalised, Figure 3 (a), so any anomalous data would likely be the result of aggregated 
species, Figure 3 (c), or foreign particles such as dust. 
 
 
Figure 3: Hydrodynamic radius presumptions a) functionalised nanoparticles, b) non-spherical 
particles, c) aggregates 
 
The technique is easily performed, simply by measuring the light scattered by particles present 
in solution. The instrumentation then manipulates the data, as described above, to fit data to 
corresponding diameter values, Figure 4. This is a very fast and reproducible technique which 
requires simple sample preparation and hence is a standard technique used to analyse 
a)     Dh         b)       Dh   c)      Dh
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nanoparticles [20]. DLS is an ideal technique to analyse how functionalising nanoparticles can 
affect their physical properties [21]. By comparing results from different samples, a size change 
in the particles in colloidal suspension can indicate if functionalization of particles has been 
achieved, and so was used throughout this research to investigate how gold nanoparticles were 
altered in appearance and behaviour when exposed to different functionalities. 
 
Figure 4: Schematic showing basic experimental procedure of DLS [reproduced from ref22] 
 
DLS results for cAuNPs: 
Distribution:  Intensity: 25.70 ± 10.01 nm  Cumulant Diameter: 26.20 nm 
Volume: 17.44 ± 6.199 nm  Polydispersity Index: 0.545 
Figure 5: Spectral data showing the size distribution of citrate nanoparticles, cAuNPs 
 
DLS results, Figure 5, indicate that the majority of the particles synthesised were ~17 nm in 
diameter, with some larger impurities present. These may have resulted from the synthesis, 
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despite the sample being filtered twice before taking the measurements, or could potentially 
have been a result of the test solution being too concentrated. 
 
4.2.2.2 Zeta (ζ) Potential 
Zeta potential is the measure of electrokinetic potential within a colloidal system. The potential 
difference measured is that between the polar solvent, typically water, and the charged area 
surrounding the surface of the nanoparticles is measured [23], Figure 6 [24]. 
 
Figure 6: Potential difference as a function of distance from a charged particle surface, 
suspended in solution [reproduced from ref24] 
 
This technique is used to determine the charge state of nanoparticle surfaces and the stability 
of particles in solution. These are indicated by the sign and magnitude of the measurement, with 
the sign indicating whether the surface is positively (+) or negatively (-) coated. The greater the 
magnitude of ζ potential, the higher the stability, as a larger potential difference is present 
between the particle surface and surrounding solution, creating a bigger repulsive force between 
particles, making them more stable [25]. 
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It is considered that particles with a ζ potential magnitude of 30 mV are moderately stable. The 
closer to zero the ζ potential gets, the less stable the particles become and more likely they will 
flocculate and aggregate over time, Figure 7. This is due to there being less potential difference 
between particle surfaces within solution, allowing for the interactions with neighbouring 
particles. 
 
Figure 7: Zeta potential values related to stability 
 
It is important that colloidal systems are stable over time, as instability can lead to aggregation 
of particles, which may result in sedimentation and the ultimate phase separation of the particles 
and solution, Figure 8 [26]. As such, the colloidal suspension would no longer have the desired 
characteristics, becoming irreversibly coagulated deeming them useless. Consequently, 
stability of the AuNPs was closely monitored on surface modification, ensuring that despite 
altering the surface functionality of the particles, the desired characteristics and reason for 
utilising these colloids, will be maintained. 
 
Figure 8: Schematic diagram demonstrating variation in colloidal stability [reproduced from 
ref26] 
-30 mV       0           +30 mV 
STABLE            UNSTABLE                  STABLE 
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Zeta Potential results for cAuNPs: 
ζ Potential (mV): -43.2 ± 17.9 
Conductivity (mS/cm): 0.761 
 
Figure 9: Spectral data showing the zeta potential distribution of cAuNPs 
 
Zeta potential experiments were repeated three times to ensure reliable results. Figure 9, shows 
typical results for cAuNPs, with a value of -43 mV, indicating very stable nanoparticles in 
solution. The negative value is due to the citrates on the surface of the gold being in a 
deprotonated state, with three COO- groups capping and stabilising the nanoparticles. 
 
4.2.2.3 Transmission Electron Microscopy (TEM) 
Transmission electron microscopy (TEM) is a technique where an electron beam is transmitted 
through an ultra-thin specimen, generating a high resolution image which is highly magnified. 
This technique can therefore be used to image nanoscale material, and is ideal to analyse cells 
and nanoparticles [27]. 
TEM has a range of applications including in cancer research [28], nanotechnology [29] and 
materials science [30]. However, there are some limitations to this technique. There is a low 
throughput of samples, with time consuming sample preparation and sample scanning. The field 
of view observed is relatively small, so the region being analysed may not represent the entire 
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sample. In the case of biological samples the electron beam may also damage or alter samples, 
giving unreliable data. Despite this, it is a technique routinely used to analyse the morphology 
of nanoparticles. 
For this work, TEM was used to gain additional knowledge on the size, shape and overall 
morphology of nanoparticles synthesised. Particle size and shape have been found to have a 
key role in bio-distribution [31], so uniform, un-aggregated particles are desired. 
TEM results for cAuNPs: 
 
 
Figure 10: TEM images of citrate coated gold nanoparticles, showing representative particles 
from two samples at a variety of magnifications 
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From TEM images of cAuNPs, Figure 10, it was observed that uniform nanoparticles of circular 
morphology were formed during synthesis using the Turkevich method. The size range 
appeared to be ~16 nm which corresponds to those results found using DLS and UV-Vis. As a 
result of these findings, these AuNPs were used for further research, to investigate if they could 
successfully be functionalised with triple stranded iron helicates. 
 
4.3 Combining Gold Nanoparticles with Supramolecular Helicates 
4.3.1 Parent Cylinder 
The cAuNPs discussed are capped with citrate molecules which surround the particles with a 
negative charge; stabilising them in solution. It was therefore investigated whether complexes 
could be attached to the surface simply through electrostatic interactions [32, 33]. 
Within the Hannon group, the triple stranded iron helicate [Fe2(C25H20N4)3]4+ was developed, 
Figure 11 [34]. This is a tetracationic species which demonstrates unique interactions with 
negatively charged DNA structures, and so has the potential to interact with the negatively 
charged surface of nanoparticles. 
H2N NH2
N
O
N
O
N N
N N
EtOH
RT
2h
FeCl2
  
Figure 11: Formation of the ligand and model structure of the tetracationic triple stranded 
supramolecular cylinder [Fe2(LP)3]Cl4 [reproduced from ref34] 
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By adding this cationic complex to a solution of cAuNPs, it was predicted that coagulation may 
occur as a result of adding a positively charged molecule to the negative nanoparticles. This 
will decrease the overall charge on the particle surface, resulting in the zeta potential becoming 
closer to 0 mV. As this occurs, the colloidal system becomes less stable, leading to aggregation 
and causing particles to sediment out of solution. This effect will be directly affected by the 
concentration of both species. 
This concept was therefore tested by adding small quantities of parent cylinder to cAuNPs, 
Figure 12. By observing the addition of a peaks at wavelengths >520 nm, aggregation of the 
nanoparticles can be analysed, signals appearing in this region will imply that large aggregate 
species have been formed.  
 
Figure 12: UV-Vis spectra of cAuNPs (0.5 nM) with the addition of Fe2(LP)3]Cl4 (10 μM). 
Legend indicates volume of Fe2(LP)3]Cl4 added to cAuNPs (µL) 
 
To cAuNPs (0.5 nM, 1 mL) [35], 10 μL aliquots of [Fe2(LP)3]Cl4 (10 μM) in water were added. 
After only two additions of complex to nanoparticles, the solution turned from red in colour to 
black with precipitate formation. The characteristic SPR peak at 524 nm of the citrate 
nanoparticles shifted to 645 nm. This broadening and shifting of the UV peak is characteristic 
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of aggregated nanoparticles, showing that adding a tetracationic complex to citrate coated 
AuNPs is not a viable technique to functionalise the nanoparticle surface. 
 
4.3.2 Surfactant Coated Gold Nanoparticles, ZAuNPs 
As the aim of this research is to functionalise AuNPs with the tetracationic cylinders developed 
within the Hannon group, a method of stabilising nanoparticles to circumvent aggregation was 
investigated. 
Zonyl FSA is a fluorosurfactant which has been used to stabilise AuNPs by other research 
groups [36], to allow for them to be functionalised with positive substituents. This surfactant is 
able to coat cAuNPs, increasing the repulsion between nanoparticles, making them more stable. 
 
Figure 13: Zonyl FSA fluorosurfactant 
 
Figure 14: UV spectra of citrate (cAuNPs) and surfactant coated AuNPs (1 nM) 
 
It was found that when only 2 μL of the surfactant solution had been added to the cAuNPs (1 
mL), the nanoparticles appear fully coated as no further shift to the SPR was observed. With 
this addition, the λmax of the nanoparticles shifted from 524 nm to 527 nm. This corresponds 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
400 500 600 700 800
Ab
so
rb
an
ce
Wavelength / nm
citrate
surfactant
159 
 
to the functionalisation of the nanoparticle surface, hence this ratio of solutions was used for all 
future experiments performed with ‘zonyl’ coated nanoparticles (ZAuNPs). 
As discussed, it is known that the use of this surfactant stabilises nanoparticles, which can be 
observed through further zeta potential analysis, Figure 15. 
 
ζ Potential (mV): -52.9 ± 12.7  
Conductivity (mS/cm): 0.0384 
 
Figure 15: Zeta potential distribution of ZAuNPs 
 
On addition of the surfactant, where a solution of cAuNPs containing the surfactant was stirred 
overnight, followed by purification by centrifugation, the ζ potential decreased by a ~10 mV. 
This implies that the nanoparticles will be more stable than the citrate coated, and hence should 
be able to withstand a higher concentration of cationic species on the surface before aggregation 
occurs. 
The size of the nanoparticles was not greatly increased on the addition of the surfactant, as 
indicated by the DLS results, Figure 16. 
 
Size Distribution:  Intensity: 34.32 ± 13.67 nm  Cumulant Diameter: 47.73 nm 
Volume: 23.86 ± 7.78 nm  Polydispersity Index: 0.770 
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Figure 16: DLS results for ZAuNPs 
 
DLS results show slightly higher diameter readings for ZAuNPs, with an increased reading 
compared to results found with the cAuNPs. This increase indicated that all nanoparticles had 
been additionally coating with surfactant [36]. The cumulate diameter was higher than 
expected, which could have been as a result of foreign material being present in the cuvette the 
sample was run in, or there may be aggregated species in the solution from purification through 
centrifugation. The samples were however filtered before being analysed, and the vast majority 
of particles appeared to be in error range of the expected diameter. Repeating this experiment 
after further purification by centrifugation and resuspension in water gave the same results, 
indicating that any excess surfactant had been purified out of solution, yet that some aggregation 
may have resulted from this purification process. 
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TEM of ZAuNPs 
 
 
Figure 17: TEM images of ZAuNPs showing representative particles from two samples at a 
variety of magnifications 
 
The diameter of particles observed via TEM was ~16 nm in size, Figure 17. This is consistent 
with results expected, as coating the AuNPs with a surfactant was not likely to increase the 
overall size very dramatically [36], and was only used to enhance the stability. Individual 
nanoparticles are observed, however clumps of nanoparticles were also present. These clusters 
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may be the cause of the larger species observed within DLS experiments, but it can clearly be 
shown that all nanoparticles are spherical and similar in size. 
As well as analysing these particles suspended in water, the stability of these particles was 
analysed in cell media (DMEM) over a period of 72 hrs, Figure 18.  
 
Figure 18: Stability of ZAuNPs (1 nM) suspended in media over 72 hrs. Legend indicates 
time / hours 
 
As shown from the UV spectra, the particles are relatively stable under these conditions, with 
only slight broadening of the peak over time. No new peaks above 575 nm were observed, 
indicating that no large aggregates were formed during this period of time. This indicates that 
these particles are stable enough to perform cell studies with, to analyse if and how they interact 
with cells without aggregation affecting results. 
 
4.4 Addition of Cylinders to ZAuNPs 
4.4.1 Parent Cylinder 
As discussed, it was hypothesised that tetracationic iron helicates have the potential to attach to 
the surface of cAuNPs via electrostatic interactions. Through stabilising these particles with 
fluorosurfactant ‘zonyl FSA’ it was hoped that on addition of the helicate, aggregation would 
not occur. This was first investigated using UV-Vis spectroscopy. 
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Figure 19: UV-Vis of ZAuNP (0.5 nM) with the addition of Fe2(LP)3]Cl4 (10 µM) in 50 µL 
aliquots. Legend indicates the volume of cylinder added in µL 
 
The AuNP signal and complex signal peaks overlap, resulting in the UV profile of the 
supramolecular cylinder being masked. On addition of [Fe2(LP)3]Cl4 to ZAuNPs, no 
aggregation was now observed. There is a slight shift in the SPR band to 527 nm but the peak 
does not appear to have broadened and no additional peak for aggregated species was detected, 
as previously observed with cAuNPs. 
Consequently, higher concentrations of parent cylinder were added to the nanoparticles in a 
ratio of 1:750 and 1:1000 ZAuNPs/cylinders, Figure 20. 
 
Figure 20: UV-Vis of ZAuNPs (0.45 nM) with varying complex solution added 
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No aggregation was observed on addition of these higher complex ratios. There was a shift in 
the SPR peak however, to 528 nm, indicating that some complex was interacting with the 
nanoparticle surface. This peak shift was not as great as those observed in literature cases, when 
functionalising nanoparticles [37, 38]. However, this was rationalised to be the result of it only 
being an electrostatic interaction and not the complex adsorbtion onto the gold surface. 
A ratio of nanoparticle (1 nM ) : complex (1 µM) was used in subsequent experiments, as this 
appeared to give a thousand times coverage of cylinder per nanoparticle, whilst maintaining the 
stability of the colloidal suspension. 
The particles were synthesised by combining the stock solution of cAuNPs (~5 nM) containing 
a 0.2 % proportion of zonyl FSA with an equal volume of 5 µM cylinder solution in water. This 
mixture was stirred at room temperature, in the dark overninght. To purify, 1 mL alliquots of 
the mixture were centrifuged at × 12000 min-1 for 30 mins or until a pellet was formed. The 
supernatant was then carefully removed and the pellet re-suspended, to repeat the purification 
step one further time. During this purificarion process, it was observed that the nanoparticles 
did not aggregate, and maintained their deep-red colour. 
As the characteristic UV spectrum of the parent cylinder is masked by that of the nanoparticles, 
it was necessary to fully characterise the functionalised nanoparticles and establish that the 
intact cylinder was electrostatically bound to the surface of the nanoparticles.  
Firstly the ζ potential of the nanoparticles was analysed. By adding the tetracationic species to 
the negative nanoparticle surface, it was predicted that the surface charge on the nanoparticle 
would decrease in magnitude and that the value would reach closer to 0 mV. 
 
ζ Potential (mV): -34.8 ± 13.3  
Conductivity (mS/cm): 0.00976 
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Figure 21: ZAuNP / [Fe2(LP)3]Cl4 at 5 nM: 5 µM ratio 
 
As expected, the zeta potential decreased in magnitude through the addition of the tetracationic 
supramolecular helicate from -52.9 mV for ZAuNP to -34.8 mV for the nanoparticles coated 
with parent cylinder (PC-ZAuNP). This loss of 18 mV indicated that a large number of cationic 
species were attached to the nanoparticles, showing that despite purification by centrifugation, 
some cationic species remain attached through electrostatic interaction. 
 By assuming this complex had been attached to the nanoparticle surface, it was investigated 
whether any characteristic DNA binding activity of the cylinder was retained. By comparing 
the PC-ZAuNP interaction with ct-DNA with the free parent cylinder, it may give an indication 
if the cylinder remains intact when interacting with the nanoparticles. 
The parent cylinder kinks and coils ct-DNA, apparent by the stiffening of DNA and reduction 
of the peak at 260 nm, Chapter 3 Figure 20. An ILD observed at 573 nm is characteristic of the 
parent cylinder as a result of the MLCT. These will be key alterations to the ct-DNA structure 
which will be analysed on addition of PC-ZAuNPs. 
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Figure 22: LD titration of 100 μM ct-DNA in 20 mM NaCl and 1 mM Tris-HCl (pH 7.2) with 
increasing concentrations of PC-ZAuNP. Legend shows ct-DNA:complex ratios (n:1) 
 
On addition of PC-ZAuNPs to ct-DNA, an ILD signal was generated at ~ 625 nm, Figure 22. 
This wavelength does not correspond to λmax in the characteristic UV-Vis spectrum of these 
nanoparticles or the free parent cylinder, so it is suitable to presume that this peak is generated 
as a result of a DNA/AuNP interactions. This induced peak indicates that the nanoparticles are 
interacting with ct-DNA in a specific manner, to become orientated in solution on binding. 
When working with nanoparticles, less concentrated solutions of the complex were used, 
compared with the free cylinder, to avoid aggregation. Despite this, spectral differences to the 
ct-DNA peak at 260 nm were observed, Figure 23, demonstrating how interacting with PC-
ZAuNPs may result in structural change on binding. 
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Figure 23: Intensity of LD signal at 260 nm for PC-ZAuNP (blue) and free [Fe2(LP)3]Cl4  (red) 
 
Initially, the signal at 260 nm decreases on addition of PC-ZAuNPs, yet once the concentration 
ratio meets 100:1 ct-DNA:PC-ZAuNPs the peak intensity increases. This is the opposite effect 
observed for the free parent cylinder, which shows continual DNA stiffening and loss of signal 
with increasing ratios of complex. These conflicting effects may indicate how by having the 
complex attached to a surface may alter the binding mode and affinity to ct-DNA. 
It was therefore investigated what effect un-functionalised, surfactant coated nanoparticles, 
ZAuNPs had on ct-DNA, Figure 24. 
 
Figure 24: LD titration of 100 μM ct-DNA in 20 mM NaCl and 1 mM Tris-HCl (pH 7.2) with 
increasing concentrations of ZAuNPs. Legend shows ct-DNA:complex ratios (n:1) 
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Equivalent ratios of ZAuNPs to ct-DNA were used, as with PC-ZAuNPs, in order to directly 
compare the effects when functionalised. No induced signal was produced when ZAuNPs were 
added to ct-DNA, as previously observed with PC-ZAuNPs. This indicates the ILD was as a 
result of the iron species being present in solution. Absence of an ILD, also indicates that 
ZAuNPs interact unselectively in a non-specific orientation with ct-DNA. 
Despite no ILD on addition of ZAuNPs, changes to the intensity of the characteristic LD peak 
at 260 nm was observed, Figure 25. Presence of ZAuNPs in solution, affected the orientation 
and perhaps structure of ct-DNA, very similar to that observed when PC-ZAuNPs were added. 
This implies that the spectroscopy observed below 300 nm is largely due to the effects of the 
nanoparticles and > 300 nm represents effects of the nanoparticle functionality. 
  
Figure 25: Intensity of LD at 260 nm, with increasing concentration of ZAuNPs 
 
To further investigate if the parent cylinder was attached to the nanoparticle surface, CD 
analysis was performed. The parent cylinder is a triple stranded helicate, formed in a racemic 
mixture containing an M and P enantiomer. As a racemic mixture the cylinder does not have a 
CD spectrum, yet when the enantiomers are separated, each enantiomer has a CD spectra, due 
to the chiral nature of the complex [39]. 
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By attaching one of these enantiomers to the nanoparticles surface, it was hoped to confirm the 
presence of the intact cylinder, through viewing the same CD spectrum as that of the ‘free’ 
enantiomer. 
  
Figure 26: CD spectra of ‘free’ M enantiomer of the parent cylinder (5 µM), compared to 
ZAuNPs (5 nM) and those functionalised with M enantiomer M-ZAuNPs (5 nM : 5 µM) 
 
The same concentration of free M enantiomer was analysed as that mixed with ZAuNPs to 
functionalise the M-ZAuNPs. The ZAuNP and those which had been exposed to the complex 
enantiomer, show very similar CD profiles, with no apparent complex peaks. This indicates that 
the species attaching to the nanoparticle surface is likely not to be the intact iron cylinder. 
It was suspected that the parent cylinder may be unstable in these given conditions, so stability 
of the iron complex was monitored in the presence of zonyl-FSA over a period of 49 hours. A 
ten times more concentrated solution of complex was used during this experiment in order to 
clearly observe the stability of the complex by UV-Vis, analysing the characteristic MLCT band 
at 572 nm of the purple coloured cylinder, to access if the complex remained stable in solution. 
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Figure 27: Stability of [Fe2(LP)3]Cl4 (50 µM) in a 2 % solution of zonyl FSA in water over 49 
hrs. Legend indicates time / hours 
 
It was observed that after 15 hours, the time in which the solution was left to stir in the presence 
of the nanoparticles, the cylinder concentration had decreased by 50 %, resulting in iron ions 
and ligand components being in solution. 
It was hoped that altering the pH of the solution would increase the observed stability of the 
complex in the presence of zonyl FSA, so slightly more acidic and basic pH solutions were 
analysed over time, Figure 28. Altering the pH however appeared to have no observable effect 
on complex stability with time. 
 
Figure 28: Stability of [Fe2(LP)3]Cl4 in a 0.2 % solution of zonyl FSA at different pHs. 
Legend indicates pH solution a time it was measured / hours 
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After collating all information on PC-ZAuNPs, it was concluded that the parent cylinder, 
[Fe2(LP)3]Cl4 was not attached to ZAuNPs via electrostatic interaction, but that it most likely 
degrades under reaction conditions, resulting in free Fe2+ ions and ligand in solution. The iron 
ions would be free to interact with the negatively charged nanoparticle surface, forming strong 
electrostatic interactions able to withstand purification via centrifugation. This would explain 
the change in ζ potential observed, and the difference in ct-DNA interaction observed by LD. 
It can therefore be concluded that this is not a viable technique to combine the known 
supramolecular helicate, [Fe2(LP)3]Cl4, with nanoparticles. 
 
4.4.2 Ruthenium Cylinder 
Stability of the parent cylinder, [Fe2(C25H20N4)3]4+ is not substantial enough to withstand 
conditions needed to functionalise AuNPs, through electrostatic interactions. Consequently, the 
ruthenium analogue of this complex was analysed, to assess whether addition of these 
tetracationic helicate structures could be attached to nanoparticles through electrostatic 
interactions. 
The ruthenium analogue has previously been synthesised within the Hannon group [40], 
showing different properties in terms of stability, solubility and synthetic technique required, 
compared with the iron complex, indicating that this may withstand exposure to nanoparticles. 
 
Figure 29: Structure of [Ru2 (LP)3]4+ cation. Ru large black spheres, N small clack spheres, C 
small gray spheres. Hydrogen atoms, anions and cocrystallized solvent molecules are omitted 
for clarity [reproduced from ref40] 
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The ruthenium helicate, [Ru2(C25H20N4)3]4+ is more stable than the iron analogue, due to more 
inert metal-ligand bonds. Consequently, it is difficult to synthesise, requiring high temperatures, 
increased reaction time or microwave reactor synthesis to form the triple stranded complex. The 
major products when reacting a ruthenium source with the bis-pyridyl-imine ligand are the 
double stranded complex and polymer species. The desired triple stranded helicate is formed in 
low yield, so the iron analogue is conventionally used, and has had more research performed 
on it. 
 The ruthenium helicate will be beneficial to use for many reasons, as well as increased stability 
in solution, it also exhibits fluorescent qualities, Figure 30 [40]. This fluorescence could be used 
to analyse if the cylinder was attached to the gold nanoparticle surface, or if the electrostatic 
interactions are not strong enough to functionalise the AuNPs. 
 
Figure 30: Absorption (solid line) and emission (dotted line) spectra (λex = 480 nm) for 
[Ru2L3](PF6)4 in MeCN (298 K) [reproduced from ref40] 
 
In order to attach the ruthenium helicate to the surface of AuNPs, the surface was coated with 
zonyl FSA for the reasons previously discussed, section 4.3.2. This would allow for a larger 
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concentration of tetracationic species to be combined with the negatively charged nanoparticles 
before aggregation occurs. 
 
4.4.2.1 Ru-ZAuNP UV-Vis 
To observe if the ruthenium cylinder was interacting with the surface of ZAuNPs, UV spectra 
of nanoparticle solutions, before and after purification were performed. 
Solutions of cAuNPs (5 nM) containing 0.2 % w/v zonyl FSA, with an equal volume of 
ruthenium cylinder (5 µM, in MeCN) were stirred overnight in darkness. 1 mL aliquots were 
purified twice by centrifugation and re-suspended in 1 mL H2O. Spectra were then run before 
and after this purification, Figure 31. 
 
Figure 31: UV spectra of AuNPs functionalised with surfactant (ZAuNP, ZAuNP P) and 
[Ru2(LP)3][PF6]4 (Ru ZAuNP, Ru AuNP P), before and after purification  
 
As demonstrated in section 4.3.2 the SPR shift of ZAuNPs was to 527 nm, this was not affected 
by purifying through centrifugation, showing that the zonyl FSA was retained on the surface. 
The absorbance intensity did decrease after purification however, due to nanoparticles being 
lost in the supernatant between purification steps. This was unavoidable, and despite changing 
the speed of centrifugation, it was found that some nanoparticles remained in suspension, so a 
speed which caused most to sediment without aggregation was used. 
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On addition of the ruthenium cylinder (1:1 volume ratio of 5µM [Ru2(LP)3][PF6]4  / 5 nM 
ZAuNP), a large shift in the SPR was observed to 538 nm. This indicated that the cylinder was 
interacting with the gold surface, even after purifying twice by centrifugation. The 
functionalised nanoparticles were less stable than the initial ZAuNP, expected due to the 
decreased repulsive forces between the nanoparticles on addition of the tetracationic cylinder.  
On purification of the Ru-ZAuNPs, some flocculation was observed, and can be seen by the 
slight broadening in the UV spectrum. It was however concluded that this purification technique 
was satisfactory for these nanoparticles, as few particles were lost during washing, and the 
majority could be re-suspended in solution, un-aggregated. Figure 32. Ru-ZAuNPs were always 
prepared just before use, to minimise any further aggregation or change in functionality of the 
particles over time. 
 
Figure 32: UV-Vis of Ru-ZAuNP (5 nM) and the supernatant from subsequent purification 
washes 
 
4.4.2.2 Ru-ZAuNP Characterisation 
 Ru-ZAuNP zeta potential ζ Potential (mV): -43.3 ± 6.85   
Conductivity (mS/cm): 0.0113 
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Figure 33: Zeta potential of Ru-ZAuNP (2.5 nM) 
 
On addition of the ruthenium cylinder to ZAuNPs, the zeta potential increased from around -53 
mV to -43 mV. This implies that a positively charged species had been added to the nanoparticle 
surface, reducing the overall negative charge, making the particles slightly less stable in 
solution. This would be consistent with the ruthenium cylinder being incorporated on the 
surface of the nanoparticles via an electrostatic interaction. 
 
 Ru-ZAuNP DLS 
Distribution:  Intensity: 26.10 ± 10.01 nm  Cumulant Diameter: 25.30 nm 
Volume: 23.18 ± 5.372 nm  Polydispersity Index: 0.252 
 
Figure 34: DLS results for Ru-ZAuNP (2.5 nM) 
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DLS data indicates that on functionalising ZAuNPs with ruthenium cylinder, the size of the 
nanoparticles slightly increased. This would be consistent with addition of a 2 nm by 1 nm 
complex, suggesting the metal complex may be intact as, on addition to the nanoparticles. 
Larger species are also present in solution, likely to be aggregates that have formed during the 
purification, resulting from the positively charged complex interacting with the negatively 
charged nanoparticles. 
 
 Ru-ZAuNP fluorescence 
The ruthenium cylinder has a key characteristic that the iron cylinder lacks, as well as being 
more stable, it is also fluorescent. This therefore gives another method of detecting the 
ruthenium cylinder on the nanoparticle surface, or whether the complex is removed during 
purification stages. 
Solutions of free ruthenium cylinder which was used during the synthetic stages of Ru-ZAuNPs 
and the subsequent nanoparticles were tested for their luminescent properties, Figure 35. 
 
Figure 35: Absorption (350-573 nm) and emission (600-800 nm) spectra (λex = 480 nm) for 
[Ru2(LP)3][PF6]4 in MeCN/H2O (5µM) ‘free’ and ‘bound’ to ZAuNP (5 nM) (298 K) 
 
From absorption and emission profiles of the free ruthenium cylinder and Ru-ZAuNPs, it was 
apparent that some ruthenium complex was bound to the nanoparticles. Approximately 15 % 
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of the original emission profile was retained on the nanoparticles, showing that even after 
purification twice by centrifugation and washing, the cylinder is retained on the nanoparticle 
surface through electrostatics. AuNPs are known to quench fluorescence of metal complexes, 
so it is not possible to quantify the amount of ruthenium cylinder attached to the nanoparticles 
by this experiment [36]. These results show that AuNPs have successfully been functionalised 
with a supramolecular helicate. 
 
 TEM of Ru-ZAuNP 
 
 
Figure 37: TEM images of Ru-ZAuNP showing representative particles from two samples at a 
variety of magnifications 
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TEM images show that the AuNPs retained their spherical shape on addition of the ruthenium 
cylinder. The size of the particles was not greatly increased compared to the bare ZAuNP 
nanoparticles. On average, the particles are still ~16 nm in diameter. The ruthenium cylinder 
has dimensions of 2 nm by 1 nm, so it was expected that the overall size of the particles would 
have increased. This may give an indication that the ruthenium complexes are lying on the 
surface of the nanoparticles so only an additional nanometre would be added around the surface. 
The ruthenium complex may also not be contrasted and therefore would be undetectable via 
this technique as only two heavy atoms lie in the core of the cylinder ~0.5 nm from the surface. 
Some larger aggregates were also detected at ~100 nm in diameter, reiterating the fact that the 
nanoparticles are less stable due to tetracationic species binding to the gold surface. 
 
4.4.2.3 Ru-ZAuNP Stability in Media 
Stability of ruthenium cylinder functionalised nanoparticles, Ru-ZAuNPs, was analysed in 
media solution, to determine whether cell toxicity studies of the particles towards cancer cell 
lines could be carried out. If it appeared the nanoparticles aggregated in media, defective 
toxicity results would be achieved, deeming such experiments useless. Stability was 
investigated by measuring the UV-Vis spectrum of the Ru-ZAuNPs suspended in media over a 
period of 24 hours, Figure 38. 
 
 
 
 
 
 
Figure 38: UV-Vis spectra of Ru-ZAuNP (5 nM) over a period of 24 hrs, legend indicates 
time solution was scanned / hours 
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Evaluating intensities of the characteristic UV peaks over time, can give an indication of the 
nanoparticle stability. After 24 hrs in media solution, 75 % of the peak intensity at 531 nm was 
retained. This indicated that some nanoparticles were lost to aggregation/degradation over time, 
but that the majority remained suspended in solution.  
 
4.4.2.4 Ru-ZAuNP / DNA Interactions 
4.4.2.4.1 Ru-ZAuNP CD 
On addition of the ruthenium functionalised nanoparticles to ct-DNA, very little observable 
effect was detected to the characteristic CD signal of ct-DNA. The ct-DNA signals increased 
in intensity slightly, however no ICD peaks were observed, indicating little binding interactions 
occurring between ct-DNA and Ru-ZAuNPs. This may be due to the compound being bound 
to the nanoparticle surface, and so not free to access grooves in the DNA structure. It does 
however indicate that the ruthenium complex is not dissociating from the nanoparticle surface 
in order to bind to the DNA. 
 
Figure 39: CD titration of 100 μM ct-DNA in 20 mM NaCl and 1 mM Tris-HCl (pH 7.2) with 
increasing concentrations of Ru-ZAuNP. Legend shows ct-DNA:complex on nanoparticle 
ratios (n:1) 
 
‐12
‐8
‐4
0
4
8
12
200 250 300 350 400
CD
 / m
de
g
Wavelength / nm
DNA
1000
750
500
250
200
150
100
75
50
40
180 
 
4.4.2.4.2 Ru-ZAuNP LD 
On addition of Ru-ZAuNP to ct-DNA, an ILD signal was observed around 633 nm, Figure 40. 
This indicated that the nanoparticles became orientated in solution, by binding to the duplex 
DNA in a specific manner. This wavelength does not correspond to λmax in the characteristic 
UV-Vis spectrum of these nanoparticles or the free ruthenium cylinder, so it is suitable to 
presume that this peak is generated as a result of a DNA/NP interactions.  
 
Figure 40: LD titration of 100 μM ct-DNA in 20 mM NaCl and 1 mM Tris-HCl (pH 7.2) with 
increasing concentrations of Ru-ZAuNP. Legend shows ct-DNA:complex on nanoparticle 
ratios (n:1)  
 
 
Figure 41: Intensity of LD signal at 260 nm for Ru-ZAuNP 
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The intensity of the characteristic ct-DNA peaks are also altered on addition of Ru-ZAuNPs to 
the solution, Figure 41. The trend on addition of these nanoparticles is the same as that observed 
with the PC-ZAuNP and ZAuNP, indicating that this structural change to ct-DNA is as a result 
of the nanoparticles being in solution, rather than the functionality attached to them.  
It was concluded that by adding this ruthenium supramolecular helicate to the surface of AuNPs 
via electrostatic interactions, the DNA binding affinity of the complex may be hindered. Being 
bound to the nanoparticle surface likely inhibits the ability of the cylindrical structure to fit into 
the grooves of DNA, to subsequently kink and coil the DNA and inhibit DNA replication. As 
a result it appeared that binding cylinders to the nanoparticles via electrostatics was not greatly 
advantageous. 
 
4.4.3 Thioacetate Cylinder 
As demonstrated in section 3.1.4 the parent 
cylinder was modified by click chemistry to 
incorporate additional thioacetate functionality, 
[Fe2(LThioacetate)3][BF4]4 where LThioacetate = 
C49H62N10O6S2. This complex is able to interact 
and bind to ct-DNA to induce structural change.  
Due to the sulphur containing moieties attached, the interaction between this iron helicate and 
AuNPs was investigated.  
 
4.3.3.1 Thioacetate-ZAuNP UV-Vis 
As demonstrated in section 4.3.2 the SPR shift of ZAuNPs is 527 nm, this was not affected by 
purifying through centrifugation, showing that the zonyl is retained on the surface. On addition 
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of [Fe2(LThioacetate)3][BF4]4 to the ZAuNPs (Thio-ZAuNP), a shift in the SPR to 537 nm was 
observed. This indicates that the cylinder is interacting with the gold surface, even after 
purifying by centrifugation.  
 
Figure 42: UV-Vis of ZAuNP (5 nM) and Thio-ZAuNP before and after purification (P) 
 
The absorbance intensity decreased after purification, as some nanoparticles were lost in the 
supernatant between purification steps. This unfortunately appeared unavoidable, and despite 
changing the speed of centrifugation and volume purified, it was found that some nanoparticles 
remained in suspension, so a speed which caused most to sediment without aggregation was 
used. 
The nanoparticles appeared to be less stable than the initial ZAuNP, which was expected due 
to adding a tetracationic complex to the negatively charged nanoparticle surface. On 
purification, some flocculation was observed, resulting in a slight broadening of the UV 
spectrum. Thio-ZAuNPs could however be re-suspended in H2O and were always prepared just 
before use, to minimise further aggregation or change in functionality of the nanoparticles. 
 
4.4.3.2 Thioacetate-ZAuNP Characterisiation 
 Thioacetate-ZAuNP DLS 
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Distribution:  Intensity: 148.4 ± 75.23 nm  Cumulant Diameter: 116.9 nm 
Volume: 69.16 ± 23.62 nm  Polydispersity Index: 0.205 
 
Figure 43: DLS results of Thio-ZAuNPs (2.5 nM) 
 
On analysing the thioacetate nanoparticles by DLS, Figure 43, it appeared that the size of 
nanoparticles had greatly increased on addition of the iron complex. This large increase 
potentially indicates that by adding the positively charged complex to the nanoparticle surface, 
the repulsive forces keeping the nanoparticles stable in solution were reduced, meaning that 
aggregation may be more likely. Other factors such as the sample being at too high a 
concentration and ineffective filtering of the sample may also have resulted in similar results. 
 
 Thioacetate-ZAuNP Zeta Potential 
ζ Potential (mV): -49.9 ± 9.05  
Conductivity (mS/cm): 0.0177 
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Figure 44: Zeta Potential analysis of Thio-ZAuNPs 
 
On addition of the thioacetate cylinder, [Fe2(LThioacetate)3][BF4]4, to ZAuNPs, the zeta potential 
increases slightly. This result indicated that a positively charged species was interacting with 
the negatively charged particles. Despite the addition of a positively charged compound in 
solution, this ζ potential indicates that the nanoparticles still have an overall negative charge 
and are stable in solution. 
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 Thioacetate-ZAuNP TEM 
 
Figure 45: TEM images of Thio-ZAuNP showing representative particles from two samples at 
a variety of magnifications 
 
As expected from DLS data, when viewing the thioacetate functionalised nanoparticles via 
TEM, large aggregate species were present. Despite being re-suspended in solution after 
purification and only a slight SPR band shift, it appeared that addition of the tetracationic 
complex caused aggregate species to be prominent in the nanoparticle solution. Individual 
nanoparticles retained their spherical shape with a diameter of ~16 nm. Despite this, the 
particles are more drawn together, despite being relatively stable in aqueous solution. This may 
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indicate that there is cross-coupling occurring between nanoparticles as a result of the cylinder 
having six thioacetate groups per complex, three on each side of the iron centres. These multiple 
linkers may be the cause of aggregate species despite the apparent high stability of the particles, 
based on UV-Vis, ζ potential and appearance. 
 
4.4.3.3 Thioacetate-ZAuNP /DNA Interaction 
4.4.3.3.1 Thioacetate-ZAuNP CD 
On addition of Thio-ZAuNP to ct-DNA, few observable changes were made to the 
characteristic B-DNA signals of ct-DNA, Figure 46. A slight ICD signal was observed at 313 
nm, indicating that there is an interaction occurring between the nanoparticles and ct-DNA, and 
that the cylinder may still be able to interact with the grooves of DNA, despite being bound to 
the nanoparticle surface. 
 
Figure 46: CD titration of 100 μM ct-DNA in 20 mM NaCl and 1 mM Tris-HCl (pH 7.2) with 
increasing concentrations of Thio-ZAuNP. Legend shows ct-DNA:complex ratios 
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4.4.3.3.2 Thioacetate-ZAuNP LD 
On addition of Thio-ZAuNP to ct-DNA the characteristic negative B-DNA signals changed 
with increasing concentration of Thio-ZAuNPs. This signal follows the same pattern as when 
other nanoparticle solutions, ZAuNP and RuZAuNP interact with ct-DNA. An induced signal 
at 304 nm indicates that the Thio-ZAuNPs are binding to DNA and becoming orientated in 
solution, Figures 47 and 48, a pattern not observed with the bare ZAuNPs.  
 
Figure 47: LD titration of 100 μM ct-DNA in 20 mM NaCl and 1 mM Tris-HCl (pH 7.2) with 
increasing concentrations of Thio-ZAuNP. Legend shows ct-DNA:complex ratios  
 
 
Figure 48: Intensity of ILD at 304 nm (blue) and 260 nm (red) with increasing concentration 
of Thio-ZAuNP 
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These results are different to those observed when the free thioacetate complex, 
[Fe2(LThioacetate)3][BF4]4, is added to ct-DNA, section 3.2.4. In the case of the free cylinder, ct-
DNA signals continually decreased with increased complex concentration due to stiffening and 
coiling of the DNA on binding and the ILD signal is at 329 nm. These spectral differences may 
be due to conflicting spectroscopy from the DNA, nanoparticle and iron complex.  
 
4.5 AuNP/3WJ Polyacrylamide Gel Studies 
Polyacrylamide gel electrophoresis, PAGE, is a technique used to separate charged 
macromolecules, based on molecular size and overall charge [41]. The technique can be used 
to investigate interactions of compounds with a variety of biological macromolecules including 
proteins, RNA and oligonucleotides [42].  
Within the Hannon group, PAGE has previously been used to show supramolecular helicates 
interacting with alternative DNA and RNA structures, specifically folk structures and three-
way junctions, 3WJ [42, 43]. Interactions between nanoparticles and DNA have previously 
been investigated using gel techniques to investigate such interactions with silver nanoparticles 
[44] and in order to fluorescently label DNA strands [45].  
Through using this technique, it was hoped to investigate whether DNA 3WJs can be formed 
in the present of helicate functionalised nanoparticles. The free tetra-cationic cylinders are able 
to stabilise 3WJs, and promote three complementary DNA strands interacting with each other 
to form junction structures [42]. It was therefore investigated what effect anchoring the helicate 
structures to AuNPs had on the ability of such compounds to stabilise the DNA, compared to 
the free cylinders, Figure 49. 
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Figure 49: Autoradiogram of gel demonstrating 3WJ formation in the presence of triple 
stranded helicates 
 
Under the conditions used, no 3WJ species are formed when only the three DNA strands were 
incubated prior to running the experiment. Only in the presence of the helicate species are 3WJ 
structures observed in the gel. 
In lanes 7-9, free cylinders were incubated with the three complementary DNA strands, prior 
to running the gel. In each of these lanes 3WJ was formed, indicated by the higher, slower 
running spots on the gel. Ratios of single stranded DNA: 3WJ were calculated by the relative 
spot intensities on the autoradiogram, Figure 50.  
Results show that the parent and ruthenium cylinders, which are of similar size and shape, 
promote equal quantities of 3WJ formation. The thioacetate cylinder, which has six additional 
groups attached to the parent structure, also promotes 3WJ formation, yet only half of much as 
for the original structures. This may be due to the bulky structure of the functionalised cylinder, 
hindering the ability of the DNA strands to come together, making for a poor fit into the central 
cavity of the junction. The spot which represents the thioacetate/3WJ species in the gel, is 
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slightly higher than the other corresponding 3WJ species, consistent with results observed in 
section 3.7, which is likely due to the higher molecular mass of the thioacetate cylinder causing 
the conjugate species to run slower in the gel. 
Lane Contents of lane 3WJ SS DNA % 3WJ 
1 S1* - 1123 - 
2 S1* + S2 - 943 - 
3 S1* + S2 + S3 - 1046 - 
4 S1* + S2 + S3 +ZAuNP - 1303 - 
5 S1* + S2 + S3 + Ru-ZAuNP 524 913 36.5 
6 S1* + S2 +S3 + Thio-ZAuNP - 1117 - 
7 S1* + S2 + S3 + Parent Cylinder 1223 585 67.6 
8 S1* + S2 + S3 + Ruthenium Cylinder 881 413 68.1 
9 S1* + S2 + S3 + Thioacetate Cylinder 506 869 36.8 
10 S1* + S2 + S3 - 879 - 
Figure 50: Table representing the contents of the gel in Figure 49, with quantitative values of 
single stranded (ss) and 3WJ ratios for each lane of PAGE gel 
 
On combining the three complimentary strands with functionalised nanoparticles, lanes 4-6, no 
induced formation of 3WJ was witnessed for ZAuNPs and Thio-ZAuNPs. It was expected for 
ZAuNPs, that no junction structures would be formed as no helicate was present and the overall 
negative charge of the nanoparticles would not encourage the negative DNA strands to come 
together. 
On incubation with Thio-ZAuNPs, no 3WJ was formed, likely resulting from the thioacetate 
cylinder being anchored onto the nanoparticle surface, making it unavailable to promote 3WJ 
formation. Lack of 3WJ may also be because of a change of the electrostatics within the system. 
The tetracationic cylinder is now incorporated into an overall negatively charged surface of the 
nanoparticles. This overall negative charge may result in the DNA strands becoming 
unreceptive to the structural advantages of the cylinder itself, and only ‘see’ the nanoparticle as 
a whole. 
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RuZAuNPs do promote some 3WJ formation, indicating that the structure is stabilised within 
the central cavity of the junction, as has previously been seen [42]. The ruthenium cylinder is 
only attached to the negatively charged particles by electrostatics, so may be labile on the 
surface, meaning it is still able to interact with the DNA strands. This may give an early 
indication, that nanoparticles could be used as a delivery mechanism for the cylinders, allowing 
them to interact solely with highly desirable DNA target. 
 
4.6 AuNP Cell studies 
4.6.1 Cell Toxicity 
As described in section 3.8.1, MTT assays can be performed to calculate the IC50 of a given 
compound for a specific cell line. This assay was performed using nanoparticles functionalised 
with the surfactant (ZAuNP), [Fe2(LThioacetate)3][BF4]4 (Thio-ZAuNP) and [Ru2(LP)3]Cl4 (Ru-
ZAuNP). Toxicity was tested in two different cancer cell lines, A2780: human ovarian 
carcinoma and A549: adenocarcinomic human alveolar basal epithelial cells, and the relative 
toxicities were compared with the known anticancer metallo-drug, cisplatin, Figure 51. 
 Cell Type 
A2780 A549 
Cisplatin 8.72 ± 0.85 14.83 ± 3.08 
ZAuNP 6.10 ± 2.43 5.63 ± 3.13 
ThioZAuNP 10.57 ± 6.52 16.81 ± 1.63 
Ru-ZAuNP 5.42 (Preliminary) 7.41 (Preliminary) 
 
Figure 51: Average toxicity results of functionalised nanoparticles after 72 hrs, IC50 / nM 
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The toxicity of these nanoparticles were analysed after 72 hours. It appeared that each of 
nanoparticles tested were highly toxic towards both cancer cell lines. This may be as a result of 
the highly anionic nature of the nanoparticle surfaces, as it has been shown this can result in 
toxic side effects, resulting from how the particles force entry into the cells through the 
negatively charged bilayer [46]. 
The nanoparticles analysed appeared to have a similar toxicity to that of cisplatin. These results 
show that by functionalising nanoparticles with triple stranded helicates, they are able to exhibit 
cytotoxic characteristics, which was the desirable effect.  
By attaching [Fe2(LThioacetate)3][BF4]4 to AuNPs, the IC50 decreases by almost half compared to 
the free cylinder for the A549 cell line, assuming the nanoparticles are functionalised 1 nM: 1 
µM, NP/complex (section 3.8). This indicates that despite hindering DNA interactions by being 
attaching to nanoparticles, the complex is able to enter cells and induce cell death more readily. 
Due to lack of compound, preliminary results were obtained for the cytotoxic effects of 
RuZAuNPs. Initial results show that through combining the ruthenium helicate with gold 
nanoparticles, a highly cytotoxic agent is formed. 
 
4.6.2 Cell Interaction 
As well as investigating how toxic the nanoparticles were to the cancer cell lines, how they 
interacted with the cells was also examined via TEM. By incubating each nanoparticle (2.5 nM) 
with cells for 24 hours, it was hoped to gain more knowledge as to how the nanoparticles enter 
cells and induce cell death.  
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4.6.2.1 A2780: human ovarian carcinoma 
Images were first taken of the cells without nanoparticles present, to view the organelles and 
general cell appearance unaltered from any outside influence. By comparing these images to 
those found when nanoparticles are present, effects to the cell were investigated. 
 
A2780 Control 
 
 
Figure 52: TEM images of control A2780 cells, showing a representative selection of cells at 
different magnifications 
 
a)      b) 
 
 
 
 
c)      d) 
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Control images, Figure 52, show cells 10-15 µm in size. Despite the cells not being stained, the 
internal structure of the cells and organelles can clearly be seen. Dark matter is present in the 
control samples around the edge of the cells, resulting from the sample preparation. These dark 
marks are >50 nm in diameter and do not have a large contrast to the rest of the cell body. As a 
result any matter of this appearance apparent in experimental cell samples will not be analysed 
as an occurrence resulting from the nanoparticles. 
 
A2780 ZAuNP 
 
 
 
 
 
 
 
 
 
 
Figure 53: TEM images of A2780 cells incubated with ZAuNPs, showing a representative 
selection of cells at different magnifications 
 
a)         b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)         d) 
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After incubation of the ovarian cancer cell line with ZAuNPs for 24 hours, it was witnessed 
that nanoparticles had entered the cells. On closer inspection, it appeared the nanoparticles were 
contained within vesicles, with multiple ZAuNPs being engulfed into the cells together. 
Definition between each nanoparticle can be seen, indicating that the highly negative surface 
charge on the nanoparticles, allows them to maintain stability in the media and cell environment 
without forming large aggregates.  
These results suggest that the nanoparticles entered the cells via endocytosis [47], where they 
are engulfed into the cells by being encapsulated within a portion of cell membrane. It has 
previously been found that larger nanoparticles, ~50 nm, may be up taken by cells my readily 
by this method, which may also be the cause of multiple nanoparticles being taken up by the 
cells [48]. 
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A2780 RuZAuNP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54: TEM images of A2780 cells incubated with RuZAuNPs, showing a representative 
selection of cells at different magnifications 
 
On addition of RuZAuNPs to A2780 cells, it was observed that the functionalised nanoparticles 
had entered cells after 24 hours. In this instance, it appeared that as well as single nanoparticles, 
aggregate species of ~100-200 nm had entered the cells. Unlike with ZAuNPs, no vesicle 
boundary was detected surrounding the nanoparticles, Figure 54 (d). Absence of this indicates 
another route was taken for the nanoparticles to enter the cell. RuAuNPs appeared to be 
sporadically located throughout the cells, indicating that uptake is not directed to a specific 
organelle, Figure 54 (a) and (b). 
a)          b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)          d) 
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A2780 Thio-ZAuNP 
 
 
 
 
 
 
 
 
 
 
Figure 55: TEM images of A2780 cells incubated with Thio-ZAuNPs showing a 
representative selection of cells at different magnifications 
 
As with Ru-ZAuNPs, on addition of the thioacetate functionalised particles, Thio-ZAuNPs, 
they appeared to have entered cells as aggregates, Figure 55 (b). These larger aggregate species 
are made up of smaller ~15 nm particles, indicating that it was Thio-ZAuNPs being observed 
in the cells. The particles appear to be entering a cell in Figure 55 (a), and once inside the cells, 
are not surrounded by vesicles, Figure 55 (d).  
Consequently it can be hypothesised that when a cylinder complex is attached to surfactant 
coated nanoparticles, ZAuNPs, the mode of action to enter the ovarian cancer cells is altered. 
a)         b) 
 
 
 
 
 
 
 
 
c)         d) 
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This may be the cause of the higher toxicity results detected for ZAuNPs within MTT assays 
(section 4.6.1). 
 
4.6.2.2 A549: adenocarcinomic human alveolar basal epithelial cells 
Equivalent experiments to those described in section 4.6.2.1 were performed with the epithelial 
cancer cell line, A549. By comparing two different cell lines, it was examined whether the mode 
of uptake and effects caused to cells were altered on changing cell type. 
 
A549 Control 
 
 
 
 
 
 
 
 
Figure 56: TEM images of control A549 cells showing a representative selection of cells at 
varying magnifications 
a)          b) 
 
 
 
 
 
 
 
 
 
 
 
 
c)       d) 
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Control images, Figure 56, show cells approximately 10 by 15 µm in size. Some internal 
structure of the cells can clearly be seen, however there is less contrast in the cells making 
specific organelles less visible. From these images, it can be seen that the cell membranes are 
not smooth and that there is no nanosized matter visible within the cells prior to treatment.   
 
A459 ZAuNP 
 
 
Figure 57: TEM images of A549 cells incubated with ZAuNPs showing a representative 
selection of cells at varying magnifications 
 
On addition of ZAuNPs to this cell line, the highly contrasting AuNPs can clearly be visualised 
within cells. As seen with the A2780s, engulfed nanoparticles appear to be within vesicle 
a)        b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)       d) 
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structures, and despite there being multiple nanoparticles within each vesicle, nanoparticles 
were mostly un-aggregated. It appears that ZAuNPs interact with the two cell lines in a similar 
way, which may result in the highly toxic nature of the nanoparticles towards both cell lines. 
 
A459 RuZAuNP 
 
 
 
 
 
 
 
 
 
 
Figure 58: TEM images of A549 cells incubated with RuZAuNPs showing a representative 
selection of cells at varying magnifications. (a) Image of entire cell, black lines indicate folds 
from the sample preparation 
 
On addition of RuZAuNPs to the A549s, it appeared nanoparticles had entered cells after 24 
hours. In this instance, it appeared that aggregates had entered the cells via vesicles of ~0.4 µm 
in size, Figures 58 (c) and (d). This is different to that observed for the A2780 cell line, where 
a)       b) 
 
 
 
 
 
 
 
 
 
 
 
 
c)        d) 
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no membrane boundary was detected around the nanoparticles. There was no evidence of the 
nanoparticles having entered the nucleus after the 24 hr incubation period, Figures 58 (a) and 
(b), indicating that they were being retained in the vesicle structures or that they were not able 
to enter the nucleus as a result of them being aggregated after incubation with the cells. 
 
A549 Thio-ZAuNP 
 
 
 
 
 
 
 
 
 
 
Figure 59: TEM images of A549 cells incubated with Thio-ZAuNPs showing a representative 
selection of cells at varying magnifications 
 
On addition of Thio-ZAuNPs to A549 cells, the nanoparticles appear to enter cells in groups, 
rather than single particles. As detected with ZAuNPs and RuZAuNPs, the nanoparticles appear 
a)     b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)      d) 
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to be surrounded by an intercellular membrane, indicating that these nanoparticles entered cells 
via endocytosis. Unlike when incubated with A2780s, Figure 55, the nanoparticles appeared to 
be less aggregated overall, with smaller clusters of nanoparticles being detected. After 24 hours 
of incubation, it appears individual nanoparticles are no longer bound within vesicle structures, 
Figure 59 (c), indicating that on further incubation, Thio-ZAuNPs may distribute throughout 
the cells. 
 
4.7 Thioacetate-Gold Surface Interaction 
Note: Experimental results were performed in collaboration with Sam Adams. Results are 
included for completeness. 
 
The thioacetate functionalised cylinder described in section 3.1.4 allows for a covalent linkage 
to be formed between the helicate complex and the gold surface of a nanoparticle. The effect 
of binding the cylinder to the nanoparticle surface has been investigated regarding DNA binding 
and cell cytotoxicity, the morphology of the cylinder, and how it interacts with the gold surface 
was also investigated with the use of ellipsometry and surface plasmon resonance, SPR. 
 
4.7.1 Ellipsometry 
Ellipsometry is an optical technique which can be used to analyse the surface of materials, 
analysing changes in polarised light over the surface. Specifically it can be used to get 
information on monolayer formation on a gold surface [49, 50]. As such, it was investigated 
what effect addition of the thioacetate cylinder in acetonitrile had to a gold surface. 
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Each thioacetate cylinder has six positions where an interaction can occur with gold, two 
thioacetate moieties per ligand. It was therefore investigated how these sulphur linkers and so 
the cylinder, interacted with a gold surface. 
Firstly a gold surface was analysed by incident radiation, to gain information of the bare gold 
surface. Additional gold surface samples were then incubated with the thioactate cylinder (1 
mg/mL in MeCN), for increasing increments of time. The samples were then washed with 
MeCN and the solvent residue remove. The incubated samples were then also analysed using 
incident radiation, to measure an optical response from the functionalised gold surfaces. By 
analysing the change in polarization from the incident radiation, on how it interacts with the 
material on the surface, changes to the surface height can be established. 
From initial ellipsometry results, it appeared that the cylinder complex was lying on the gold 
surface. Dimensions of the parent cylinder are known to be 2 nm by 1nm [34], and as such the 
overall length of the thioacetate functionalised cylinder would be much greater at approximately 
6.5 nm. On attaching this helicate to the gold surface, a maximum coating of 1.7 nm was 
observed. This increase to the gold surface indicates that the cylinder is binding as a result of 
the sulphur containing moieties and strongly suggests that it is lying on the surface, in a 
horizontal orientation, Figure 60. 
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Figure 60: Cylinder model demonstrating how [Fe2(LThioacetate)3][BF4]4 may interact with a 
gold surface 
 
From modelling the structure of the cylinder, based on models previously produced in the 
Hannon group for the parent cylinder, it appeared that only four of the six sulphur groups would 
be able to orientate to the gold surface at one time. The model indicates that both sides of the 
cylinder would be able to interact with the gold surface, giving an indication as to why the 
complex is lying on the metal surface as opposed to attaching end on. These four interactions 
would be more desirable than three from one end of the cylinder. 
The thioacetate complex lying along the surface of the gold may be the cause of little/different 
activity observed with ct-DNA in section 4.4.3.3 and 3WJ structures in section 4.5. As the 
helicate is lying on the surface it would be unable to bind to the DNA major groove or enter the 
heart of a DNA 3WJs as previously observed with the free cylinder, sections 3.1.4 and 3.7. In 
order to prevent this from occurring, a reproducible method to functionalise the cylinder on one 
side is required. 
 
 
1.693 nm ± 
0.139 
Gold Surface 
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4.7.2 Surface Plasmon Resonance: SPR 
Another technique used to investigate the thioacetate cylinder interacting with a gold surface 
was surface plasmon resonance, SPR. This technique can be used to measure adsorption of a 
material onto a metal surface and as such is used as an optical chemical or biosensor [51-53]. 
Within this research, SPR was used to investigate what affinity the thioacetate cylinder had to 
various DNA structures when attached to a gold surface. By flowing various DNA solutions 
over the gold surface, it was hoped that an affinity would be observed when the cylinder was 
present. 
Within these experiments three different DNA structures were analysed: ct-DNA, ds-26 (double 
stranded DNA of 26 bases) and h-Telo quadruplex DNA. These DNA structures were tested as 
most of the DNA binding studies were performed with ct-DNA, and it was hoped that binding 
affinities to shorter duplex DNA may be easily detected. A folded G-quadruplex structure was 
analysed to identify if the helicate, which was suspected to be lying on the gold surface, would 
be able to interact with the planar surface of a quadruplex, an interaction which has previously 
been identified [54]. 3WJ DNA was not tested as it was already shown in section 4.5, that on 
binding the thioacetate helicate to AuNPs, the binding affinity to such structures was lost. 
It was first investigated whether the bare gold surface showed any affinity to the DNA solutions, 
without the iron helicate present. After 10 minutes of the system equilibrating, the various DNA 
solutions (15 µM) were injected over the bare gold surface. These solutions were washed over 
the surface for 30 minutes before being washed away with tris-HCl buffer (pH 8.0). After this 
period, the gold surface showed no affinity to the duplex DNA solutions. There was a slight 
affinity of the gold surface to quadruplex DNA, but this was a weak interaction, Figure 61.  
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Figure 61: SPR date for DNA binding affinity onto bare gold surface 
 
When the thioacetate cylinder (1 mM) was added in acetonitrile to the gold surface, as with the 
ellipsometry data, a binding affinity was observed, Figure 62. Even after washing the surface 
with excess acetonitrile (at 2400 s), the cylinder was still bound to the surface, another 
indication that the cylinder does indeed bind to gold and therefore to AuNPs. 
 
Figure 62: SPR data showing [Fe2(LThioacetate)3][BF4]4 on the Au surface with MeCN blank 
 
Once the cylinder was attached to the gold surface, the DNA solutions were washed over the 
surface to explore the binding affinity of the bound cylinder. This experiment showed no 
binding affinity towards ct-DNA and only a slight interaction with the quadruplex and ds-26 
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DNA strands, Figure 63. These results were higher than for the bare gold surface, but were not 
comparable to literature results [51-53]. 
 
Figure 63: SPR data for DNA interactions over a gold surface with [Fe2(LThioacetate)3][BF4]4 
bound 
 
4.8 Conclusions 
Through addition of metal helicate species to the surface of gold nanoparticles, it can be 
concluded that stable, functionalised nanoparticles were formed which were able to interact 
with DNA structures and enter cancer cells. 
Through electrostatic interactions, a ruthenium helicate was incorporated onto the surface of 
AuNPs. These fluorescent particles were able to interact with ct-DNA to induce a structural 
change and promoted formation of other DNA structures such as 3WJs. Initial studies suggested 
that these particles were highly toxic towards certain cancer cell lines. It would therefore be 
advantageous to explore the toxicity and selective drug delivery capabilities of these 
nanoparticles further, in the future. 
Through adding additional functionality to the parent cylinder developed within the Hannon 
group, it was possible to alter the helicate properties, and through addition of new sulphur 
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moieties, a triple stranded iron helicate, [Fe2(LThioacetate)3][BF4]4, was attached to AuNPs and 
gold surfaces through covalent bonding. Whilst attached to the nanoparticle surface these 
structures were able to interact with ct-DNA and induce a structural change.  
The activity of this ‘thioacetate complex’ was however hindered by binding to the gold surface, 
shown by CD, LD, PAGE and SPR studies. The free complex is able to kink and coil ct-DNA 
on binding and can induce 3WJ formation. The Thio-ZAuNPs however, showed weaker 
interactions with ct-DNA and only minor binding affinities to ds-26 and quadruplex DNA. 
These results indicate that it is important for future work in this area, to synthesise helicate 
structures which are only functionalised on one side of the cylindrical structure. This would 
allow the cylinders to be more mobile on the gold surface and so able to interact with the 
grooves of ct-DNA and other DNA structures, such as the heart of a 3WJ. 
The main intention of this project however was achieved, providing useful insight into how this 
area of research can be progressed in the future, to hopefully produce a successful anticancer 
therapy, using supramolecular chemistry with nanotechnology. 
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Chapter 5 
Conclusions and Future work 
 
5.1 Conclusions 
As a result of past success within the Hannon group, developing supramolecular helicates based 
on the cylinder structure [Fe2(C25H20N4)3]Cl4, it was hoped to add new functionality to this 
triple stranded complex in order to enhance the DNA binding and cell recognition of the 
metallo-cylinders. This was hoped to be achieved by conjugating new functionality onto the 
ligand termini via a novel synthetic route (Chapter 2) and then functionalising gold 
nanoparticles, AuNPs, with the cylinder compounds (Chapter 4). 
The novel used of click chemistry was used to successfully add different functional groups onto 
the ligand structure of triple stranded helicates (Chapter 2). Three new complexes were 
synthesised through this novel method, functionalised with an ester, piperidine and thioacetate 
groups: [Fe2(LEster)3]Cl4, [Fe2(LPiperidine)3]Cl4  and [Fe2(LThioacetate)3][BF4]4  respectively.  
It was also attempted to synthesise asymmetric ligands and ruthenium analogues with the newly 
functionalised aldehydes used within ligand synthesis. However, challenges were faced when 
purifying these compounds due to the labile nature of the imine bonds within asymmetric 
ligands and low yields formed for ruthenium complexes. As such only iron cylinders with di-
functionalised ligands and the parent ruthenium cylinder were further analysed within this 
research. 
These newly synthesised cylinders were then analysed for their DNA binding and cell 
recognition properties (Chapter 3). Through the use of CD and LD experiments, it was found 
that each of these new complexes were able to bind to ct-DNA and induce a structural change. 
[Fe2(LEster)3]Cl4 binds to ct-DNA in a specific manner, indicated by the ILD produced on 
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addition of increasing ratios of complex to DNA. This interaction results in ct-DNA becoming 
disorientated in solution, indicating a kinking/coiling effect. Despite this, the ester 
functionalised complex was least toxic towards cancer cell lines tested, indicating that the 
complex may not be able to access and interact with DNA in the cells. 
[Fe2(LPiperidine)3]Cl4 was also able to interact with ct-DNA, indicated by an ICD produced on 
addition of the complex to ct-DNA. This structure caused DNA to become disorientated in 
solution, almost to the same degree as the parent cylinder. [Fe2(LPiperidine)3]Cl4 promoted least 
DNA 3WJ to form and was less toxic to cells than the parent cylinder. As such, it appeared that 
addition of piperidine functionality to the cylinder structure was not advantageous to bio-
recognition. 
The third new compound synthesised was functionalised with a thioacetate group, 
[Fe2(LThioacetate)3][BF4]4. This complex was able to bind to ct-DNA, showing induced chirality 
and orientation on binding by CD and LD respectively. This complex was able to displace 
Hoechst from ct-DNA indicating that there was some minor groove binding interaction. Of the 
new compounds, this structure promoted most DNA 3WJ formation and had on par cytotoxicity 
to cells as the parent cylinder.  
The aim of work detailed in Chapter 4 was to determine whether these metallo-cylinder 
structures could be attached to the surface of AuNPs. [Fe2(LThioacetate)3][BF4]4 contained 
additional sulphur moieties, allowed for it to be bound to AuNPs and a gold surface. Addition 
of this complex to surfactant coated nanoparticles resulted in particles which were able to 
interact with ct-DNA and enter cancer cells resulting in cytotoxicity. Activity of this complex 
was however hindered on binding to AuNPs, Thio-ZAuNPs showed weaker interactions with 
ct-DNA by CD, LD and PAGE analysis than the ‘free’ cylinder. Through analysis of 
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[Fe2(LThioacetate)3][BF4]4 attached to a gold surface, evidence indicated that the complex was 
lying along the surface which may have resulted in this decreased activity. 
It was also attempted to attach these tetra-cationic helicates to AuNPs via electrostatic 
interactions. The iron parent complex appeared not to be stable in contact with the 
nanoparticles, but the ruthenium complex [Ru2(LP)3]4+, was attached to the surface of surfactant 
coated nanoparticles. In turn, Ru-ZAuNPs were able to interact with ct-DNA and induce a 
structural change. They also promoted DNA 3WJ formation, thought to be resulting from 
dissociation of the complex from the nanoparticle surface and initial results indicate that they 
are highly cytotoxic to cancer cell lines. 
This work demonstrates that on adding new functionality to supramolecular helicates, DNA 
binding and cytotoxic effects can be manipulated. It also shows that such compounds could be 
attached to the surface of gold nanoparticles, with the ability to interact with DNA and cellular 
structures. 
 
5.2 Future Work 
Supramolecular helicate structures functionalised through click chemistry and gold 
nanoparticles coated with cylinders have been described herein.  
On binding the sulphur functionalised cylinder to gold surfaces, it was found that the complex 
was likely lying on the gold surface through binding interactions on both ends of the complex. 
As a result of these sulphur moieties being present at either end of the cylinder structure, 
multiple interactions can occur with the AuNPs and it was shown through TEM images that the 
Thio-ZAuNPs were prone to aggregation. 
These results indicate that it is important for future work in this area, to synthesise helicate 
structures which are only functionalised on one side of the cylindrical structure, Figure 1. This 
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would allow the cylinders to be more mobile on the gold surface and so able to interact with 
the major groove of ct-DNA and other DNA structures, such as the heart of a 3WJ. 
 
Figure 1: Capped cylinder structure functionalised on one side [adapted from ref1] 
 
It was attempted to form asymmetric ligands within this research, where only one side of the 
ligand had additional functionality. However it was hypothesised that this would result in a 
mixture of helicate products forming, with the major product being a complex with 2:1 
functional groups being on either side of the complex. In the case of nanoparticle binding, this 
would cause similar effects to those observed with [Fe2(LThioacetate)3][BF4]4. As such, by forming 
one end of the complex first, or capping one end of the complex before functionalising the 
helicate with desired functionality, it was thought to dispel such issues. One such possible 
synthesis is demonstrated in Figure 2. 
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Figure 2: Proposed synthetic route to a one end functionalised triple stranded complex 
 
Within future research, alternative metal centres of helicates can also be investigated. On 
binding cylinders to the surface of AuNPs, the UV-Vis spectra of the iron and ruthenium 
helicates were masked by the nanoparticle absorbance. As such, nickel could be investigated 
which are characteristically orange in colour and therefore will absorb light at a lower 
wavelength ~480 nm [2]. It may therefore be possible to detect whether the complex is intact 
on the gold surface by UV-Vis analysis, making it easier to identify and quantify the complex 
attached. 
 
5.3 References 
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Chapter 6 
Experimental 
 
6.1 General Procedures 
All solvents and commercially available reagents were bought from Sigma-Aldrich, VWR, 
Fisher Scientific, Fluorochem and Acros Organics and used without further purification. 
Deuterated NMR solvents were purchased from Goss Scientific. Water was deionized by use 
of an Elga Option 3 water purifier. All experiments were carried out in oven-dried glassware 
under atmosphere or an inert argon atmosphere, as stated. 
NMR spectra were recorded using Brüker AVIII300 (300 MHz) and AVIII400 (400 MHz) 
spectrometers. Chemical shifts (δ) are quoted in parts per million (ppm), using residual 
protonated solvent as an internal standard and were assigned on the basis of chemical shift and 
coupling constants using COSY and HSQC experiments where necessary. Abbreviations of 
multiplicities are: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m 
(multiplet). Coupling constants (J) are quoted to the nearest 0.1 Hz.  
Electrospray Ionisation (ESI) spectra were recorded on a Micromass LCT TOF Mass 
Spectrometer m/z values are reported in Daltons. Elemental analysis was obtained using a CE 
Instruments EA1110 elemental analyser. Analysis performed by the analytical facility at the 
University of Birmingham. 
Infrared spectra were recorded using a PerkinElmer, Spectrum 100, FT-IR Spectrometer. 
Absorption maxima (νmax) were recorded in wavenumbers (cm-1) and are classified as strong 
(s), medium (m), weak (w), broad (br).Thin layer chromatography (TLC) was performed using 
pre-coated aluminium sheets (Silica Gel 60 F254). Spots were visualised using UV fluorescence 
(254 nm). Retention factors (Rf) are reported with the solvent used. Flash column 
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chromatography was performed on Merck 60 silica gel, with a particle size of 40-63 μm, in the 
solvent system quoted in each case. UV-Vis spectra were recorded on a Cary 5000 Varian 
spectrometer using 1 cm quartz cuvettes. 
CD and LD spectra were recorded on a Jasco J-810 spectropolarimeter. Dynamic Light 
Scattering (DLS) and Zeta Potential data was obtained using Delca Nano.  DLS measurements 
were taken using disposable cuvettes and results are quoted with units. TEM images were 
obtained using JEOL 1200EX TEM, 100 kV max, using carbon on copper TEM grids. 
 
6.2 Synthesis of Cylinders 
6.2.1 Parent Cylinder 
6.2.1.1 Parent Ligand, LP 
Phb
Phb
Pha
Pha 1
N
im3
4
5
6
N
N
N
 
 
4,4’-Methylenedianiline (1.505 g, 7.59 mmol) was dissolved in EtOH (25 mL), 2-pyridine 
carboxaldehyde (1.40 ml, 14.71 mmol) was added via syringe followed by an excess of EtOH 
(35 mL) to encourage stirring. The reaction was stirred at rt for 2 hr in which time a yellow 
precipitate had formed in solution. Solid collected via suction filtration, washing with copious 
amounts of EtOH and diethyl ether, to yield a cream solid (2.542 g, 91.8 %). 
1H NMR: 300 MHz (CDCl3): δ 8.70 (1H, d, J = 5.1 Hz, H6), 8.62 (1H, s, Him), 8.19 (1H, d, J = 
8.1 Hz, H3), 7.81 (1H, t, J = 8.1 Hz, H4), 7.35 (1H, t, J = 6.0 Hz, H5), 7.26 (4H, s, HPha+b), 4.04 
(1H, s, H1). 
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13C NMR (CDCl3): δ 160.30 (Cim), 154.91 (C6), 149.95 (C3), 136.90 (C4), 130.02 (CPha), 125.30 
(C5), 121.63 (CPhb), 41.32 (C1). 
Mass spectrum (+ve ESI): m/z 377.3 [M]+, 378.3 [M+H]+, 399.3 [M+Na]+, 400.3 [M+Na+H]+, 
415.3 [M+Na+O]+, 431.3 [M+Na+MeOH]+, 432.3 [M+Na+MeOH+H]+, 463.3 
[M+2Na+2K+2H]+, 464.3 [M+2Na+2K+3H]+. 
  
6.2.1.2 Parent Cylinder [Fe2(LP)3]Cl4 
[Fe2(LP)3][Cl]4 LP =
Phb
Phb
Pha
Pha 1
N
im3
4
5
6
N
N
N
 
The parent ligand, LP (1.9589 g, 5.20 mmol) was dissolved in methanol (50 mL) and heated to 
50 ºC. FeCl2.4H2O (0.7078 g, 3.56 mmol) was added to the first solution in (20 mL) methanol. 
The reaction mixture was heated for 2 hrs, then left to stir at room temperature overnight. Excess 
NH4PF6 was added to the now purple solution, causing the cylinder to precipitate out of 
solution. The product was collected by filtration and washed with copious amounts of MeOH, 
H2O and Et2O. The purple solid was then suspended in methanol and stirred with DOWEX for 
2 hrs. The DOWEX and unreacted PF6- cylinder were collected by filtration. The chloride salt 
of the cylinder was then precipitated from the filtrate using ether, yielding a purple solid 
(2.0757g, 86.6 %). 
1H NMR (CDCl3): δ 9.15 (1H, s, Him), 8.69 (1H, d, J = 7.8 Hz, H6), 8.49 (1H, t, J = 7.8 Hz, H3), 
7.85 (1H, t, J = 6.3 Hz, H4), 7.44 (1H, d, J = 6.3 Hz, H5), 7.02 (2H, s, broad, HPha/b), 5.61 (2H, 
s, broad, HPha/b), 4.06 (1H, s, H1). 
Mass spectrum (+ve ESI): m/z 310.2 [M]4+, 425.3 [M+Cl]3+, 467.3 [M-LP]2++Cl, 592.5 [M-
Fe]2+, 775.7 [M-2Fe-LP]++Na, 843.7 [M-FeLP]+Cl 
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Elemental Analysis: Theoretical C: 57.63, H: 5.16, N: 10.75; Experimental C: 58.19, H: 5.10, 
N: 10.84. Corresponding to [Fe2(LP)3]Cl4.10H2O 
UV-Vis (H2O) λmax (εmax/dm3mol-1cm-1): 239 (63 799), 278 (54 654), 326 (25 120), 527 (8 779), 
576 (11 759) nm. 
 
6.2.2 Alkyne Formation 
6.2.2.1 Synthesis of 5-((trimethylsilyl)ethynyl)picolinaldehyde 
 
 
5-Bromopyridine-2-carbaldehyde (0.9662 g, 5.19 mmol), Pd(PPh3)2Cl2 (0.1410 g, 0.20 mmol), 
CuI (77.1 mg, 0.40 mmol) and PPh3 (0.1052 g, 0.40 mmol) were dissolved in THF (5 mL) in a 
3 headed flask attached to a condenser and put under Argon. Triethylamine (20 mL) and THF 
(5 mL) were then added. Trimethylsilylacetylene (1 mL, 7.03 mmol) was then added drop wise 
to the reaction mixture at room temperature. The reaction mixture was then heated to 80 ºC for 
5 hr. Solvent was evaporated giving a crude brown solid. Purification by silica column in DCM 
yielded a pale brown solid (0.90 g, 85 %). 
Rf : 0. 71 (100 % DCM) 
1H NMR (CDCl3): δ 9.83 (1H, s, H2), 8.58 (1H, t, J = 1.4 Hz, H4), 7.67 (2H, m, H3+6), 0.08 (9H, 
s, HMe). 
13C NMR (CDCl3): δ 192.68 (C2), 153.18 (C6), 140.28 (C4), 121.02 (C3), 84.22 (CMe). 
Mass spectrum (+ve ESI): m/z 226 [M+Na]+. 
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2.2.2.2 Synthesis of 5-ethynylpicolinaldehyde: Aldehyde 1 
 
 
4-Trimethylsilylethynyl-1-formyl pyridine (0.72 g, 3.54 mmol) was dissolved in MeOH (45 
mL) and K2CO3 was added. The reaction mixture was put under Argon and stirred at room 
temperature overnight. Solvent was then evaporated and the crude product was extracted with 
ethyl acetate, washing with water and brine. Purification on silica column in DCM yielded a 
white solid (0.35 g, 75 %). 
Rf : 0. 63 (100 % DCM) 
1H NMR (CDCl3): δ 10.02 (1H, s, H2), 8.80 (1H, t, J = 1.4 Hz, H6), 7.88 (2H, m, H3+4), 3.43 
(1H, s, H5). 
13C NMR (CDCl3):   192.68 (C2), 153.19 (C6), 140.27 (C4), 121.02 (C3), 77.36 (C5). 
Mass spectrum (+ve ESI): m/z 154 [M+Na]+, 155 [M+Na+H]+. 
 
6.2.3 Synthesis of Ester Helicate 
6.2.3.1 Synthesis of methyl 2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)acetate: 
Ester Aldehyde  2 
 
 
222 
 
To a solution of 5-ethynylpicolinaldehyde (0.1998 g, 1.52 mmol) and methyl 2-azidoacetate 
(0.15 mL, 1.52 mmol) in t-butanol and H2O (1:1, 16 mL) were added CuSO4.5H2O (86.1 mg, 
0.34 mmol) and sodium ascorbate (0.1269 g, 0.64 mmol). The resulting red/brown solution was 
stirred at room temperature overnight. The reaction mixture was then diluted with H2O and the 
product was extracted using CH2Cl2. The organic layer was then dried with MgSO4 and 
volatiles removed in vacuo to give a peach solid (283.8 mg, 76 %). 
IR (solid): 3128 (m), 3003 (w), 2956 (m), 2820 (m), 1743 (s), 1712 (s), 1596 (m), 1575 (w), 
1458 (w), 1434 (m), 1222 (s), 1195 (s), 830 (s), 786 (m), 689 (s), 629 (s) cm-1. 
1H NMR (CDCl3): δ 10.11 (1H, d, J = 0.76 Hz, H6), 9.22 (1H, d, J = 2.0 Hz, H2), 8.39 (1H, td, 
J = 8.0, 2.2, 0.76 Hz, H4), 8.14 (1H, s, H7), 8.06 (1H, d, J = 8.2 Hz, H5), 5.29 (2H, s, H8), 3.87 
(3H, s, H9). 
13C NMR (CDCl3):   192.80 (C6), 147.34 (C2), 133.77 (C4), 122.43 (C7), 122.07 (C5), 53.33 
(C9), 50.92 (C8).  
Mass spectrum (+ve ESI): m/z 269 [M+Na]+. 
Calculated mass: 269.0651, High Res mass: 269.0640 for C11H10N4O3Na. 
 
6.2.3.2 Synthesis of dimethyl 2,2'-(4,4'-(6,6'-((1E,1'E)-((methylenebis(4,1-
phenylene))bis(azanylylidene))bis(methanylylidene))bis(pyridine-6,3-diyl))bis(1H-1,2,3-
triazole-4,1-diyl))diacetate: LEster  
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Methyl 2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)acetate (85.8 mg, 0.35 mmol) was 
‘dissolved’ in ethanol (5 mL). 4,4’-methylenedianiline (35.5 mg, 0.17 mmol) was dissolved in 
ethanol (2 mL) and added dropwise. The reaction mixture was stirred under Ar, at room 
temperature overnight. The precipitate was then filtered and washed with ethanol and diethyl 
ether to give a brown solid (107.2 mg, 94 %). 
IR (solid): 3373 (br, m), 3087 (w), 2953 (m), 1742 (s), 1626 (w), 1502 (w), 1456 (m), 1438 (m), 
1222 (s), 821 (m), 784 (s), 704 (m), 682 (m), 635 (m) cm-1. 
1H NMR (d6-DMSO) (300): δ 9.22 (1H, dd, J = 2.3, 0.9 Hz, H7), 8.82 (1H, s, H4), 8.64 (1H, s, 
H8), 8.41 (1H, dd, J = 8.1, 2.1 Hz, H6), 8.24 (1H, d, J = 8.1 Hz, H5), 7.35 (4H, s, H2+3), 5.55 
(2H, s, H9), 4.03 (1H, s, H1), 3.75 (3H, s, H10). 
13C NMR: 145.84 (C7), 132.70 (C8), 129.23 (C2/3), 123.78 (C4), 121.05 (C2/3), 120.85 (C6), 
113.61 (C5), 55.59 (C10), 52.25 (C1), 50.17 (C9). 
Mass spectrum (+ve ESI): m/z 677 [M+Na]+, 678 [M+Na+H]+. 
Calculated Mass: 655.253, High Res mass: 655.252 for C35H31N10O4. 
 
6.2.3.3 Synthesis of [Fe2(LEster)3]Cl4  
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Methyl 2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)acetate (11.4 mg, 0.046 mmol) was 
dissolved in methanol (1.5 mL). 4,4’-methylenedianiline (4.6 mg, 0.023 mmol) was dissolved 
in methanol (1 mL) and added dropwise. This mixture was stirred for 15 mins, then FeCl2.4H2O 
(3.1 mg, 0.015 mmol) in methanol (0.5 mL) was added dropwise, turning the solution 
immediately purple. The reaction mixture was stirred at room temperature overnight. The 
product was then precipitated out of solution with diethyl ether and washed copiously to give a 
purple solid (14.1 mg, 83 %). 
IR (solid): 3377 (br, m), 2188 (w), 2017 (w), 1746 (s), 1601 (m), 1501 (m), 1459 (m), 1216 (s), 
1048 (m), 979 (m), 786 (m), 685 (m) cm-1. 
1H NMR (CD3OD) (400): δ 9.20 (1H, s, H7), 8.85 (1H, dd, J = 8.0, 1.8 Hz, H6), 8.78 (1H, d, J 
= 8.2 Hz, H5), 8.66 (1H, s, H4), 8.17 (1H, s, H8), 7.06 (2H, br s, H2/3), 5.69 (2H, br s, H2/3), 5.40 
(2H, s, H9), 4.08 (1H, s, H1), 3.79 (3H, s, H10). 
Mass spectrum (+ve ESI): m/z 519 [M]4+, 698 [M+Na]3++H. 
UV-Vis (CH3OH) λmax (εmax/dm3mol-1cm-1): 248 (80 500), 321 (87 200), 594 (9 751) nm. 
 
6.2.4 Synthesis of Piperidine Helicate 
6.2.4.1 Synthesis of 1-(2-Azidoethyl)piperidine: Piperidine Azide  
 
 
A solution of sodium azide (4.2983 g, 66.12 mmol) and 1-(2-chloroethyl)piperidine hydrogen 
chloride (4.0133 g, 21.80 mmol) in 30 mL H2O was heated at 80 ºC for 17 hrs. The resulting 
solution was cooled in an ice bath; ether (100 mL) and then solid KOH (8 g) were added, 
keeping the temperature below 10 ºC. The organic layer was then separated and the aqueous 
225 
 
layer further extracted with ether (2 × 40 mL). The combined organic layers were dried on 
Na2SO4 and the solvent removed to give pale yellow oil (3.07 g, 91 %). 
1H NMR (CDCl3) (300): δ 3.27 (2H, t, J = 6.3 Hz, H4), 2.47 (2H, t, J = 6.3 Hz, H5), 2.36 (4H, 
br t, J = 5.4 Hz, H1), 1.52 (4H, m, H2), 1.36 (2H, m, H3). 
13C NMR (CDCl3) (400): δ 57.82 (C4), 54.60 (C1), 48.37 (C5), 25.87 (C2), 24.24 (C3). 
Mass spectrum (+ve ESI): m/z 155.1 [M+H]+ 
 
6.2.4.2 Synthesis of 5-(1-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)picolinaldehyde: 
Piperidine Aldehyde 3 
 
 
5-ethynylpicolinaldehyde (5.6 mg, 0.043 mmol) was dissolved in t-butanol (3 mL). 1-(2-
azidoethyl)piperidine (6.6 mg, 0.043 mmol) was added as an oil with (1 mL) water. Aqueous 
solutions of CuSO4.5H2O (2.2 mg, 8.81 µmol) and sodium ascorbate (3.8 mg, 0.019 mmol) 
were then added to give a resulting solvent system of (t-butanol/water, 1:1). The resulting 
red/brown solution was stirred at room temperature overnight. The reaction mixture was then 
diluted with H2O and the product was extracted using CH2Cl2. The organic layer was then dried 
with MgSO4 and volatiles removed in vacuo to give a yellow solid (7.2 mg, 59 %). 
IR (solid): 2931 (s), 1707 (s), 1596 (m), 1576 (w), 1448 (m), 1259 (m), 1259 (s), 1082 (s), 1022 
(s), 799 (s), 696 (m) cm-1. 
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1H NMR (CDCl3) (400): δ 10.10 (1H, s, H2), 9.20 (1H, d, J = 2.2 Hz, H6), 8.37 (1H, dd, J = 8.8, 
2.2 Hz, H4), 8.20 (1H, s, H7), 8.05 (1H, d, J = 8.8 Hz, H3), 4.54 (2H, t, J = 6.2 Hz, H8), 2.81 
(2H, t, J = 6.4 Hz, H9), 2.47 (2H, t, J = 4.8 Hz, H10), 1.60 (2H, m, H11), 1.47 (1H, m, H12). 
13C NMR (CDCl3) (400): δ 210.2 (C2), 148.25 (C6), 130.69 (C7), 128.40 (C3), 122.02 (C4), 
58.06 (C9), 54.50 (C10), 47.99 (C8), 26.04 (C11) 24.07 (C12). 
Mass spectrum (+ve ESI): m/z 258.3 [M-CO]+, 286.3 [M+H]+, 308.3 [M+Na]+, 309.3 
[M+Na+H]+, 340.3 [M+Na+MeOH]+. 
Calculated mass: 308.1487, High Res mass: 308.1502 for C15H19N5ONa. 
 
6.2.4.3 Synthesis of (NE,N'E)-4,4'-methylenebis(N-((5-(1-(2-(piperidin-1-yl)ethyl)-1H-
1,2,3-triazol-4-yl)pyridin-2-yl)methylene)aniline): LPiperidine 
1b
1b
1a
1a 7
N
23
4
6
N
N
NN
N
N 5 N
N
N
8
9
N N10
11
12 11
10
 
 
5-(1-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)picolinaldehyde, aldehyde 3 (3.1 mg, 10.9 
μmol) was dissolved in methanol (1 mL) and 4,4’-methylenedianiline (1.4 mg, 7.06 μmol) was 
added in (0.5 mL) methanol. The solution was stirred at room temperature overnight, by which 
time a cream solid had precipitated out of solution. This was collected by filtration and washed 
with excess methanol and diethyl ether (1.1 mg, 30 %). 
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IR (solid): 2930 (s), 1978 (w), 1627 (m), 1503 (s), 1445 (m), 1229 (m), 1189 (m), 1108 (m), 
971 (m), 816(s), 756 (m), 683 (m) cm-1. 
1H NMR (CDCl3) (400): δ 9.12 (1H, d, J = 2.4 Hz, H6), 8.65 (1H, s, H5), 8.33-8.26 (2H, m, 
H3+4), 8.13 (1H, s, H2), 7.28 (4H, s, H1), 4.54 (2H, t, J = 6.4 Hz, H8), 4.06 (1H, s, H7), 2.82 (2H, 
t, J = 6.4 Hz, H9), 2.48 (2H, t, J = 4.8 Hz, H10), 1.60 (2H, m, H11) 1.47 (1H, m, H12). 
13C NMR (CDCl3) (400): δ 210.88 (C2), 184.93 (C6), 179.49 (C4), 159.49 (C3), 146.20 (C5), 
129.75 (C1a/b), 121.40 (C1a/b), 58.16 (C9), 54.52 (C10), 47.98 (C8), 26.04 (C11), 24.10 (C12). 
Mass spectrum (+ve ESI): m/z 755.5 [M+Na]+ 
Calculated mass: 755.4023, High Res mass: 755.4031 for C43H48N12Na. 
 
6.2.4.4 Synthesis of [Fe2(LPiperidine)3]Cl4  
 
 
(NE,N'E)-4,4'-methylenebis(N-((5-(1-(2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)pyridin-
2-yl)methylene)aniline) (3.3 mg, 4.50 mmol) was suspended in EtOH (1 mL) and a solution of 
FeCl2.4H2O (0.7 mg, 3.52 mmol) in EtOH (0.5 mL) was added dropwise. Overnight the solution 
turned purple and the product was isolated by precipitation with ether, and purified by copious 
washing with ether to yield a purple powder (3.3 mg, 41 %). 
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IR (solid): 3323 (br, m), 2159 (w), 2135 (w), 1990 (w), 1609 (m), 1513 (s), 1198 (m), 1034 (m), 
978 (m), 911 (m), 840 (m), 674 (m) cm-1. 
1H NMR (CDCl3) (300): δ 9.19 (1H, s, H6), 8.81 (2H, m, H3+4), 8.71 (1H, s, H5), 8.14 (1H, s, 
H2), 7.07 (2H, s, br, H1a/b), 5.71 (2H, s, br, H1a/b), 4.68 (2H, t, J = 6.3 Hz, H8), 4.07 (1H, s, H7), 
3.07 (2H, m, H9), 2.68 (2H, s, H10), 1.62 (2H, m, H11), 1.51 (1H, m, H12). 
Mass spectrum (+ve ESI): m/z 466.29 [L-Aldehyde+2H]2+, 577.58 [M+Cl4]4+, 733.52 [L]+, 
734.53 [L+H]+, 782.13 [M+Cl]3+. 
UV-Vis (CH3OH) λmax (εmax/dm3mol-1cm-1): 240 (96 900), 330 (104 000), 536 (7 200), 587 (8 
400) nm. 
 
6.2.5 Synthesis of Undecyl-thioacetate Helicate 
6.2.5.1 Synthesis of 1-azidoundecan-11-ol 
 
 
To DMF (70 mL), Br(CH2)11OH (4.9310 g, 19.63 mmol) and NaN3 (1.7082 g, 26.28 mmol) 
were added. The flask was put under an argon atmosphere and refluxed for 24 hrs. After cooling, 
the product was extracted with diethyl ether and washed with H2O three times. The organic 
phase was then dried over MgSO4 and the solvent removed yielding a yellow oil (6.10 g, 100 
%). 
IR (oil): 3404 (br), 2926 (s), 2854 (s), 2093 (S), 1668 (s), 1585 (vw), 1465 (w), 1388 (w), 1349 
(w), 1417 (vw), 1256 (m), 1102 (w), 1056 (m), 904 (w), 739 (w), 722 (w), 662 (m), 625 (w) 
cm-1. 
1H NMR (CDCl3) (300): δ 3.45 (2H, q, J = 6.9 Hz, H11), 3.12 (t, J = 6.9 Hz, H1), 1.50-1.36 (4H, 
m, H2+10), 1.28-1.12 (14H, m, H3-9). 
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Mass spectrum (+ve ESI): m/z 236 [M+Na]+, 186 [M-N2+H]+. 
 
6.2.5.2 Synthesis of 1-Azidoundecan-11-methylsulfonate  
 
 
1-azidoundecan-11-ol (2.98 g, 13.97 mmol) was dissolved in THF (60 mL) and 
methanesulfonyl chloride (3.24 mL, 41.86 mmol) was added. In a separate vial, triethylamine 
(5.84 mL, 41.90 mmol) and THF (10 mL) were combined and then added slowly to the first 
solution over 5 mins. The reaction mixture was then stirred at room temperature for 3 hrs. Ice-
cold water H2O (50 mL) was then added to the reaction mixture and the organic phase was 
separated from the aqueous phase. The aqueous phase was then extracted twice with ether (2 × 
35 mL) and the combined organic phases combined and washed with 1M HCl, H2O, NaHCO3 
sol. and H2O. It was then dried over MgSO4 and the solvent removed yielding pale yellow oil 
(3.80 g, 98 %). 
IR (oil): 2927 (s), 2855 (m), 2095 (s), 1722 (w), 1465 (w), 1355 (s), 1174 (s), 971 (m), 750 (m) 
cm-1. 
1H NMR (CDCl3) (300): δ 4.17 (2H, t, J = 6.6 Hz, H11), 3.21 (2H, t, J = 6.9 Hz, H1), 2.96 (3H, 
s, H12), 1.70 (2H, m, H10), 1.55 (2H, m, H2), 1.24 (14H, m, H3-9). 
13C-NMR (CDCl3) (400): 70.2 (C11), 52.6 (C1), 37.4 (C12), 29.4-28.8 (C4-8), 29.0 (C2), 28.8 
(C10), 26.7 (C3), 25.4 (C9). 
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6.2.5.3 Synthesis of 1-Azidoundecan-11-thioacetate  
 
 
1-azidoundecan-11-methylsulfonate (1.0848 g, 3.74 mmol) and potassium thioacetate (0.8443 
g, 7.39 mmol) were dissolved in MeOH (30 mL). The reaction mixture was then refluxed under 
Ar for 3 hrs. The solution was then cooled and water added. The product was then extracted 
using ether three times and the combined organic layers washed with H2O which was then dried 
over MgSO4 and the solvent was removed. The crude product was then purified by column 
chromatography (10 % EtOAc in Hexane) to give a yellow oil (188.9 mg, 19 %). 
Rf : 0. 58 (EtOAc/Hexane, 1:9) 
IR (oil): 2924 (s), 2853 (s), 2093 (s), 1692 (s), 1463 (w), 1351 (w), 1259 (m), 1134 (m), 953 
(w), 628 (m) cm-1. 
1H NMR (CDCl3) (300): δ 3.21 (2H, t, J = 6.9 Hz, H11), 2.82 (2H, t, J = 7.2 Hz, H1), 2.28 (3H, 
s, H12), 1.60-1.47 (4H, m, H2+10), 1.30-1.20 (14H, m, H3-9). 
13C-NMR (CDCl3) (400): 70.3 (C1), 51.5 (C12), 37.4 (C10), 29.5-28.8 (C2,4-6,10), 26.7 (C9), 25.4 
(C3). 
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6.2.5.4 Synthesis of S-(11-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)undecyl) 
ethanethioate: Undecyl-thioacetate Aldehyde 4  
 
N
O
N
N
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S
O
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5-ethynylpicolinaldehyde (72 mg, 0.5 mmol) and 1-azidoundecan-11-thioacetate (133 mg, 0.5 
mmol) in 13 mL tBuOH with 8 mL water was combined with solutions of CuSO4.5H2O (66 
mg, 0.25 mmol) and sodium ascorbate (103 mg, 0.25 mmol) in 5 mL water. After stirring at 
room temperature for six days the solution was diluted with 25 mL water and the light brown 
precipitate was collected by filtration and washed with 50 mL water, methanol and diethyl ether 
and dried under vacuum (189 mg, 94 %). 
IR (solid): 2922 (m), 2850 (m), 1720 (w), 1694 (m), 1674 (m), 1617 (w), 1592 (w), 1575 (w), 
1553 (w), 1518 (w), 1460 (w), 1405 (w), 1330 (w), 1260 (m), 1217 (w), 1168 (w), 1136 (w), 
1097 (m), 1012 (s), 869 (m), 798 (s), 727 (w), 688 (w), 661 (w) cm-1. 
1H-NMR (CDCl3) (300): 10.05 (s, 1H, H1), 9.13 (s, 1H, H6), 8.33 (d, 1H, J = 8.1 Hz, H4), 8.03 
(d, 1H, J = 8.4 Hz, H3), 7.89 (s, 1H, H8), 4.38 (t, 2H, J = 7.5 Hz, H9), 2.77 (t, 2H, J = 6.9 Hz, 
H19), 2.25 (s, 3H, H21); 1.94 (t, 2H, J = 6.9 Hz, H18), 1.55 (m, 4H, H10+11), 1.22 – 1.42 (m, 12H, 
H12-17). 
13C-NMR (CDCl3) (400): 196 (C20), 192 (C1), 152 (C2), 147 (C7), 144 (C6), 134 (C5), 131 (C4), 
122 (C8), 121 (C3), 51 (C9), 31 (C19), 30 (C21), 26 – 30 (C10-18). 
Mass spectrum (+ve ESI): m/z 425.2 [M+Na]+. 
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Calculated mass: 425.1987, High Res mass: 425.1972 for C21H30N4O2Na. 
 
6.2.5.5 Attempted synthesis of [Fe2(LUndecyl-thioacetate)3][ClO4]4 
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[Fe2(LUndecyl-thioacetate)3][ClO4]4
LUndecyl-thioacetate =
 
Undecyl-thioacetate aldehyde 4 (50.4 mg, 0.13 mmol) and 4,4’-methylenedianiline (12.8 mg 
(0.06 mmol)  were suspended in methanol (15 mL), heated to 60 °C for 2 h and stirred at room 
temperature for additional 16 h. An off-white precipitate was formed and collected by filtration, 
followed by washing with copious quantities of methanol and diethyl ether (32 mg).  
This highly insoluble solid could not be fully characterised as a result of insolubility, so was 
just taken on to the next reaction step. 
LUndecyl-thioacetate (20 mg, 0.021 mmol) was then stirred in methanol (2 mL) with Fe(ClO4)2.7H2O 
5 mg (0.013 mmol) and heated to reflux for 5 min. The resulting precipitate was collected by 
filtration, dried in vacuum and extracted with 6 mL acetone to yield a deep purple solution. 
Evaporation of the solvent yielded a purple solid (2 mg). 
Again, this product was not very soluble, and so full characterisation was not achieved.  
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1H NMR (CDCl3) (300): δ 9.41 (1H, s, H4), 9.14 (1H, s, H8), 8.58 (1H, s, H3), 8.50 (1H, s, H4), 
8.22 (1H, s, H2), 7.42 (2H, HPha/b), 7.09 (12H, HPha/b), 4.33 (2H, t, J = 6.8 Hz, H9); 3.79 (1H, s, 
H1); 2.69 (2H, m, H19), 2.28 (3H, s, H21), 1.79 (2H, s, H18), 1.37 (4H, m, H10+11), 1.02 – 1.22 
(12H, H12-17). 
Educated assignment based on undecyl-thioacetate aldehyde spectra. 
 
6.2.6 Synthesis of Thioacetate Helicate 
6.2.6.1 Synthesis of 2-(2-(2-azidoethoxy)ethoxy)ethan-1-ol  
 
 
Sodium azide (3.047 g, 46.88 mmol) suspended in ethanol (30 mL) was stirred under argon at 
rt. to which 2-(2-(2-chloroethoxy)ethoxy)ethan-1-ol (3.4 mL, 23.39 mmol) was added slowly 
to, as on oil. Sodium iodide (7.00 g, 40.27 mmol) was dissolved in ethanol (20 mL) and added 
dropwise to the first solution. The reaction mixture was then refuxed at 79 ºC overnight. The 
solvent was evaporated and the residue was diluted with water (100 mL) and extracted with 
dichloromethane (2 × 100 mL). The combined organic phases were dried over MgSO4, and the 
solvent removed by reduced vacuo yielding a colourless oil (3.14 g, 76%). 
1H NMR (CDCl3) (300): δ 3.63-3.75 (8H, m, H2-6), 3.57 (2H, t, J = 5.1 Hz, H8), 3.37 (2H, t, J 
= 5.4 Hz, H9), 2.52 (1H, s, HOH).  
13C NMR (CDCl3) (400): δ 50.5 (C9), 61.5 (C2), 69.9 (C3), 70.1 (C5), 70.5 (C6), 72.5 (C8). 
Mass spectrum (+ve ESI): m/z 191.1 [M-OH]++MeOH, 198.1 [M+Na]+, 199.1 [M+Na]++H. 
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6.2.6.2 Synthesis of 2-(2-(2-azidoethoxy)ethoxy)ethyl methanesulfonate  
 
 
2-(2-(2-azidoethoxy)ethoxy)ethan-1-ol (1.4743 g, 8.42 mmol) was dissolved in diethyl ether, 
under Ar at 0 ºC. Triethyl amine (3.5 mL, 25.11 mmol) was added dropwise, followed by mesyl 
chloride (1.0 mL, 12.92 mmol) under a flow of Ar. Reaction mixture was left to reach rt. and 
stirred for 24 hrs. The reaction was then quenched with water (50 mL) and the product extracted 
with diethyl ether. The combined organic layers were washed with water and dried over MgSO4, 
the solvent was removed to yield a pale yellow oil (1.58 g, 74 %). 
1H NMR (CDCl3) (300): δ 4.38-4.34 (2H, m, H1), 3.78-3.73 (2H, m, H2), 3.67-3.63 (6H, m, H3-
5), 3.37 (2H, t, J = Hz, H6), 3.05 (3H, s, HMe). 
13C NMR (CDCl3) (400): δ 72.58 (C3), 71.58 (C4), 70.88 (C5), 70.31 (C2), 69.38 (C1), 50.90 
(C6), 37.89 (CMe). 
Mass spectrum (+ve ESI): m/z 269.2 [M+O]+, 271.3 [M+H2O]+, 276.2 [M+Na]+, 277.2 
[M+Na+H]+, 296.2 [M+K]+. 
 
6.2.6.3 Synthesis of S-(2-(2-(2-azidoethoxy)ethoxy)ethyl) ethanethioate: Thioacetate Azide 
 
 
2-(2-(2-azidoethoxy)ethoxy)ethyl methanesulfonate (2.340 g, 9.24 mmol) was dissolved in 
ethanol (250 mL) to which a suspension of potassium thioacetate (5.80 g, 50.81 mmol) in (30 
mL) ethanol was added. The reaction was heated at 80 ºC under Ar overnight. Ethanol was then 
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removed and the reaction quenched with water (100 mL). The product was then extracted with 
dichloromethane (3 × 75 mL). The combined organic layers were dried over MgSO4 and the 
solvent removed. The resulting oil was purified via flash column chromatography 
(EtOAc/pentane 2:8) to yield a yellow/orange oil (2.01 g, 93 %). 
1H NMR (CDCl3) (400): δ 3.62-3.57 (9H, m, H2-5), 3.37 (2H, t, J = 5.6 Hz, H1), 3.08 (2H, t, J 
= 6.8 Hz, H6), 2.32 (3H, s, HMe). 
13C NMR (CDCl3) (400): δ 195.60 (CO), 70.69, 70.44, 70.17, 69.91 (C2-5), 50.77 (C6), 30.65 
(C1), 28.92 (CMe). 
Mass spectrum (+ve ESI): m/z 289 [M+Na+MeOH]+, 272 [M+K]+, 256 [M+Na]+, 234 [M+H]+. 
 
6.2.6.4 Synthesis of S-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy) ethyl) ethanethioate: Thioacetate Aldehyde 5 
4
6
N
3 2
O
N
N
N 7
8
9
O
10
11
O
12
13
S
14
O
5
 
 
To a solution of 5-ethynylpicolinaldehyde (20.7 mg, 0.158 mmol) and S-(2-(2-(2-
azidoethoxy)ethoxy)ethyl) ethanethioate (52.7 mg, 0.226 mmol) in t-butanol/water (5/1 mL) 
were added CuSO4.5H2O (11.3 mg, 0.045 mmol) followed by sodium ascorbate (13.6 mg, 0.069 
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mmol) in water solutions, giving an overall solvent system of 1:1 t-butanol/water . The resulting 
red/brown solution was stirred at room temperature overnight. The reaction mixture was then 
diluted with H2O and the product was extracted using CH2Cl2. The organic layer was dried with 
MgSO4 and volatiles removed in vacuo to give a yellow solid. This was purified using column 
chromatography (10 % MeOH/DCM) giving a yellow solid (38.8 mg, 67 %). 
IR (solid): 2893 (br, m), 2036 (w), 1694 (s), 1596 (m), 1354 (m), 1196 (m), 1101 (s), 969 (m), 
841 (m), 678 (m) cm-1. 
1H NMR (CDCl3) (400): δ 10.09 (1H, s, H2), 9.23 (1H, d, J = 1.6 Hz, H6), 8.36 (1H, dd, J = 8.0, 
2.4 Hz, H4), 8.23 (1H, s, H7), 8.03 (1H, d, J = 8.0 Hz, H3), 4.65 (2H, t, J = 4.6 Hz, H8), 3.92 
(2H, t, J = 4.6 Hz, H9), 3.66-3.56 (6H, m, H10,11,12), 3.05 (2H, m, H13), 2.31 (3H, s, H14). 
13C NMR (CDCl3) (400): δ 192.79 (C2), 147.21 (C6), 133.46 (C4), 122.53 (C7), 121.96 (C3), 
70.47 (C10/11/12), 70.06 (C10/11/12), 69.75 (C10/11/12), 69.26 (C9), 50.54 (C8), 30.50 (C14), 28.62 
(C13). 
Mass spectrum (+ve ESI): m/z 289.1 [M-SC(O)CH3]+, 365.2 [M+H]+, 366.2 [M+2H]+, 381.1 
[M+OH]+ 
Calculated mass: 365.1286, High Res mass: 365.1284 for C16H21N4O4S. 
 
6.2.6.5 Synthesis of S-(2-(2-(2-(4-(6-((E)-((4-(4-(((E)-(5-(1-(2-(2-(2-
(acetylthio)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)pyridin-2-
yl)methylene)amino)benzyl)phenyl)imino)methyl)pyridin-3-yl)-4,5-dihydro-1H-1,2,3-
triazol-1-yl)ethoxy)ethoxy)ethyl) ethanethioate: Thioacetate Ligand, LThioacetate  
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S-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethyl)  
ethanethioate, aldehyde 5 (2.0 mg, 5.49 μmol) was dissolved in methanol (1 ml) and a 
methanolic solution (1 mL) of 4,4’-methylenedianiline (0.7 mg, 3.53 μmol) was added. The 
solution was stirred at rt. overnight and the solvent removed in vacuo to yield a pale brown 
solid (2.1 mg, 86 %). 
IR (solid): 3119 (br, w), 2866 (br, m), 2164 (w), 1689 (s), 1352 (m), 1106 (s), 973 (s), 822 (s), 
783 (m), 677 (m) cm-1. 
1H NMR (CDCl3) (300): δ 9.15 (1H, s, H6), 8.65 (1H, s, H5), 8.31 (1H, d, J = 9.0 Hz, H4), 8.28 
(1H, d, J = 8.4 Hz, H3), 8.17 (1H, s, H2), 7.28 (4H, s, H1), 4.65 (2H, t, J = 4.8 Hz, H8), 3.94 (2H, 
t, J = 5.1 Hz, H9), 3.64-3.57 (6H, m, H10,11,12), 3.07 (2H, t, J = 6.6 Hz, H13), 2.01 (3H, s, H14). 
13C NMR (CDCl3) (400): δ 159.6 (C2), 146.9 (C6), 133.4 (C4), 129.8 (C3), 121.5 (C5), 70.6 
(C10/11/12), 70.2 (C10/11/12), 69.5 (C10/11/12), 28.62 (C13). 
238 
 
Mass spectrum (+ve ESI): m/z 913.3 [M+Na]+, 891.3 [M+H]+, 567.3 [M-(C16H20N4O3S) +H 
+Na]+, 545.3 [M-(C16H20N4O3S) +2H]+, 468.2 [M]2+ +Na, 387.2 [M-(C29H30N5O3S) +2H+Na 
]+. 
Calculated mass: 891.3434, High Res mass: 891.3441 for C45H51N10O6S2. 
 
6.2.5.6 Synthesis of [Fe2(LThioacetate)3][BF4]4  
 
 
 
 
 
 
 
 
 
 
S-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethyl)  
ethanethioate, aldehyde 5 (2.6 mg, 7.13 μmol) was dissolved in methanol (1 ml) and a 
methanolic solution (1 mL) of 4,4’-methylenedianiline (0.8 mg, 4.03 μmol) was added. 
Fe(BF4)2.6H2O was added dropwise in methanol (1 mL), turning the reaction mixture gradually 
purple with time. The solution was stirred at rt. overnight. The product was precipitated out 
using diethyl ether and collected by filtration, yielding a purple solid (3.5 mg, 94 %). 
IR (solid): 2868 (br, m), 1687 (s), 1502 (m), 1459 (m), 1352 (m), 1201 (m), 1102 (s), 973 (s), 
822 (m), 674 (m) cm-1. 
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1H NMR (CD3CN) (400): δ 8.90 (1H, s, H6), 8.74 (1H, d, J = 8.0 Hz, H4), 8.62 (1H, d, J = 8.0 
Hz, H3), 8.30 (1H, s, H2), 8.04 (1H, s, H7), 6.96 (2H, br, s, H1a/b), 5.64 (2H, br, s, H1a/b), 4.53 
(2H, t, J = 6.0 Hz, H8), 4.02 (1H, s, H15), 3.84 (2H, t, J = Hz, 5.0 Hz, H9), 3.55-3.44 (6H, m, 
H10+11+12), 2.94 (2H, t, J = 6.0 Hz, H13), 2.25 (3H, s, H14). 
Mass spectrum (+ve ESI): m/z 695.9 [M]4+, 696.7 [M+H]4+, 891.3 [LThioacetate]+, 956.2 
[M+(BF4)]3+, 1153.3 [M+(BF4)4]3++Na+BF4, 1497.4 [M+(BF4)2]2++H2O, 1501.5 
[M+(BF4)2]2++Na. 
UV-Vis (CH3CN) λmax (εmax/dm3mol-1cm-1): 237 (108200), 329 (110900), 534 (9300), 589 
(13500) nm. 
Elemental Analysis: Theoretical: C: 51.77 %, H: 4.83 %, N: 13.41 %; Experimental: C: 51.81 
%, H: 4.92 %, N: 13.34 % for C135H150N30O18S6Fe2B4F16. 
 
6.2.7 Synthesis of Lipoic acid Helicate 
6.2.7.1 Synthesis of methyl 6-formylnicotinate  
 
 
Methyl 6-methylnicotinate (4.45 g, 29.46 mmol) was mixed with iodine (7.4847 g, 29.49 
mmol), and a small amount of DMSO (2 mL) to encourage mixing. After mixing for 5 min, 
DMSO (20 mL) was added and this solution was added to a heated solution of DMSO (35 mL) 
at 130 ºC. The temperature was then slowly increased to 160 ºC and the solution was stirred at 
this temperature for 15 min.  After cooling down the reaction to room temperature, a saturated 
solution of aqueous Na2CO3 was added. The product was then extracted with diethyl ether. 
Volatiles were removed in vacuo to give a crude product, which was purified via a silica column 
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(CH2Cl2/EtOAc = 4:1) (Rf = 0.85). Product was obtained as a cream/ yellow solid (1.82 g, 37 
%). 
Rf : 0.85 (EtOAc/DCM, 1:4) 
1H NMR (CDCl3): δ 10.14 (1H, d, J = 0.9 Hz, H6), 9.36 (1H, dd, J = 2.0, 0.9 Hz, H2), 8.47 (1H, 
ddd, J = 8.1, 2.0, 0.9 Hz, H4), 8.03 (1H, dd, J = 8.1, 0.9 Hz, H5), 4.00 (3H, s, CH3). 
13C NMR (CDCl3): δ 192.80 (C6), 151.38 (C2), 129.37 (C4), 121.25 (C5), 53.02(C7). 
Mass spectrum (+ve ESI): m/z 188 [M+Na]+, 189 [M+H+Na]+. 
 
6.2.7.2 Synthesis of 6-dimethoxymethyl-nicotinate  
 
 
Methyl 6-formylnicotinate (1.78 g, 10.78 mmol) was dissolved in trimethyl orthoformate (46 
mL), formic acid (7 mL) and sulphuric acid (5 drops). The mixture was heated to 50 ºC and 
stirred for 30 min. The mixture was then stirred at room temperature overnight. Water and 
diethyl ether were then added to the reaction mixture and the two layers were separated. The 
aqueous layer was further extracted with more diethyl ether. The combined diethyl ether layers 
were then washed with aqueous saturated Na2CO3 and dried with MgSO4. Volatiles were 
removed in vacuo to give a crude product, which was purified via a silica column 
(CH2Cl2/EtOAc = 4:1) (Rf = 0.58). Product was obtained as yellow oil (1.15 g, 50 %). 
Rf : 0.58 (EtOAc/DCM,1:4) 
1H NMR (CDCl3): δ 9.13 (1H, dd, J = 2.2, 0.75 Hz, H2), 8.26 (1H, dd, J = 8.1, 2.2 Hz, H4), 7.57 
(1H, d, J = 8.2, H3), 5.35 (1H, s, H6), 3.88 (3H, s, HMe), 3.33 (6H, s, H7). 
13C NMR (CDCl3): δ 150.4 (C2), 137.8 (C4), 120.9 (C5), 103.4 (C6), 53.7 (C7), 52.4 (CMe). 
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Mass spectrum (+ve EI): m/z 210 [M-H]+. 
 
6.2.7.3 Synthesis of 6-dimethoxymethyl-nicotinic acid  
 
 
6-Dimethoxymethyl-nicotinate (1.1482 g, 5.44 mmol) was dissolved in MeOH (10 mL) and 
then 1M NaOH (10 mL). This mixture was then stirred at room temperature overnight. 1M HCl 
was then used to acidify the reaction mixture to pH 3. The product was then extracted using 
ethyl acetate and dried with MgSO4. Volatiles were removed in vacuo yielding a cream/yellow 
solid (0.90 g, 84 %). 
1H NMR (CDCl3): δ 9.35 (1H, dd, J = 2.1, 0.82 Hz, H2), 8.45 (1H, dd, J = 8.2, 2.2 Hz, H4), 7.73 
(1H, d, J = 11.2 Hz, H5), 5.51 (1H, s, H6), 3.44 (6H, s, H7). 
13C NMR (CDCl3): δ 150.72 (C2), 138.55 (C4), 121.18 (C5), 103.12 (C6), 53.75 (C7). 
Mass spectrum (+ve ESI): m/z 198 [M+H]+, 242 [M+2Na-H]+. 
 
6.2.7.4 Synthesis of N-(2-aminoethyl)-5-(1,2-dithiolan-3-yl)pentanamide  
 
 
(±)-α-Lipoic acid (1.9835 g, 9.61 mmol) and 1,1’-carbonyldiimidazole (2.4465 g, 15.09 mmol) 
were dissolved in anhydrous chloroform (15 mL) and stirred under a flow of Ar for 30 mins at 
room temperature. Ethylenediamine (3.4 mL, 50.86 mmol) was cooled in an ice bath and the 
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lipoic acid mixture was added dropwise and the mixture was left to stir under Argon for 2 hr. 
The reaction mixture was then washed with brine and 10 mM NaOH solution. The chloroform 
layer was then dried with MgSO4 and the volatiles removed in vacuo yielding a yellow solid/gel 
which was not fully dried due to the gel like nature of the compound (2.36 g, 99 % wet). 
1H NMR (CDCl3): δ 7.75 (1H, t, J = 5.4 Hz, NH), 3.65-3.56 (1H, m, H10), 3.24-3.10 (2H, m, 
H12), 3.02 (2H, q, J = 6.6 Hz, H6), 2.53, (2H, t, J = 6.6 Hz, H2/3), 2.41 (1H, sex, J = 6.2 Hz, 
H11a/b), 2.06 (2H, t, J = 7.2 Hz, H2/3), 1.86 (1H, sex, J = 6.6 Hz, H11a/b), 1.68-1.48 (4H, m, H7+9), 
1.34 (2H, q, J = 7.8 Hz, H8). 
13C NMR (CDCl3): δ174.21 (C4), 56.55 (C10), 42.01 (C10), 41.48 (C3), 41.03 (C2), 40.35 (C11), 
38.59 (C12), 36.48 (C6), 34.72 (C9), 29.00 (C8), 25.50 (C7).  
Mass spectrum (+ve ESI): m/z 232 [M-NH2]+, 249 [M+H]+, 271 [M+Na]+. 
 
6.2.7.5 Synthesis of N-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethyl)-6-(dimethoxymethyl) 
nicotinamide  
 
 
6-dimethoxymethyl-nicotinic acid (0.7845 g, 3.98 mmol), N-(2-aminoethyl)-5-(1,2-dithiolan-
3-yl)pentanamide (0.84 g, 3.38 mmol) and HOBt (0.7765 g, 5.75 mmol) were dissolved in DMF 
(10 mL) and stirred at 0 ºC. EDC (0.9950 g, 5.19 mmol) was then added in DMF (5 mL). The 
reaction mixture was then left to stir at room temperature overnight. Saturated NaHCO3 solution 
was then added and the product was extracted with EtOAc, which was washed with H2O and 
brine. The organic layer was dried with MgSO4 and volatiles removed in vacuo giving a cream 
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solid. Purification on silica column in 10 % MeOH in DCM yielded a cream solid (0.25 g, 17 
%). 
IR (solid): 3287 (s), 3084 (w), 2931 (m), 2857 (w), 1719 (w), 1634 (s), 1538 (s), 1442 (w), 683 
(s), 631 (m) cm-1. 
1H NMR (CDCl3) (400): δ 9.05 (1H, d, J = 2.1 Hz, H2), 8.16 (1H, dd, J = 8.2, 2.2 Hz, H4), 7.66 
(1H, t, J = 4.6 Hz, NH1), 7.63 (1H, d, J = 8.2 Hz, H5), 6.21 (1H, t, J = 5.6 Hz, NH2), 5.41 (1H, 
s, H6), 3.60 (2H, m, H8), 3.54 (2H, m, H9), 3.41 (6H, s, H7), 3.12 (2H, m, H16), 2.41 (1H, sex, J 
= 6.4 Hz, H15a/b), 2.22 (2H, t, J = 7.4 Hz, H10), 1.86 (1H, sex, J = 6.4 Hz, H15a/b), 1.65 (5H, m, 
H11+13+14), 1.43 (2H, m, H12). 
13C NMR (CDCl3):   147.9 (C2), 135.5 (C4), 121.1 (C5), 103.5 (C6), 56.3 (C14), 53.7 (C7), 42.1 
(H8), 40.2 (C15/16), 39.6 (C9), 38.5 (C15/16), 36.3 (C10), 34.5 (C11/13), 28.8 (C12), 25.3 (C11/13).  
Mass spectrum (+ve ESI): m/z 450 [M+Na]+, 451 [M+Na+H]+. 
Calculated mass: 450.1497, High Res mass: 450.1474 for C19H29N3O4NaS2. 
 
6.2.7.6 Synthesis of N-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethyl)-6-
formylnicotinamide: Aldehyde 6  
 
 
N-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethyl)-6-(dimethoxymethyl)Nicotinamide (237.9 mg, 
0.56 mmol) was dissolved in THF (34 mL) and cooled to 0 ºC. 1M HCl (6.8 mL) was then 
added and the solution stirred for 5 days. The product was then extracted with EtOAc, washing 
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with NaHCO3 solution and H2O. The organic layer was then dried with MgSO4 and volatiles 
removed in vacuo to give a cream solid (93.9 mg, 72 %). 
IR (solid): 3284 (s), 3071 (w), 2924 (m), 2853 (m), 1720 (m), 1632 (s), 1541 (s), 1446 (w), 826 
(m), 800 (m), 687 (m), 631 (w) cm-1. 
1H NMR (CDCl3) (300): δ 10.11 (1H, d, J = 0.7 Hz, H1), 9.23 (1H, dd, J = 2.3, 0.7 Hz, H2), 
8.30 (1H, ddd, J = 7.8, 2.1, 0.7 Hz, H3), 8.16 (1H, s, H5), 8.02 (1H, dd, J = 8.1, 0.7 Hz, H4), 
6.35 (1H, s, H8), 3.60-3.56 (4H, m, H6+7), 3.10-3.05 (2H, m, H15), 2.40 (1H, sex, J = 6.0 Hz, 
H14a/b), 2.23 (2H, t, J = 7.8 Hz, H9), 1.85 (1H, sex, J = 6.0 Hz, H14a/b), 1.62 (5H, m, H10+12+13), 
1.36 (2H, m, H11). 
13C NMR (CDCl3):   192.7 (C1), 149.1 (C2), 135.9 (C3), 121.3 (C4), 43.0 (C6), 40.3 (C14), 39.3 
(C7), 38.4 (C15), 36.2 (C9), 34.5 (C12), 30.3 (C13), 28.7 (C11), 25.2 (C10). 
Mass spectrum (+ve ESI): m/z 404.1 [M+Na]+, 450.2 [M+3Na]+. 
 
6.2.7.7 Synthesis of 6,6'-((1E,1'E)-((methylenebis(4,1-
phenylene))bis(azanylylidene))bis(methanylylidene))bis(N-(2-(5-(1,2-dithiolan-3-
yl)pentanamido)ethyl)nicotinamide): LLipoic  
 
 
N-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethyl)-6-formylnicotinamide, aldehyde 6 (13.9 mg, 
0.036 mmol) was dissolved in ethanol (3 mL). 4,4’-methylenedianaline (3.7 mg, 0.019 mmol) 
was then added dropwise in ethanol (2 mL). The reaction mixture was stirred at room 
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temperature, under Ar overnight. The precipitate was filtered and washed with ethanol and 
diethyl ether, giving a highly insoluble cream solid (107.2 mg, 94 %). 
This compound could not be analysed due to its insolubility. It was attempted to dissolve the 
ligand in CDCl3, CH3CN, H2O, CH3OH and DMSO, but an insufficient amount of compound 
could be dissolve, so not data was obtained. As a result a one-pot reaction was used to form the 
cylinder of this ligand, straight from the aldehyde (6). 
IR (solid): 3292 (s), 2926 (s), 1637 (s), 1541 (s), 1433 (m), 1244 (m), 1072 (w), 696 (m), 680 
(m) cm-1. 
 
6.2.7.8 Synthesis of [Fe2(LLipoic)3][BF4]4 
 
 
N-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethyl)-6-formylnicotinamide (8.2 mg, 0.021 mmol) 
was dissolved in ethanol (1 mL). 4,4’-methylenedianaline (2.4 mg, 0.012 mmol) was then added 
dropwise in ethanol (0.7 mL). This solution was left to stir for 10 mins, until the solution turned 
cloudy. Fe(BF4)2.6H2O (2.5 mg, 0.007 mmol) in ethanol (0.7 mL) was then added turning the 
solution dark blue/purple. The reaction mixture was stirred at room temperature, overnight. The 
precipitate was filtered and washed with ethanol and diethyl ether, giving blue/purple solid (8.5 
mg, 71 %). 
IR (solid): 3289 (br, m), 2928 (br, m), 2037 (w), 1638 (s), 1537 (m), 1065 (s), 811 (m), 673 
(w), 658 (w) cm-1. 
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This complex was insoluble in all solvents tested. Consisting of: MeOH, MeCN, CHCl3, DCM, 
Acetone, H2O, DMF, OEt2, EtOH, EtOAc. As a result, no further analytical data could be 
obtained. 
 
6.2.8 Synthesis of Half Ligand 
6.2.8.1 Synthesis of S,S-Dimethyl-N-(2-pyridyl)sulfilimine  
 
 
2-Aminopyridine (9.42 g, 0.10 mol) and dimethyl sulfide (8 mL) were dissolved in 
dichloromethane (100 mL). N-chlorosuccinimide (13.33 g, 0.10 mol) was dissolved in 
dichloromethane (250 mL) and added dropwise to the first solution over a period of 1 hr whilst 
maintaining the temperature at -20 ºC. The reaction mixture was the stirred at -20 ºC for 1 hr 
and then for 1 hr at rt. A solution of sodium methoxide in methanol (9.20 g, 0.17 mol in 75 mL 
methanol) was then added and stirring continued for 10 mins. Water (150 mL) was then added 
and stirred for 4 hrs. The organic layer was then separated and the aqueous layer extracted with 
water (2 × 50 mL). The organic layer was dried and evaporated to give yellow oil. The oil was 
recrystallised from diethyl ether to provide a cream solid (7.42 g, 48 %). 
1H NMR (CDCl3): δ 7.98 (1H, dd, J = 5.2, 1.2 Hz, H6), 7.32 (1H, td, J = 7.8, 1.9 Hz, H5), 6.73 
(1H, d, J = 9.0 Hz, H4), 6.48 (1H, td, J = 6.0, 0.6 Hz, H3), 2.73 (6H, d, J = 3.0 Hz, 2 × CH3). 
13C NMR (CDCl3): δ 147.0 (C6), 136.7 (C4), 114.1 (C5), 111.5 (C3), 33.7 (CH3). 
Mass spectrum (+ve EI): m/z 154 [M]+, 139 [M-CH3]+. 
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6.2.8.2 Synthesis of 2-Nitosopyridine  
 
 
S,S-Dimethyl-N-(2-pyridyl)sulfilimine (5.54 g, 35.92 mmol) was dissolved in dry 
dichloromethane ( 35 mL). This was added to a solution of m-chloroperbenzoic acid (10.64 g, 
61.65 mmol) in dry dichloromethane (200 mL) cooled to 0 ºC. The reaction mixture was stirred 
at 0-5 ºC for 2.5 h, dimethyl sulfide (2.7 mL) added and then stirring continued for 90 mins. 
Saturated aqueous sodium carbonate solution (200 mL) was then added to the reaction mixture. 
The green organic layer was separated and washed with water, dried and evaporated to dryness 
to give a light brown solid. The solid was recrystallised from ethanol to provide yellow crystals 
(1.22 g, 31 %). 
The compound exists as two tautomeric forms which are denoted in the NMR data as a and b. 
1H NMR (CDCl3): δ 8.81 (1H, dd, J = 4.5, 0.6 Hz, H6a/b), 8.08 (1H, td, J = 7.7, 1.8 Hz, H5a/b/4a/b), 
8.01 (1H, dd, J = 4.8, 0.9 Hz, H6a/b), 7.94 (1H, td, J = 7.8, 1.8 Hz, H5a/b/4a/b), 7.86 (1H, d, J = 6.0 
Hz, H3a/b), 7.67 (1h, ddd, J = 12.0, 4.5, 0.9 Hz, H5a/b/4a/b), 7.40 (1H, d, J = 6 Hz, H3a/b), 7.31 (1H, 
ddd, J = 12.3, 4.8, 1.2 Hz, H5a/b/4a/b). 
13C NMR (CDCl3): δ 146.9 (C6), 139.4 (C4), 125.6 (C5), 118.8 (C3). 
Mass spectrum (+ve EI): m/z 108 [M]+. 
 
6.2.8.3 Synthesis of Half-Ligand, LHalf  
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2-Nitosopyridine (1.22 g, 11.26 mmol) was dissolved in dichloromethane (10 mL). An excess 
of 4,4’-methylenedianiline (8.97 g, 45.24 mmol) in dichloromethane (35 mL) and glacial acetic 
acid were added and the orange solution was stirred at r.t overnight. The volatiles were then 
removed in vacuo to yield an orange solid which was then recrystallised from methanol (0.55 
g, 22 %). 
1H NMR (CDCl3): δ 8.73 (1H, dq, J = 4.8, 0.7 Hz, H6), 7.98 (2H, d, J = 8.4 Hz, H7), 7.89 (1H, 
td, J = 7.7, 1.8 Hz, H4/5), 7.81 (1H, dt, J = 8.1, 1.0 Hz, H3), 7.39 (1H, m, H4/5), 7.34 (2H, d, J = 
8.4, H8), 7.01 (2H, d, J = 8.4 Hz, H9), 6.65 (2H, d, J = 6.5 Hz, H10), 3.96 (2H, s, CH2), 3.61 
(2H, broad s, HNH2). 
13C NMR (CDCl3):   149.5 (C6), 138.3 (C4/5), 129.9 (C9), 129.5 (C8), 125.0 (C4/5), 123.8 (C3), 
121.4 (C7), 115.4 (C10), 41.1 (CCH2). 
Mass spectrum (+ve ESI): m/z 289 [M+H]+. 
 
6.2.9 Synthesis of Asymmetric Ligands 
6.2.9.1 Synthesis of N-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethyl)-6-((E)-((4-(4-((E)-
pyridin-2-yldiazenyl)benzyl)phenyl)imino)methyl)nicotinamide: LAsym-Lipoic  
 
 
N-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethyl)-6-formylnicotinamide (7.5 mg, 0.020 mmol) 
was dissolved in ethanol (3 mL). Half-ligand (5.9 mg, 0.020 mmol) was dissolved in ethanol (2 
mL) and added dropwise to the aldehyde solution under Ar. The reaction mixture was then left 
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to stir at room temperature overnight. The volatiles were then removed in vacuo, resulting in a 
crude orange solid (16.0 mg, 120 %). 
This compound could not be purified by column chromatography, recrystallisation or by 
isolation through selective solubility, so could not be characterised. 
 
6.2.9.2 Synthesis of S-(2-(2-(2-(4-(6-((E)-((4-(4-((E)-pyridin-2-
yldiazenyl)benzyl)phenyl)imino)methyl)pyridin-3-yl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethyl) ethanethioate: LAsym-Thioacetate 
 
 
S-(2-(2-(2-(4-(6-formylpyridin-3-yl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy) ethyl) 
ethanethioate, aldehyde 5 (10.3 mg, 0.028 mmol) and the half-ligand, LHalf (8.1 mg, 0.028 
mmol) were dissolved in ethanol (3 mL) with 2 drops of glacial acetic acid. The reaction mixture 
was then left to stir at room temperature for 5 days. The volatiles were then removed in vacuo, 
resulting in a crude orange solid (17.8 mg, 100 %). 
This compound could not be fully purified by column chromatography, recrystallisation or by 
isolation through selective solubility, so could not be characterised. 
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6.3 Synthesis of Ruthenium Cylinders 
6.3.1 Parent Ruthenium Cylinder 
 
 
Ru(DMSO)4Cl2 was first synthesised by refluxing RuCl3 (1.012 g, 4.88 mmol) in DMSO (5 
mL) at 195 ºC for 5 mins. The solution was then cooled and half the DMSO removed by rotary 
evaporation. On addition of cold acetone, a yellow solid precipitated from solution. This was 
collected by filtration and washed with cold acetone. The yellow product indicated that the 
Ru(DMSO)4Cl2  complex was successful formed and so was used in subsequent reactions. 
Parent ligand, LP (359.6 mg, 0.955 mmol) was then added to a 50 mL microwave reaction vial 
containing a magnetic stirrer, degassed ethylene glycol (30 mL) and Ru(DMSO)4Cl2 (308.4 mg, 
0.637 mmol). Ar(g) was then flushed over the reaction mixture before the vial lid was attached. 
The reaction vial was then placed into the microwave the reactor, where the temperature was 
increased to 200 ºC within 3 mins. The reaction mixture was stirred under this temperature for 
4 hours, to give a dark orange/red solution. The ruthenium compounds were then precipitated 
out of solution using a saturated methanolic solution of NH4PF6. The dark brown solid was then 
collected by suction filtration and washed with copious quantities of water. It was then purified 
using column chromatography (20:1:1, MeCN/H2O/KNO3(aq) on alumina) to yield a dark 
orange solid (5.0 mg, 0.9 %). The complex was left in the PF6- salt form as this was soluble in 
MeCN which could easily be removed from analytical samples, minimising the amount of 
product lost.  
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1H NMR (CD3CN): δ 8.72 (1H, s, Him), 8.47 (1H, d, J = 7.8 Hz, H6), 8.31 (1H, t, J = 7.8 Hz, 
H3), 7.74 (1H, t, J = 6.9 Hz, H4), 7.67 (1H, d, J = 6.0 Hz, H5), 6.99 (2H, d, J = 8.4 Hz, HPha/b), 
5.74 (2H, d, J = 8.4 Hz, HPha/b), 4.04 (1H, s, H1). 
Mass spectrum (+ve ESI): m/z 333.3 [M-(PF6)4]4+, 444.7 [M-(PF6)4]3+, 667.0 [M-(PF6)4]2+. 
UV-Vis (H2O) λmax (εmax/dm3mol-1cm-1): 235 (38 493), 276 (28 702), 324 (22 380), 492 (7 939) 
nm. 
 
6.3.2 Thioacetate Ruthenium Cylinder 
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LThioacetate =
 
 
LThioacetate (116.1 mg, 0.130 mmol) was added to a 50 mL microwave reaction vial containing a 
magnetic stirrer, degassed ethylene glycol (20 mL) and Ru(DMSO)4Cl2 (27.2 mg, 0.088 mmol). 
Ar(g) was then flushed over the reaction mixture before the vial lid was attached. The reaction 
vial was then placed into the microwave the reactor, where the temperature was increased to 
200 ºC under 3 mins. The reaction mixture was stirred under this temperature for 4 hours, to 
give a dark orange/red solution. The ruthenium compounds were then precipitated out of 
solution using a saturated methanolic solution of NH4PF6. The dark solid was then collected by 
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suction filtration and washed with copious quantities of water. It was then attempted to purify 
the product using column chromatography. It was first attempted by using the same solvent 
system used for the parent cylinder (8:1:2, MeCN/H2O/NH4PF6 solution on alumina). However 
after multiple columns, it was not possible to completely isolate the triple stranded product, 
evident by broad 1H NMR spectra, impurities seen in the mass spectrum and multiple spots on 
the TLC. Therefore it was attempted to purify using silica column chromatography (15 mM 
NH4PF6 3:1 MeCN/H2O) and through preparative TLCs on alumina and silica. However, pure 
triple stranded complex was not achieved. 
1H NMR (CD3CN): Broad peaks contaminated with Ru3+ complex. 
Mass spectrum (+ve ESI): m/z No peaks corresponding to [Ru2(LThioacetate)3]4+ 
 
6.4 DNA binding studies 
All DNA binding studies were carried out using ultrapure water (18.2 MΩ) purchased from 
Fisher Scientific. Highly polymerised calf thymus (ct-) DNA was purchased from Sigma 
Aldrich, kept frozen and used without further purification. Stated concentrations of ct-DNA are 
calculated based on concentration of bases, as determined from the UV absorbance at 260 nm 
when ɛ = 6600 mol-1dm3cm-1. 
Stock solutions of ct-DNA (3000 µM) in water were prepared and kept frozen until the day of 
experiment. Sodium chloride (1 M) and sodium cacodylate (Na(CH2)2AsO2.3H2O) (100 mM) 
(pH 6.8) or tris-HCl (100 mM) (pH 7.2) buffer stock solutions were used to prepare final ct-
DNA solutions with 20 mM Nacl and 1 mM sodium cacodylate/tris-HCl. 
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6.4.1 CD/LD Titrations 
CD and LD experiments were recorded using a Jasco J-810 spectropolarimeter. CD experiments 
were performed in quartz cuvettes of 1 cm pathlength. LD measurements were recorded in a 
flow coquette cell (Krometek) with a 0.1 cm pathlength. 
CD and LD titrations were carried out using three solutions; solution A (100 µM ct-DNA 
containing NaCl (20 mM) and sodium cacodylate/tris-HCl (1 mM)); solution B (167 µM 
complex solution) and solution C (200 µM ct-DNA solution containing NaCl (40 mM) and 
sodium cacodylate/tris-HCl (2 mM)). Solution A was recorded first, followed by the addition 
of equal aliquots of solutions B and C, keeping the concentration of ct-DNA constant 
throughout the titration. Increasing quantities where then added to obtain ct-DNA:complex 
ratios of 60:1 increasing to 4:1. A blank buffer solution was subtracted from the resulting 
spectra, and results are presented without any further smoothing. Each spectra shows the 
average signal over four scans and each experiment was repeated to ensure reproducibility. 
 
6.4.2 Ethidium Bromide displacement 
Fluorescence spectra for the ethidium bromide displacement experiments were recorded in a 
Shimadzu RF-5301 PC Fluorescence spectrophotometer (λexc= 480 nm; emission range:400-
600 nm; resolution= 0.4 nm; speed medium; excitation split= 5; emmision split= 1.5). A 
solution of ethidium bromide (15 µM) with ct-DNA (12 µM) in NaCl (20 mM) and sodium 
cacodylate buffer (1 mM) was measured and titrated with the different complexes from ratios 
EB:complex 200-1 to 1-1, keeping the concentration of ethidium bromide and ct-DNA constant. 
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6.4.3 Hoechst 33258 displacement 
Fluorescence spectra for the Hoechst 33258 (Hoechst) displacement experiment were recorded 
in a Shimadzu RF-5301 PC Fluorescence spectrophotometer (λexc=350 nm; emission range 
=400-600 nm; resolution=0.4 nm; speed medium; excitation split=5; emmision split=1.5). A 
solution of Hoechst (1.5 µM) with ct-DNA (12 µM) in NaCl (20 mM) and sodium cacodylate 
buffer (1 mM, pH 6.8) was measured and titrated with the different complexes from ratios of 
Hoechst:complex 200-1 to 4-1, keeping the concentration of Hoechst and ct-DNA constant. 
 
6.5 Polyacrylamide Gel Electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis (PAGE) was used to identify whether three-way junction 
(3WJ) DNA structures where formed on interaction with new helicate structures. 
 
6.5.1 DNA radioactive labelling 
Three complementary oligonucleotide sequences were purchased from MWG Eurofin (S1: 
CGGAACGGCACTCG, S2: CGAGTGCAGCGTGG, S3: CCACGCTCGTTCCG). One 
strand (S1) was radiolabelled with 32P at the 5’ terminus using [γ-32P] adenosine 5’-triphosphate 
(Perkin Elmer). Firstly milliQ water (4.8 µL), 10x T4 polynucleotide kinase buffer (1 µL), 
oligonucleotide S1 (1.2 μl of 100μM), bacteriophage T4 polynucleotide kinase (1 μl) (New 
England Biolabs) and ATP (2 μl of 3000 Ci/mmol) were incubated in an eppendorf at 37°C for 
an hour. The solution was then heated to 80°C for three mins, in order to deactivate the 
polynucleotide kinase. 
To purify the radioactive labelled DNA sequences from any unreacted [γ-32P]-ATP, a QIAquick 
nucleotide removal kit (QIAgen) was used. 10 volumes of PNI buffer to 1 volume reaction 
mixture were loaded onto a QIAquick spin column with a 2 mL collection tube, centrifuged at 
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6000 rpm for 1 minute and the flow through discarded. PE buffer (500 µL) was then added with 
a new collection tube, and centrifuged at 6000 rpm for 1 minute, again the flow through was 
put to waste and this washing with PE buffer was repeated, then centrifuged at 13000 rpm for 
1 minute to remove residual buffer. The column was then transferred to a new Eppendorf, and 
milliQ water (30 µL) added and left for 5 minutes. After a final centrifugation at 13000 rpm for 
2 minutes, the flow through was collected and diluted by half to give the radiolabelled stock 
solution of DNA (2 µM). 
 
6.5.2 Polyacrylamide gel preparation 
A stock solution of 15 % native polyacrylamide gel (1 L) was first prepared by mixing 40 % 
acrylamide (29:1, 375 mL) (Geneflow), 10x TB buffer (100 mL) containing 10.8 g tris-base 
and 5.5 g boric acid and HPLC grade water (525 mL). This solution was stored at 4 ºC, wrapped 
in foil until needed. 50 mL of this gel solution was then combined with 150 µL of 10 % (w/v) 
ammonium persulfate and 25 µL tetramethylenediamine (TEMED) and left to polymerise 
between a set of glass plates for 40 minutes. Wells within the gel were washed with running 
buffer (TB buffer) and the gel was pre-run at 300 V, 400 A for 10 minutes before loading 
samples. 
 
6.5.3 PAGE Experiment 
Sample solutions were prepared by mixing solutions of the complexes with stoichiometric 
amounts of the three oligonucleotides in TBN buffer (89 mM tris(hydroxymethy)amino 
methane, 89 mM of boric acid and 100 μM NaCl) (pH 8.3) to give a final concentration of 0.2 
μM for each single strand (0.6 μM total concentration of DNA) and 0.6 μM of complex or 0.5 
nM/0.5 µM of nanoparticle/complex. The sample solutions were incubated for 1 hour at room 
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temperature and then in ice for 15 minutes. Prior to loading samples onto the gel, 5 μL of 30 % 
glycerol was added to each sample, ensuring the DNA/complex solutions would fall to the 
bottom of the wells on loading. 13 μL of each sample was then loaded onto the 15% 
polyacrylamide gel.  
The gel was run for 4 hours at 120 V, 300 A using Gel System equipment (Thermo Scientific 
UK). It was then exposed on a phosphor imaging plate for 1 hour and an autoradiogram was 
obtained using a Molecular Imager FX (Bio-Rad). The gel was quantified using Quantity One 
software. 
 
6.6 Cell studies 
All cell lines were cultured in T75 tissue culture flasks (Costar) at 37 ºC in a 5: 95 CO2/Air 
incubator. Cells were maintained in DMEM (MDA-MB-231, A549) and RPMI 1640 (A2780) 
supplemented with FBS (10 % v/v), streptomycin (100 µg/mL), penicillin (100 U/mL) and L-
glutamine (2 mM). Cells were sub-cultured twice each week, using a standard trypsin-EDTA 
protocol. 
 
6.6.1 MTT assays 
The MTT assay was used to estimate cell toxicity of the free and nanoparticle bound helicate 
structures over 72 hours. 15,000 cells were seeded in complete medium (100 µL) into each well 
of a 96 well plate. The cells were then incubated for 24 hours to allow for attachment. To treat 
the cells, 100 µL of compound solutions in complete media and up to 5 % MeOH/MeCN were 
added to the cells (10, 25, 50 and 75 µM). Following incubation for 72 hours, each well was 
washed with PBD and then complete media (100 µL) containing MTT (0.5mM) was added to 
each well. This was incubated for 2 hours (37 ºC, 5 % CO2), after which time the media was 
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removed and 100 µL DMSO was added to solubilise the purple formazan product. Absorbance 
at 540 nm was then measured for each well against a DMSO blank, and so the IC50 was 
calculated. Each complex was tested in triplicate against a cisplatin standard. DMSO breaks 
down the helicate structures, so therefore was no absorbance interference from the complexes 
during these experiments. 
 
6.6.2 TEM  
Cells for TEM analysis with AuNPs were prepared to analyse how the nanoparticles interact 
with the cell structure and hence how they may induce cell toxicity.  
Cells were initially seeded onto cover slips which had been sterilised in EtOH and washed with 
PBS. These were placed into 6 well plates where cells (150,000 in 3 mL) were suspended in 
media and left to adhere for 24 hours. Cells were then washed with PBS (3 mL) and treated 
with nanoparticles suspended in media (5 nM, 3 mL). The cell were then incubated for 24 hours 
(37 ºC, 5 % CO2), before being washed with PBS. The coverslips were then transferred into a 
falcon tube containing glutaraldehyde in phosphate buffer, used as a fixative for the cells.  
Samples were then prepared onto TEM grids by Theresa Morris, Electron Microscope 
Applications Technician, School of Metallurgy and Materials, University of Birmingham. 
 
6.7 AuNP / Gold Surface Studies 
For all reactions involving AuNPs, glassware was washed with aqua regia and copious 
quantities of distilled water prior to used, ensuring any residual particles are dissolved which 
may interfere with the synthesis. The nanoparticles where also synthesised and functionalised 
in darkness, to help maintain stability over time. All nanoparticles were filtered through an 
Acrodisc glass fibre membrane syringe filter, 1 µm (Sigma Aldrich) before use. 
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6.7.1 Citrate AuNP Synthesis 
A solution of 1 mM HAuCl4.3H2O (100 mL) was brought to 100 ºC and intensely stirred. A 
38.8 mM solution of Na3(C6H5O7).2H2O (10 mL) was then added into the centre of the stirring 
vortex and the mixture was heated for 10 mins and then stirred without heat for 15 mins. This 
resulted in a deep red/purple solution. 
UV absorption: 524 nm 
DLS diameter by volume: 17.44 ± 6.199 nm 
Zeta Potential: -43.2 ± 17.9 mV 
TEM diameter: Average 16 nm  
Concentration of cAuNPs: 5 nm (see Appendix, calculated using diameter observed from TEM 
images) 
 
6.7.2 AuNP Functionalisation 
Gold nanoparticles were functionalised with surfactant to form ZAuNPs by mixing the stock 
solution of cAuNPs with zonyl FSA (2 µL in 1 mL) overnight. The particles were then purified 
by centrifugation at 13000 rpm for 20 mins. This produced a red pellet, which was re-suspended 
in milliQ water, after the supernatant had been removed. This process was repeated and the 
nanoparticles were left suspended in milliQ water at the same concentration as the original 
cAuNP solution. All functionalised particles were formed over the night prior to experimental 
analysis. 
All helicate functionalised particles were formed by reacting equal volumes of the complex 
solution (5 µM) with the surfactant coated particles, ZAuNPs (5 nM) overnight. They were then 
purified by centrifugation at 11000 rpm for 30 mins, which produced a pellet of particles which 
259 
 
were re-suspended in milliQ water. This purification step was repeated, and the resulting 
nanoparticles were used in milliQ water unless otherwise stated, at half the volume of the 
reaction mixture, giving 5 nM particles with 5 µM complex attached. 
 
6.7.3 Ellipsometry 
*Ellipsometry experiments were performed in collaboration with Sam Adams, Zoe Pikramenou 
group, University of Birmingham, with the complex solution provided. 
Ellipsometry experiments were performed on Jobin-Yvon UVISEL ellipsometer with a xenon 
light source. The technique uses elliptically polarized monochromatic light to determine the 
thickness of a surface. 
The surface of a thin gold film on silicon was first measured, giving the thickness of the gold 
surface. Gold samples were then submerged in a solution of [Fe2(LThioacetate)3][BF4]4 (1 mg/mL 
in MeCN) for increasing periods of time (1, 2, 5, 10, 20 and 30 mins). Excess cylinder solution 
was then washed off these incubated samples with MeCN, and the gold surfaces measured. 
With increasing time, a maximum growth in surface height on cylinder binding was 1.69 nm.  
 
6.7.4 Surface Plasmon Resonance 
*SPR experiments were performed in collaboration with Sam Adams, Zoe Pikramenou group, 
University of Birmingham, with complex, buffer and DNA solutions provided. 
Surface Plasmon Resonance (SPR) experiments were performed on a Reichert SR7000DC. 
Experiments were performed to determine whether a gold surface had affinity to various DNA 
solutions, bare and with the thioacetate cylinder, [Fe2(LThioacetate)3][BF4]4 bound.  
Three DNA solutions were flowed over the gold surfaces: polymeric ct-DNA (Sigma Aldrich), 
double stranded DNA of 26 bases: ds26 5’-CAA-TCG-GAT-CGA-ATT-CGA-TCC-GAT-TG-
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3’ (MWG Eurofin) and human telomeric DNA: h-Telo quadruplex DNA 5’-AGG-GTT-AGG-
GTT-AGG-GTT-AGG-G-3’ (MWG Eurofin). The two shorter DNA sequences; ds26 and h-
Telo were annealed before use, heating to 90 ºC for 5 mins and slowly cooling to room 
temperature, to ensure that the sequences were in their helical and quadruplex structures 
respectively. Solutions were made to 15 µM (concentration in bases, based on their UV 
absorbance at 260 nm) in tris-HCl buffer (pH 8.0). (ct-DNA/ds26 ɛ260=6600 mol-1dm3cm-1, h-
Telo ɛ260=244 300 mol-1dm3cm-1). 
Gold surface sensor chips, bare and functionalised with the helicate were measured for bio-
affinity, by first equilibrating the system for 10 minutes, then flowing the various DNA 
solutions (15 µM) over the gold surface by injecting into the flow cell. These solutions were 
washed over the surface for 30 minutes before being washed away with tris-HCl buffer (pH 
8.0). Affinity of the DNA solutions to the gold surface was then analysed based on changes in 
the response units. 
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Appendix 
A.1 2D NMR and Mass Spectra 
A.1.1 Ester Aldehyde 
 
COSY 
 
 
 
 
 
 
 
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
 
HSQC 
 
 
 
 
 
 
 
 
1H-13C HSQC NMR (400 MHz, CDCl3, 298 K) 
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ESI Mass Spectrum 
 
 
A.1.2 Ester Cylinder 
 
COSY 
 
 
 
 
 
 
 
1H-1H COSY NMR (400 MHz, CD3OD, 298 K) 
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ESI Mass Spectrum of [Fe2(LEster)3]Cl4 
 
ESI Mass Spectrum of [Fe2(LEster)3]4+ 
 
A.1.3 Piperidine Aldehyde 
 
COSY 
 
 
 
 
 
 
 
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
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HSQC 
 
 
 
 
 
 
 
1H-13C HSQC NMR (400 MHz, CDCl3, 298 K) 
 
ESI Mass Spectrum 
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A.1.4 Piperidine Cylinder 
 
COSY 
 
 
 
 
 
 
 
1H-1H COSY NMR (400 MHz, CD3OD, 298 K) 
 
ESI Mass Spectrum [Fe2(LPiperidine)3]Cl4 
 
 
 
 
 
 
 
 
266 
 
ESI Mass Spectrum [Fe2(LPiperidine)3]4+ 
 
 
A.1.5 Thioacetate Aldehyde 
 
COSY 
 
 
 
 
 
 
 
 
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
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HSQC 
 
 
 
 
 
 
 
 
1H-13C HSQC NMR (400 MHz, CDCl3, 298 K) 
ESI Mass Spectrum 
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A.1.6 Thioacetate Cylinder 
 
COSY 
 
 
 
 
 
1H-1H COSY NMR (400 MHz, CD3CN, 298 K) 
 
ESI Mass Spectrum [Fe2(LThioacetate)3][BF4]4 
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ESI Mass Spectrum [Fe2(LThioacetate)3]4+ 
 
A.2 Calculation of Nanoparticle Concentration  
It was possible to estimate the concentration of AuNPs from TEM experiments, using the 
following assumptions for large spherical metal clusters, such as a gold nanoparticle:  
Vcluster = NVatom  (eq. 1)  
4/3 π (Rcluster)3 = N 4/3 π (Ratom)3  (eq. 2)  
Rcluster = N1/3 Ratom  (eq. 3) 
(V: cluster or atom volume, R: cluster or atomic radius, N: total number of atoms within the 
cluster) 
The cluster radius is obtained from TEM imaging, so the surface (S) area of a nanoparticle can 
be calculated using: 
Scluster = 4 π (Rcluster)2  (eq. 4)  
For larger clusters, the number of surface atoms, Ns, can also be calculated by dividing the 
surface area of the cluster by the cross section of an individual cluster atom, and simplifying 
using the relationship in (eq. 3):  
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Ns = (4 π (Rcluster)2) / (π (Ratom)2) = 4 N2/3  (eq. 5)  
From the TEM result presented (see Chapter 4), we know that Rcluster ≈ 8 nm, and Ratom = 0.l37 
nm. The number of gold atoms per nanoparticle was estimated using (eq. 3):  
N = (Rcluster / Ratom)3 = ((8 x 10-9 ) / (137 x 10-9 ))3 = 199 107 gold atoms per nanoparticle. 
 The number of surface atoms, Ns, on a single gold nanoparticle was also estimated using (eq. 
5): Ns = 4 N2/3 = 4 x (199,117) 2/3 = 13640 gold surface atoms per nanoparticle.  
From N, the molecular weight (Mw) of a single nanoparticle was calculated using the relative 
molecular mass of a single gold atom (Mgold): Mw = Mgold x N Mw = 196.97 x 199117 Mw 
= 39220 kDa  
Calculation of the amount of nanoparticles formed (NNP) when 1 dm3 of 1 mM HAuCl4 is 
reduced by citrate was then calculated: Moles of HAuCl4 = 1 x 1 x 10-3 = 1 x 10-3 mol  
No. of gold atoms, Natom = 1 x 10-3 x NA = 1 x 10-3 x 6.022 x 1023 = 6.022 x 1020  
NNP = Natom / N NNP = (6.022 x 1020) / (199117) = 3.024 x 1015 nanoparticles formed per 1 
x 10-3 mol HAuCl4. 
Hence the final concentration of the gold colloid, was estimated by dividing NNP by 
Avagadro’s number (NA):  
CAuNP = NNP / NA = (3.024 x 1015) / (6.022 x 1023) = 5.022 x 10-9 mol dm-3 
All concentrations of nanoparticles presented in this thesis are calculated from the initial stock 
solution of citrate coated nanoparticles, cAuNPs, being 5 nM. 
